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Summary 
 
Ghrelin is a 28 amino-acid peptide produced predominantly by the stomach. Two main 
isoforms of ghrelin are currently known (octanoyl- and desoctanoyl ghrelin). It 
functions as a circulating orexigenic hormone In addition, it has an effect on the 
nervous, cardiovascular and immune system. Current data suggest that ghrelin may have 
beneficial anti-inflammatory effects. Chapter 3 in this thesis primarily examines the 
relationship between ghrelin and inflammation in Crohn’s disease (CD). Modulation of 
inflammation with infliximab, a powerful anti-TNFα antibody therapy, can increase 
total ghrelin concentration by 25%. In addition, a normal physiological post-prandial 
decrease in ghrelin following a meal is restored when infused with infliximab, 
suggesting a dysregulation of ghrelin in CD patients with active inflammation. At 
cellular level, there is evidence that ghrelin may have an immunosuppressive effect on 
activated T-lymphocytes. Chapter 4 of this thesis examines the effect of ghrelin, a 
manufactured agonist and des-octanoyl ghrelin on NFκB activation on a human B-
lymphocyte cell line. This study demonstrated that exposure to octanoyl ghrelin confers 
an initial increase of NFκB activation in inactivated cells of up to 50% which suggests a 
pro-inflammatory effect. However, NFκB activation appears to decrease at much higher 
concentrations of octanoyl ghrelin, which may indicate toxicity at supra-physiological 
levels. Ghrelin is also involved in the regulation of gastric motility and has structural 
similarities to motilin. Symptoms of delayed gastric emptying can occur long after 
cancer chemotherapy has ended. Chapter 5 of this thesis compares the contractility and 
pro-motility neurotransmitter expression in chemotherapy and non-chemotherapy 
exposed stomach tissues obtained from patients undergoing surgery for oesophago-
gastric cancers. Chemotherapy exposed tissues have reduced contractility to carbachol 
and apparent destruction of the cholinergic activity. The tendency for ghrelin receptors 
to increase suggests an attempt to upregulate compensating systems. In conclusion, 
ghrelin can be altered by inflammation and may have beneficial effects on gastric 
motility. 
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Chapter 1 
 Introduction 
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1.1 “Starve the fever, feed the cold”: The benefit of hunger or starvation 
 
Hunger is a natural self-preservation instinct incorporated in all living animals. As it 
drives food intake it preserves energy balance and ensures survival. However, it is 
generally accepted that unwell animals do not eat well. Hunger, in particular is 
severely diminished in many disease states.  It is also true that in many disease states 
energy expenditure is usually increased, particularly in inflammatory conditions.  
 
 To preserve energy to deal with the illness, physical activity is decreased as a result 
of lethargy, hence the common medical advice of ‘bed rest’. It is indeed questionable 
why animals lose the hunger mechanism, if energy expenditure is increased. Clearly 
ongoing severe inflammatory process will lead to detrimental consequences to the 
body, in particular cachexia, in event of inadequate feeding. This is contrary to 
survival instinct in non-diseased animals. 
 
 Normal hunger mechanism is usually re-established once disease associated 
inflammatory process have resolved, usually by natural biological mechanisms or 
medical intervention. Crisis arises if the disease maintains a chronic inflammatory 
state, and if not adequately treated will lead to health decline. This eventually leads to 
malnutrition and vulnerability to secondary diseases e.g. Poor wound healing, 
infection etc. which may lead to the animal’s demise.  
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There may be a plausible explanation to why hunger is so severely diminished in the 
disease state.  Could there be a physiological need for starvation during acute illness? 
Is there a possibility that not eating during the illness, at least in the short term may be 
of benefit to the animal? If so, could it be possible that hunger and/or starvation 
actually alter an animal’s immune activity and help it to survive an illness? These 
questions are currently not adequately explained by current understanding of the 
hunger mechanisms in inflammatory related illnesses. 
 
“Fasting is a great remedy for fever” a familiar anecdote first described by a 16th 
century lexicographer John Withals in 1574, from which the widely believed phrase 
“starve the fever, feed the cold” is thought to have originated. This has been widely 
dismissed as a myth and deemed unscientific.  More recently, Dutch scientists have 
shown the feeding stimulated the release of IFN-γ which is a key signalling cytokine 
in defence against viral infection (van den Brink et al. 2002). Fasting, on the other 
hand appeared to increase IL-4 production, which is implicated in stimulation of B-
cells and proliferation of T-cells which, in turn, may stimulate humoral defence 
mechanisms against extracellular organisms. Hence, the bona fide ancient idiom may 
have finally earned its legitimacy.  
 
It is quite possible that the phrase may have originated from the observation that 
nutrient intake can beneficially alter immune response. Indeed, there is evidence that 
even trace nutrients e.g. Glutamine can have beneficial effects in mortality 
particularly in patients with critical illness  (Avenell et al. 2009). Indeed, glutamine 
has been shown to prevent apoptosis, attenuates inflammation and decreases insulin 
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resistance (Singleton et al. 2008; Wischmeyer et al. 2008; Wischmeyer et al. 2007) 
thus may be clinically beneficial in critically unwell patients.  
 
The mechanism of appetite loss in inflammation is poorly understood. In unwell 
animals with high inflammatory load, appetite and food intake is reduced, partly due 
to circulating cytokines e.g. TNFα directly inhibiting the hunger centre. This thesis 
describes a novel hunger mechanism that is uncovered when modulating 
inflammation in Crohn’s disease, and a proposed mechanism for appetite loss in 
patients with high inflammatory load. 
 
There is currently a growing interest in nutritional support for acutely ill patients. It is 
estimated that approximately one third of patients admitted to hospital for an acute 
illness are at least moderately malnourished, and early detection and recognition of 
these patients was poor (McWhirter et al. 1994). Early artificial nutritional 
intervention is now associated with better outcomes, including shorter hospital stay  
(Von Meyenfeldt et al. 1992; Delmi et al. 1990), reduction in complications, 
including infections  (Heyland et al. 1998) and promotes recovery. 
 
Such compelling evidence of nutrition support in acutely ill patients has precipitated 
much interest in delivering nutrition as part of overall treatment for these patients. In 
the UK, the National Institute of Clinical Excellence (NICE), an independent 
organisation responsible for providing national guidance on promoting good health, 
preventing and treating ill health has developed national guidance on nutrition support 
to improve outcomes of patients in hospital (NICE CG32, 2006). There is clinical 
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evidence that nutrition delivery during acute illnesses, where hunger mechanisms 
were severely diminished, may actually improve outcomes of these patients.  
 
This effect may have evolved possibly from the improved overall well being of the 
patient after being fed, or perhaps nutrition itself has immune-modulating activity in 
regulating inflammatory process. It has been previously reported that different 
nutrients have an impact on the overall function of the immune system. In general, 
malnutrition per is associated with a decrease in immune cell functions, hence their 
vulnerability to poor healing and tissue regeneration.  
 
Deficiencies in nutrients in particular protein, iron, zinc and certain vitamins have an 
overall decrease in immune cell activity and even complement system  (Shronts et al. 
1993). When nutrient deficiencies are replenished, this would restore optimum 
immune function, and benefit patients in clinical outcomes with early nutritional 
intervention. This evidence would contradict the natural response of animals to stop 
eating, with loss of appetite during illnesses. Further studies are needed to determine 
if starvation during illnesses, particularly in the short term during acute illness, 
confers any benefit. 
 
 
 
 
 
6 
 
1.2 Ghrelin 
1.2.1 The Origins, Structure and Genetics of Ghrelin 
Ghrelin is a novel 28 amino acid peptide predominantly by the stomach .In humans, 
ghrelin is genetically encoded in chromosome 3  (Seim et al. 2007). It is highly 
conserved between species and structurally related to motilin in amino acid sequence. 
Soon after the discovery of ghrelin, another peptide isolated from the stomach by 
another group was described as “motilin related peptide” as it was noted to have 
similar structure to motilin  (Tomasetto et al. 2000). The structure was in fact ghrelin 
prior to octanoylation. The association was elusive as it was not known that the N-
terminus could undergo post translational modification. If ghrelin has such structural 
similarities, it would be expected to have functional characteristics of motilin. In 
animal and human studies, ghrelin is involved in the modulation of gastric and 
intestinal motility, including migrating motor complex, which are physiological 
peristaltic waves transporting stomach contents distally in the GI tract  (Kitazawa et 
al. 2005; Tack et al. 2006). 
 
 Figure 1.1 The amino acid sequence of mouse ghrelin (adapted from Peeters TL, 
Gut 2005;54:1638-1649). This illustrates the striking similarities in the sequence 
of rat and human motilin, differing in only 2 amino acid residues, which is 
probably due to differences between species. 
 
Studies have shown that ghrelin is decreased following gastrectomy and the stomach 
produces approximately two thirds of circulating ghrelin (Ariyasu et al. 2001; 
Dornonville de la et al. 2005). Ghrelin is produced in abundance by the X/A neuro-
endocrine cells of the stomach, mainly in the fundus (Date et al. 2000). The ghrelin 
producing cells GI tract have been characterised in animal studies and these cells were 
confined mainly to the mucosal layer.  
 
 
 
7 
 
8 
 
Morphological differences of these ghrelin-producing cells have been described 
previously. The stomach and intestinal cells have been shown to differ in shape and 
structure. In the stomach the cells are so called “closed-type” cells and in the 
intestines “open-type” cells  (Sakata et al. 2002). The “closed” type cells tend to be 
small and round shaped. In contrast, the “open-type” cells are elongated. “Open-type” 
cells are usually positioned to be in contact with the lumen, presumably regulated by 
luminal contents including nutrients and acidity. “closed-type” cells on the other hand 
where buried deep in the glandular pits are probably regulated hormonally, neuronally 
or even by mechanical distension  (Sakata et al. 2010).  
 
The density of the ghrelin producing cells decrease towards the lower GI tract. Apart 
from the stomach, smaller amounts of ghrelin has been produced by many other 
organs including pancreas (Broglio et al. 2003b), kidneys (Mori et al. 2000; Yabuki et 
al. 2006), placenta (Gualillo et al. 2001), testes (Ishikawa et al. 2007), pituitary 
(Korbonits et al. 2001) and bowel (Krsek et al. 2002). The diverse distribution of 
ghrelin production raises the possibility that every tissue may contribute to the overall 
energy homeostasis of an intact animal. Another possibility could be that ghrelin may 
be involved in regulation of an unknown function specific to the tissues involved. 
 
 
 
 
 
 
The ghrelin gene is encoded in chromosome 3p25-p25 (locus tag 
UNQ524/PRO1066). This gene encodes the ghrelin-obestatin preproprotein. 
Subsequent cleavage of this preproprotein produces ghrelin and obestatin. 
 
Figure 1.2 indicating the non-sequence coordinate location of the ghrelin 
sequence on chromosome 3. (Source : Gene database, Pubmed) 
 
The ghrelin gene is conserved is highly conserved in cow, chimpanzee, mouse, dog 
and rat. There are many variants of mRNA transcripts identified but some do not 
translate into protein. There are 5 known mRNA transcript and protein variants: 
1. Isoform 1 : NM_016362.3 → NP_057446.1.  Encodes the longest isoform 
which includes both ghrelin and obestatin ligands. 
2. Isoform 2 : NM_001134941.1 → NP_001128413.1.  An alternative splice 
acceptor site resulting in omission of 3 nt compared to variant 1.This isoform 
includes both ghrelin and obestatin ligands and lacks a single amino acid 
compared to isoform 1 
3. Isoform 3 : NM_001134944.1 → NP_001128416.1. This variant is generated 
from a more distal promoter. This isoform has a shorter and distinct N-
terminus in comparison to isoform 1 and includes the obestatin ligand 
4. Isoform 4 : NM_001134945.1 → NP_001128417.1. This variant is generated 
from a more distal promoter and also an alternate splicing site is used resulting 
in the omission of 3 nt. This resulting isoform has a shorter and distinct N-
terminus  compared to isoform 1. This also includes the obestatin ligand 
9 
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5. Isoform 5 : NM_001134946.1 → NP_001128418.1. This variant is also 
generated from a distal promoter and includes an alternate first exon which 
contains an upstream in-frame AUG codon and omits 2 in frame coding exons 
compared to isoform 1. This isoform is shorter and a has a distinct N-terminus 
compared to isoform 1. Also includes the obestatin ligand 
 
There are 3 known ghrelin single nucleotide polymorphisms 
1. rs34911341 
 CCGGGCGGAGCCAGCCTGCTAGAGCT [C/T] GGGCTGCAGCTTGGCTGGTGGCTT 
2. rs4684677  
CCAGGGCCTGGCTGTGCTGCTGGTAC [A/T ] GAACCCCTGACAGCTTGATTCCAAC 
3. rs696217  
TGCAGAGGTACCGACCCGGACTTCCA [G/T] TTCATCCTCTGCCCCTTCTGCTTGA 
 
Ghrelin SNP is associated with hypertension but also thought to have some protective 
effects against gestational diabetes  (dos, I et al. 2010). A study on Amish population 
suggests that these polymorphisms are also associated with increased risk of 
metabolic syndrome (Steinle et al. 2005). It is also possible that ghrelin SNPs are 
associated with increased susceptibility to bulimia nervosa (Ando et al. 2006). 
 
 
 
 
 
Chromosome 3p25‐26
“Preproghrelin”
ObestatinGhrelin
Acylated 
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Acyl‐ modification
cleavage
Acylation
Deacylation
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Figure 1.3 Schematic diagram of the ghrelin gene to active peptide. Ghrelin is 
encoded on chromosome 3. Resulting exon from transcription and splicing is 
translated into a 117 amino acid precursor protein preproghrelin. Subsequent cleavage 
of this precursor protein produces ghrelin and obestatin. Ghrelin then undergoes acyl-
modification to produce a 28 amino acid ‘active’ acylated ghrelin. Des-acylated 
ghrelin is also thought to be either a precursor to acylated ghrelin or a product of 
deaclyation of acylated ghrelin 
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Subsequent cleavage of the pre-proghrelin precursor produces 2 main forms of ghrelin 
(figure 1.3). The first is a 28 amino acid with post-translational n-octanoylation of 
serine residue at position 3, which is known as acyl-ghrelin, also thought to be the 
‘biologically active’ isoform. The octanoylation of ghrelin is essential for binding to 
the GHSR-1a receptor to exert its biological activity  (Kojima et al. 1999). The 
second form of ghrelin produced is the des-[Gln14] formed from alternated splicing of 
the ghrelin gene (Hosoda et al. 2000), known as des-acyl ghrelin. This isoform of 
ghrelin may represent the product of deacylation of the acylated ghrelin or possibly a 
precursor to prior to acylation  (Kojima et al. 2005). When devoid of the 
octanoylation of serine3 at the N terminus, the biological activity of ghrelin is reduced 
by a factor of 2300  (Matsumoto et al. 2001). This form of ghrelin can also undergo 
octanoylation and become biologically active. Ghrelin has a short half life and 
vulnerable to degradation by circulating proteases. Hence it is recognized as a 
dynamic hormone in which circulating concentrations vary rapidly within minutes. 
The half life of total ghrelin is estimated to be 27-31 minutes and acylated ghrelin 9-
13 minutes (Akamizu et al. 2004).  
1.2.2. Ghrelin: The Receptor and Regulatory Mechanisms  
The ghrelin receptor, GHSR-1a, is widely expressed. This receptor for ghrelin is 
found in abundance in the arcuate nucleus of the hypothalamus (Howard et al. 1996b). 
This receptor is also widely expressed other various tissues e.g. Pancreas, 
myocardium, adipose tissue, kidney, liver, placenta and even lymphocytes  
(Gnanapavan et al. 2002). The distribution of this receptor suggests a wide range of 
possible activity and function of ghrelin, which is discussed later in this chapter.  
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A variant of this receptor, the GHSR-1b, arise from the same genetic locus. A study 
using a synthetic GH secretagogue MK0677 showed low affinity of the GH 
secretagogue for the GHSR1-b and failed to demonstrate the intracellular release of 
calcium in the COS-7 cells which over expresses the GHSR 1b cDNA  (Howard et al. 
1996a). This suggests that the GHSR-1b is a redundant receptor and currently thought 
to have no functional properties. It is accepted that the GHSR-1a is the predominant 
active ghrelin receptor, particularly in regulation of appetite and GH release.  
 
Ghrelin is regulated by many factors including hormonal, neural and local controls. 
Ghrelin has diverse physiological functions (see below) and as expected, there is 
usually a putative feedback mechanism that self regulates ghrelin release in many 
instances. This balance may in fact be crucial in normal physiological function. In 
disease states, the regulation of ghrelin release can be profoundly affected. Based on 
current evidence, it is still unclear if ghrelin is a major player in some pathological 
states or a small player in a complex repertoire of hormonal regulation. 
 
Ghrelin secretion can be influenced by dietary manipulation. Carbohydrate rich meals 
has been shown to decrease ghrelin secretion  (Shiiya et al. 2002) and this effect is 
proportional to the calorific load  (Callahan et al. 2004). Protein ingestion appears to 
increase plasma ghrelin, and this effect may be augmented by gastrin stimulation 
(Erdmann et al. 2003). In contrast, high fat meal decrease ghrelin secretion, probably 
because of high calorie load. However, lipid when infused intravenously did not 
influence ghrelin concentration (Mohlig et al. 2002). This suggests the stomach, via 
humoral and neural mechanisms, may regulate ghrelin secretion by macronutrient 
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intake locally. It is also possible that ghrelin secreting cells are capable of detecting 
high calorific substances on ingestion.  
 
Insulin has been implicated in regulating ghrelin release and it is shown to be 
inversely correlated to ghrelin  (Blom et al. 2005; Purnell et al. 2003). The association 
between insulin and ghrelin regulation has not been fully explained. Intravenously 
administered glucose and insulin did not alter ghrelin concentration significantly in 
healthy human subjects  (Caixas et al. 2002). However, a study has shown that insulin 
resistance, measured by HOMA-IR, is positively associated with acylated ghrelin, but 
negatively associated with desacylated ghrelin and total ghrelin in patients with 
metabolic syndrome. The investigators found that obesity with metabolic syndrome 
had lower total and desacylated ghrelin but comparable acylated ghrelin levels when 
compared to non-obese individuals. 
 
Obesity has been shown to alter the ghrelin profile. Obese individuals were found to 
have higher acylated to des-acylated ratio (Pacifico et al. 2009) and higher acylated 
ghrelin is associated with insulin resistance. In addition, glucagon and somatostatin 
appear to have a role in negatively influencing ghrelin secretion (Norrelund et al. 
2002; Arafat et al. 2006). An animal study have implicated glucagon in satiety and 
meal termination  (Le et al. 1993). It was postulated that ghrelin is most likely 
mechanism of which glucagon exert this effect.  The mechanism underlying the 
ghrelin regulation by glucagon is via the hypothalamic-pituitary axis.  Other appetite 
suppressing peptides e.g.  Peptide YY and oxyntomodulin have also been shown to 
decrease ghrelin concentrations (Batterham et al. 2003; Cohen et al. 2003). 
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Many factors may increase ghrelin concentrations apart from fasting. Acetylcholine 
has been demonstrated to increase ghrelin secretion in humans by direct stimulation of 
muscarinic receptors (Broglio et al. 2004). This relationship is also reciprocal in effect 
(see below). In a study of undernourished patients with anorexia nervosa, it was 
demonstrated that oestrogen and recombinant insulin growth factor 1(IGF-1) 
administration in these patients significantly increase ghrelin concentration  
(Grinspoon et al. 2004). 
 
Ghrelin secretion also has neural regulation. One study has demonstrated an increase 
in plasma ghrelin after truncal vagotomy  (Lee et al. 2002). This would be in keeping 
with neural control during the fasting state where vagal activity is decreased. This 
brain-gut neural axis influence is probably essential in initiating hunger. It has been 
reported that gastrin administration can synergistically increase ghrelin levels 
(Fukumoto et al. 2008) which results in increasing gastric acid secretion. However, 
this effect of acid secretion is abolished in vagotomised animals. This suggests that 
gastrin probably directly stimulates ghrelin secretion, and its effect on gastric acid 
secretion is regulated by a neural pathway. In addition, a study previously undertaken 
in this department has shown an increase in circulating ghrelin and intra-gastric 
acidity following Helicobacter Pylori eradication  (Nwokolo et al. 2003) with an 
observed non-significant decrease in gastrin concentration. The increase in gastric 
acid secretion by ghrelin may be influenced by neural regulation. 
 
16 
 
 
 
1.3 Ghrelin: Physiological Function and Therapeutic Use 
1.3.1 Appetite and Hunger 
Ghrelin is a potent orexigen. When infused into humans, ghrelin stimulates appetite 
initiates feeding without time or food related cues (Cummings et al. 2004). It has been 
shown that ghrelin increases food intake in animals (Asakawa et al. 2001) and 
humans (Wren et al. 2001). It is widely regarded as the only known circulating 
‘hunger hormone’ in intact mammals and is thought to play an important role in 
energy balance. A study on GHSR-1a knockout mice has shown that these mice loses 
its ability to respond to ghrelin (Chen et al. 2004), suggesting this receptor is crucial 
for the augmentation of hunger.   
 
Ghrelin has also been shown to stimulate the release of Neuropeptide-Y(NPY)  (Wren 
et al. 2002), the most powerful orexigen known, and also Agouti-related Peptide 
(AgRP) in the arcuate neurons of the hypothalamus  (Nakazato et al. 2001). The 
ability of ghrelin to stimulate hunger is eliminated in NPY/AgRP knockout mice, 
which reinforces the suggestion that it is the likely mechanism for the hunger 
stimulating effects of ghrelin  (Chen et al. 2004). There is evidence that ghrelin also 
acts peripherally to exert its orexigenic effects. In a rat study, gastric afferent 
vagotomy or vagal nerve block  appears to abolish the hunger effects of peripheral 
ghrelin administration (Date et al. 2002). Therefore, ghrelin has central and peripheral 
mechanisms in inducing hunger. 
 HungerTNFα
Afferent 
vagal signal
Circulating 
Ghrelin
Ghrelin to afferent 
vagal neuron terminals
↑POMC
↓AGRP
NPY
↑ AgRP
↑
Brain
Stomach
 
Figure 1.4 Ghrelin mechanism of hunger. Ghrelin can exert hunger effects via 
afferent vagus nervous system and circulating ghrelin can also act directly on the  
hypothalamus to induce secretion of  neuropeptide-Y (NPY), a potent orexigen, and 
also agouti-related peptide (AgRP). In contrast, circulating TNFα has an anorexigenic 
effect by inducing pro-opiomelanocortin (POMC) and also decreases expression of 
AgRP, diminishing hunger in presence of inflammation. It is not clear if TNFα has 
direct influences on ghrelin secretion. 
 
 
In humans, ghrelin concentrations are high pre-prandially and associated with a 
decrease post-prandially (Callahan et al. 2004; Cummings et al. 2001) which 
coincides well with the concept of ghrelin as a signal inducing hunger before meals. 
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The stomach is the first major organ to receive and store food; therefore, it seems 
appropriate that it has an important biological function as a control centre for appetite 
control and food intake.  Hence, the stomach has earned its role as an important 
endocrine organ contributing to the regulation of energy homeostasis in an intact 
animal.  
 
In obese individuals, the post-prandial decrease in ghrelin is blunted or abolished, 
suggesting a dysregulation of ghrelin in these individuals which may contribute to 
abnormal energy homeostasis (English et al. 2002). This has created much interest in 
the targeted signalling approach in treatment of obesity. 
 
As a hunger-stimulating hormone, ghrelin may have a role in the treatment of 
cachexia. For example, in rats with heart failure ghrelin treatment is associated with 
an increase in body mass with an increase in gastronemius muscle weight to bone 
ratio (Nagaya et al. 2001). This increase in body weight by ghrelin administration is 
probably GH-independent  (Tschop et al. 2000). Ghrelin is also known to have 
beneficial effects on cancer cachexia. A small randomised placebo- controlled human 
study on cachexia in cancer patients demonstrated an 31% increase  in energy intake 
following ghrelin infusion (Neary et al. 2004). In addition, a randomised placebo 
controlled study demonstrated that ghrelin has therapeutic potential in improving 
appetite and food intake in patients with post total gastrectomy cachexia  (Adachi et 
al. 2010).  
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1.3.1.1 Leptin, Ghrelin and obesity 
Leptin is a 16kDa hormone, which is a product of the obesity gene (OB) encoded in 
chromosome 7 (7q31.3). First identified in 1994  (Zhang et al. 1994), leptin was 
found in abundance in the adipose tissues, although other tissues e.g. Placenta, 
stomach and heart secrete smaller quantities  (Sobhani et al. 2000; Hoggard et al. 
2001; Green et al. 1995) . The primary secretors of leptin in animals are white adipose 
tissues. Leptin acts centrally, in part by crossing the blood brain barrier and the 
cerebrospinal fluid concentration appears to correlate with BMI  (Schwartz et al. 
1996c).  
 
The leptin receptor is encoded on chromosome 1 and widely expressed in the 
hypothalamus and cerebellum (Chung et al. 1996). Leptin is thought to have 
influences in both orexigenic (e.g. NPY and AgRP) and anorexigenic peptides (Pro-
opiomelanocortin, corticotrophin-releasing hormone and brain derived neurotrophic 
factor  (Sahu et al. 1998; Bariohay et al. 2005).  Leptin functions as a long term 
signalling peptide reflecting the energy stores, in particular body adiposity (Schwartz 
et al. 1996) and also functions as a long term mediator of energy balance. Therefore, 
an increase in BMI may result in an increase in circulating leptin concentration.  
 
In animal studies, leptin has been found to be an important hormone in decreasing 
food intake and regulating energy homeostasis (Halaas et al. 1995). In addition, leptin 
maintains weight, increases physical activity and resting metabolic state in animals.  
There have been implications on the interplay between ghrelin and leptin in obesity. It 
has been observed that obese individuals have high leptin and low ghrelin 
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concentrations, although the converse is expected  (Tschop et al. 2001; Lonnqvist et 
al. 1995). However, leptin treatment in obese individuals did not have the desired 
effect of weight loss  (Heymsfield et al. 1999; Hukshorn et al. 2000). Chronic 
treatment of leptin appears to decrease the hypothalamic sensitivity to leptin  (Sahu et 
al. 2002).  
 
Many authors conclude obese individuals are resistant to leptin.  In obese individuals 
lower CSF concentration of leptin is observed in comparison to plasma concentration 
(Schwartz et al. 1996) which suggests another altered regulating mechanism at the 
leptin transporter level. There is evidence that leptin resistance is demonstrated in 
peripheral but not central administration of leptin  (Van et al. 1997). This implicates 
that the blood brain barrier may act as a mechanism for insulin resistance. 
 
1.3.1.2 Leptin, Ghrelin and Inflammation 
The involvement of leptin in inflammation is poorly understood. The structure of 
leptin have a resemblance to the cytokine family  (Zhang et al. 1997) with a four helix 
bundle strikingly similar to the long-chain helical cytokines. The leptin receptor bears 
resemblance to the class 1 cytokine receptor family, and have signalling capabilities 
of the IL-6 receptor which are gp-130 related  (Baumann et al. 1996). It is possible 
that leptin has an immune regulatory function. Studies have shown that leptin levels 
are increased in presence of acute inflammation and infectious stimuli, in particular 
bacterial lipopolysaccharide and cytokines  (Grunfeld et al. 1996; Sarraf et al. 1997).  
Leptin has been shown to have a role in modulating macrophage phagocytosis and 
cytokine production  (Lee et al. 1999; Loffreda et al. 1998). In addition leptin also 
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modulates lymphocyte proliferation and sensitivity to pro-inflammatory stimulus 
(Faggioni et al. 1999; Howard et al. 1999). Leptin is classified as a cytokine because 
of its ability to influence the immune system and promote inflammation. 
 
Ghrelin on the other hand was initially thought to have a reciprocal relationship to 
leptin in regulating the immune system. This is unsurprising since ghrelin and leptin 
has opposing effects in the control of food intake and energy balance. The interplay 
between these two hormones may contribute to the regulation of the immune response 
to an inflammatory stimulus.  
 
The imbalance of the two hormones may drive or promote inflammation. A  study on 
haemodialysis patients with protein energy wasting have demonstrated low circulating 
ghrelin, high leptin and CRP levels in these patients  (Carrero et al. 2010). This would 
support the conclusion that inflammation may be associated with the imbalance of 
both these hormones. In contrary, there is evidence that modulating inflammation may 
not affect either ghrelin or leptin concentrations significantly  (Gonzalez-Gay et al. 
2009). The role of ghrelin and leptin in inflammation may be disease specific or 
perhaps related to adiposity and energy balance as a primary function. Further studies 
are needed to establish the relationship between ghrelin, leptin and inflammation, 
including trial therapy with ghrelin may shed some light into its potential as a 
therapeutic target 
. 
 
 
22 
 
1.3.2 Endocrine function 
1.3.2.1 Growth Hormone Release 
Although ghrelin was initially discovered as a a growth hormone secretagogue, its 
physiological role is still undetermined despite being potent stimulator of growth 
hormone release in humans (Arvat et al. 2000). Ghrelin is not known to be important 
in the physiological regulation of GH secretion, as ghrelin-null mice are not growth 
impaired (Sun et al. 2003).  In addition, normal physiological release of GH is 
unaffected by the absence of ghrelin. Ghrelin appears to regulate the pulsatile release 
of GH (Sun et al. 2004),  and it is possible that ghrelin may somewhat regulate 
anabolic metabolism although the physiological effects of this is still unclear. Ghrelin-
induced GH secretion is shown to be unrelated to IGF-1 influences, which may 
differentiate it from GHRH-mediated GH secretion  (Goodyear et al. 2010).  
 
It has been reported that ghrelin administration in animals can possibly reverse certain 
characteristics of aging, particularly improving food intake, body weight and 
maintaining low adiposity  (Ariyasu et al. 2008). These effects presumably related to 
GH secretion by ghrelin as GH increases protein anabolism and adipose utilisation. 
Ghrelin is also shown to decrease adipose utilisation quite the opposing effect to that 
of GH. Perhaps this is beneficial in the physiological sense to maintain body 
adiposity. In addition exogenous GH administration appear to decrease ghrelin 
secretion which suggest a feedback mechanism of self regulation (Eden et al. 2003). 
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1.3.2.2 Other Endocrine Effects 
Apart from regulating the release of GH, ghrelin is also known to have other 
endocrine actions. For example, growth hormone secretagogue has been shown to 
have stimulatory effects on the hypothalamic-pituitary-adrenal axis. The postulated 
mechanism via the arginine-vasopressin release rather than the corticotrophin-
releasing hormone stimulation (Korbonits et al. 1999).  
 
In a human study, ghrelin induces a gender independent release of prolactin, ACTH 
(adreno-corticotrophin hormone) and cortisol. Ghrelin also decreases insulin and 
increase glucose levels, which are independent of both age and gender. Glucagon 
levels were unaffected by ghrelin administration (Broglio et al. 2003). Therefore, 
ghrelin may act directly on the hepatic glycogenolysis rather than the pancreas. These 
findings are interesting which adds to the wider activity and function of ghrelin, 
which the clinical significance is still yet to be explored. 
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1.3.3 Gastrointestinal Tract 
1.3.3.1 Gastric acid secretion 
The reported effects of ghrelin on gastric acid secretion on animals are conflicting 
(Takayama et al. 2007; Sibilia et al. 2002). Under normal physiological conditions, 
gastric acid secretion is initiated by the release of gastrin usually after a meal which in 
turn stimulates the release of histamine by enterochromaffin-like cells (ECL). This 
then stimulates the parietal cells in the stomach to produce acid. There are also vagal 
influences on the parietal and ECL cells exerting further control of acid secretion.  
 
In a study on rats, ghrelin appear to have little effect on the activation of G-cells nor 
ECL cells when administered subcutaneously to an animal. However, it is believed 
that ghrelin, when administered intravenously can increase gastric acid secretion via 
vagal pathways (Masuda et al. 2000).This is consistent with evidence that sight and 
smell of food induces gastric acid secretion (Feldman et al. 1986) and ghrelin may be 
part of this mechanism. Ghrelin has been also shown be increased up to 75% 
following the successful eradication of Helicobacter Pylori, a bacterium capable of 
surviving in an acidic environment of the stomach.  This effect appears to increase 
intragastric acidity by 14% (Nwokolo et al. 2003). It was postulated that this rise in 
ghrelin may increase appetite and food intake, and possibly have contributed to the 
rise in obesity in the developed world. This may in turn explain the rise in incidence 
of gastro-oesophageal reflux disease (GORD) and in turn may be associated with an 
observed increase in incidence of oesophageal cancers in western countries. 
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1.3.3.2 Gastrointestinal Motility 
Ghrelin is capable of regulating gastrointestinal motility. In animal studies, ghrelin 
promotes gastric contractility and postulated to act via vagal innervations (Masuda et 
al. 2000). Similarly, it has been shown to stimulate small intestinal motility. This 
action was inhibited by atropine, which suggests it acts locally via the cholinergic 
innervation at the neuromuscular level  (Edholm et al. 2004). 
 There has been much interest in the pro-motility therapeutic potential of ghrelin. 
Ghrelin has been shown to alleviate gastroparesis in animals (Trudel et al. 2002) and 
humans (Tack et al. 2005). The therapeutic potential of ghrelin was soon realised. A 
pilot randomised placebo controlled study had demonstrated that ghrelin infusion 
improves gastric emptying in diabetic gastroparesis (Murray et al. 2005).  
 
The other most obvious therapeutic application would be related to post-operative 
patients where ileus is a common complication. Ghrelin has been shown to be an  
effective pro-motility agent in post-operative animal models with ileus  (Poitras et al. 
2005; Trudel et al. 2003). This warrants further human studies on the efficacy of 
ghrelin in post-operative ileus.    Another application of ghrelin as a pro-motility agent 
is in cancer associated symptoms of gastroparesis. It has been demonstrated in rodents 
that ghrelin alleviates the cancer chemotherapy associated dyspepsia (Liu et al. 
2006b). This will be discussed in detail in Chapter 4 of this thesis. 
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1.3.4 Cardiovascular Effects 
Ghrelin receptors has been shown to be expressed in cardiac tissues in animals 
(Bodart et al. 1999) and humans (Muccioli et al. 2000). In an animal study, 
administration of ghrelin resulted in a significant vascular vasodilatory effects 
(Okumura et al. 2002). This is consistent with a human study where healthy 
volunteers showed a significant decrease in mean arterial blood pressure when 
administered with ghrelin (Nagaya et al. 2001a) . 
 
 Ghrelin is also shown to increase cardiac output and also improve cardiac cachexia 
associated with heart failure (Nagaya et al. 2003). Therefore, ghrelin may not only 
exerts protective effects on the cardiovascular system but be beneficial in reversing 
cachexia in chronic heart failure. It is possible that some of this effect may be related 
to GH secretion, but the side effects of fluid retention and heart failure by GH may be 
counteracted by effects of ghrelin on the heart. This warrants further clinical studies. 
 
1.3.5 Immunity and inflammation 
Appetite control and energy homeostasis is a well studied function of ghrelin. More 
recently, there is emerging evidence that ghrelin may have some immune-modulatory 
function. The discovery of GHSR receptors in human immune cell lines suggests that 
ghrelin may play a role in the function or activity of human lymphocytes (Hattori et 
al. 2001).  
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This has created much speculation to the exact role of ghrelin in the immune system. 
Subsequent study has demonstrated that ghrelin dosing of activated primary human 
immune cells, in particular T-cells and monocytes, decreases the production of pro-
inflammatory cytokines in human monocytes and lymphocytes, namely TNFα, IL-1β 
and IL-6. This appear to be reciprocal to that of leptin (Dixit et al. 2004).  
 
In an animal study, ghrelin has been demonstrated to attenuate pancreatic damage 
induced by caerulin in rats possibly by suppressing the production of pro-
inflammatory IL-1β cytokine (Dembinski et al. 2003). In endotoxaemia induced by 
bacterial LPS (lipopolysaccharide), ghrelin  proved to be beneficial in reducing 
mortality and alleviates hypotension related to sepsis (Chang et al. 2003). Ghrelin has 
also been demonstrated to be protective in ethanol induced gastric ulceration (Sibilia 
et al. 2003; Brzozowski et al. 2004; Konturek et al. 2004).  
 
In addition, ghrelin agonists have been shown to improve experimentally induced 
inflammatory arthritis presumably by suppressing the production of IL-6 (Granado et 
al. 2005). Further in vitro studies on human endothelial cells suggest that ghrelin may 
suppress TNFα-induced pro-inflammatory cytokine production. This may, in part, 
play an important role in the development of atherosclerotic disease in obese patients, 
where ghrelin levels are reduced (Li et al. 2004).  
 
In patients with metabolic syndrome, which encompasses a spectrum of clinical 
conditions including hyperlipidaemia, hypertension, obesity and type 2 diabetes, the 
development of insulin resistance is thought to be related to a pro-inflammatory 
process. A previous study has demonstrated that patients with NASH have lower 
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acylated ghrelin concentration compared to controls, due to dysregulation of ghrelin, 
which may provide a pro-inflammatory environment for progressive liver damage. In 
addition, the prevalence of small intestinal bacterial overgrowth in NASH patients 
may facilitate the production of significant endogenous ethanol causing further 
damage to the liver  (Sajjad et al. 2005). 
 
There is a recent suggestion that caloric restriction can prolong lifespan by delaying 
age-onset disease, improving stress resistance and reduce functional decline over time 
(Ingram et al. 2004). Intermittent fasting in an intact animal is shown to have 
beneficial in glucose regulation and also protects against neuronal injury (Anson et al. 
2003). As fasting is associated with an increase in circulating ghrelin and a decrease 
in leptin, it is possible that in a fasting state these changes may have anti-
inflammatory properties that may, in turn, be life-prolonging (Dixit et al. 2005).  This 
certainly warrants further investigation. 
  
As previously described, ghrelin administration has a beneficial effect on the cardiac 
function in patients with chronic heart failure. A recent animal study in rats post 
myocardial infarction has suggested that the beneficial effects of ghrelin may be 
mediated by the anti-inflammatory effects of ghrelin. This includes attenuation of 
TNFα and IL-1β , with a reduction of matrix metalloproteinase expression, such as 
MMP-2 and MMP-9, which leads to improved cardiac remodelling, decreased 
ventricular dilatation with decreased cardiac cell apoptosis and limits cardiac scar 
thickness (Huang et al. 2009).  
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If ghrelin has an immune-modulatory role, it is possible that circulating ghrelin 
concentration may change when cytokine profile is altered in chronic inflammatory 
conditions since there is now evidence that ghrelin may in some way influence 
immune activity and inflammation. It would be desirable to observe the consequence 
to ghrelin once inflammation is subdued. A hypothesis that modulating an 
inflammatory condition may alter circulating plasma ghrelin was developed and 
investigated as part of this thesis. 
1.4 Aims of this Thesis  
This department has previous experience in studying ghrelin and its dynamics  
(Goodyear et al. 2010; Goodyear et al. 2010; Mottershead et al. 2007; Nwokolo et al. 
2003; Sajjad et al. 2005) . This has been invaluable in the conceptualisation of study 
design in this thesis, particularly in profiling of ghrelin and data analysis. This thesis 
primarily investigates the effects of ghrelin on immune system and gastrointestinal 
motility.  
 
This thesis has the following aims: 
 
• To investigate the consequence of modulating inflammation on the ghrelin 
profile in patients with Crohn’s disease. 
Crohn’s disease a chronic inflammatory bowel disease that can affect the 
entire luminal gastrointestinal tract. This study investigates the profile of 
ghrelin in patients with Crohn’s disease before and after administration of anti 
TNFα therapy. 
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• To investigate the effects of ghrelin dosing on NFκB activation and 
cytokine production in human lymphocyte cells lines.  
Recent studies on primary human lymphocytes suggest that ghrelin attenuates 
the release of pro-inflammatory cytokines and exerts its anti-inflammatory 
properties at cellular level. In B-cells, NFκB acts as a gene enhancer for κ light 
chain and also crucial in the development and maturation of B-cell (Sha et al. 
1995b) .  It also has a pivotal role in driving and coordinating the innate and 
adaptive immune response to an antigen (Bonizzi et al. 2004a).  This 
experiment will explore the effects of ghrelin and a ghrelin agonist on NFκB 
in a lymphocyte cell loine, which will provide some insight into the function 
of ghrelin and the immune system, upstream from cytokine production. 
 
• To investigate the effects of cancer chemotherapy on motility gastric 
neurotransmitters and gastric smooth muscle contractility.  
It is evident that a cancer chemotherapy regime can induce gastric dysmotility 
in animal studies. This may lead to symptoms that resemble dyspepsia, 
frequently experienced by these patients following treatment. This experiment 
compares the gastric contractility and neurotransmitter expression in 
chemotherapy exposed and non-chemotherapy exposed gastric tissues.  
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Chapter 2 
Research Methodology 
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This chapter will outline and describe the general experimental methods and materials 
used in this thesis. Information on specific methods for each experiment will be 
discussed in the appropriate chapters. 
 
2.1 Patient recruitment: Ghrelin in Crohn’s disease 
 
Patients with Crohn’s disease were recruited from the hospital database on patients 
scheduled to receive infliximab therapy. Patients were contacted prior to their 
scheduled infliximab treatment and outline of the study was conveyed. All patients 
receiving infliximab therapy were included in this study. Patients with previous 
gastric surgery were excluded, as the stomach is the predominant ghrelin producer and 
can affect the physiological profile. In addition, patients with ulcerative colitis or 
indeterminate colitis receiving infliximab therapy were also excluded. 
 
2.1.2 Experimental protocol 
Each patient was studied on two occasions, immediately before and 1 week after an 
infusion of infliximab (5 mg⁄ kg). All studies were started between 08:00 and10:00 h. 
All patients were fasted overnight and on arrival consent was obtained. An 18 G 
cannula port-free was inserted into a vein in the forearm. A needle free port 
(SmartSite needle free injection port, Alaris Medical Cat: 2000E) was attached to 
cannula to enable blood sampling without the need for repeated venopuncture. Blood 
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samples were collected in a lithium heparin tube (BD Vaccutainer Cat: 367880, BD, 
NJ, USA) and also in a spray coated silica tube with polymer gel separation (BD 
Vaccutaner SST Cat: 367986, BD, NJ USA) to collect serum equivalent samples. All 
blood tubes were added with 20 U⁄mL of aprotonin (Trasylol, Bayer Healthcare, NJ, 
USA). Aprotinin is a 58 amino acid bovine lung derived protease inhibitor. It binds to 
active sites of proteases and forms stable complexes. In this study, it provides 
protection against the breakdown of ghrelin by inhibiting protease enzymes. 
 
Firstly, an initial fasting blood sample was taken. This is followed by consumption of 
a 450 cal meal consisting of a cereal bar, a slice of buttered toast, a glass of orange 
juice (250 mL) and a cup of tea with milk (180 mL). Minor variations to this diet was 
allowed e.g. for dairy intolerance, omission of butter or food dislikes, coffee rather 
than tea. However, an identical meal was consumed in the second study occasion.  
 
After the meal is consumed, further blood samples were taken every 20 minutes for 2 
hours. During this time, data was collected on the patients’ weight, height, site of 
disease and concurrent drug treatment. Once this was completed, the patients 
proceeded to receive their infliximab therapy. In exactly 1 week, an identical study 
was conducted without the infliximab infusion. In five patients, the study conducted 
in reverse order i.e. A study ‘1 week after’ infliximab was performed first followed by 
the ‘immediately before’ study performed just before the next infusion, usually 7 
weeks later. This excludes any effects that could be attributed to the order in which 
the studies were conducted.  
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Blood samples collected were centrifuged immediately (2000 rpm for 15 minutes for 
plasma, 3000 rpm for 10 minutes for serum), plasma extracted and stored at -80oC for 
later analysis. This was later used for assays were performed for plasma total ghrelin, 
acylated ghrelin, desacyl ghrelin, C-reactive protein and a panel of cytokines. Total, 
acylated and desacylated ghrelin were assayed using commercially available ELISA 
based kits. In this experiment, plasma samples were compatible with the commercial 
assays available. Initial experiments with serum samples did not reveal significant 
differences in the results when either plasma or serum samples were used. All 
commercially available assay kits were compatible with use of plasma samples. 
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Figure 2.1. Schematic diagram of the blood sampling protocol. After an 
overnight fast, an initial blood sample of taken at t=0 followed by ingestion of a 
450Cal meal. Blood is then sampled every 20 minutes followed by infusion of 
infliximab. In the next visit, this is repeated without the infusion. Some patients 
are studied in reverse order. 
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2.1.3 Principles of Enzyme Immunoassays  
The enzyme immunoassays are based on a double-antibody sandwich system. The 
commercially available EIA kits comprise usually of antibody coated wells on a plate 
specifically to the antigen in question e.g. Ghrelin. The antibody binds to the antigen 
when samples were introduced to the wells. A secondary antibody with an attached 
enzyme (usually a peroxidase or alkaline phosphatase) is then introduced to these 
wells, which then binds to the primary antibody to the antigen. 
 
Following an incubation period, excess secondary antibody is removed by another 
series of washes. Finally, an addition of an enzyme substrate will then colour the 
wells. When the reaction is complete, the intensity of the colour is analysed using a 
plate reader. The optical density, which reflects the colour intensity, is proportional to 
the amount of primary antibody-antigen complex in each well. The EIA kits also 
contain controls and samples of known varying quantities of the antigen. Using the 
optical densities of the ‘known’ samples, a standard curve is then generated. Using 
this curve, specific quantification of the antigen in unknown samples can be 
determined. All enzyme immunoassays performed in this thesis were assayed in 
duplicates. 
2.1.4 Principles of Multiplex Assay 
Multiplex assays techniques allow the measurement of multiple analytes efficiently 
from a small sample. This utilizes the colour-coded beads which are coated for the 
analyte specific primary antibody. Detection of the analyte is then made possible 
using the antibody-antigen sandwich, similar to the enzyme immunoassays that 
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measure a single analyte. Expression levels are determined following incubation with 
a biotinylated detection antibody and streptavidin-conjugated phycoerythrin (PE). 
Using a laser analyser, the colour of each bead is detected and the magnitude of the 
phycoerythrin signal is determined. This is proportional to the quantity of analyte in 
the sample. 
 
2.2 Lymphocyte Cell Line Experiment 
2.2.1 Lymphocyte cell-line selection 
Four lymphocyte cell lines were selected for experimental use: 2 B-lymphocyte 
(WILCL, ECACC Cat: 89120565; DAUDI, ECACC: Cat: 85011437) and 2 T-
lymphocyte (JM, ECACC Cat: 86010201; HUT-78, ECACC Cat: 88041901). 
All lymphocyte cell lines were cultured in accordance to previously described 
methods unless specified otherwise. Specific requirements for individual cell lines 
described were in accordance to methods recommended by the commercial supplier. 
 
2.2.1.1 WILCL (Normal B-Lymphocyte) 
 
WILCL is a normal caucasian human B cell line of a patient with a lung tumour. 
Morphologically it is a lymphoblast, and commercial karyotype analysis of this particular cell 
line was normal. WILCL is cultured  in media containing RPMI 1640 + 2mM Glutamine + 
10% Foetal Bovine Serum (FBS).  
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2.2.1.2 JM cell line 
JM is a human T-cell lymphoblast cell line. Cells were cultured in RPMI 1640 
enriched with 2mM Glutamine + 10% Foetal Bovine Serum.   
 
2.2.1.3 Hut 78 
Hut 78 is a T-cell lymphoma cell line derived from a 50 year old male with Sezary 
syndrome. This cell line has characteristics of a mature T-cell line with an inducer and 
helper phenotype. An established product of this cell line is Interleukin-2  
(Gootenberg et al. 1981) 
 
2.2.1.4 DAUDI 
DAUDI is a human Burkitt’s B-cell lymphoma cell line. It is derived from a 16 year 
old black male. Positive for EBNA, carries EBV markers, complement receptors, 
surface bound immunoglobulin and surface markers for the Fc fragment of IgG  
(Klein et al. 1968; Klein et al. 1967; Nilsson et al. 1977).  Media requirement are 
RPMI 1640 + 2mM Glutamine + 10% FBS.  
 
2.2.2 Cell culture methods 
2.2.2.1 General lymphocyte cell line resuscitation 
Cell line resuscitation and culture procedures and protocols provided by the 
commercial distributor ECACC (European Collection of Cell Cultures) were 
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followed, including specific media requirements for each cell line described further in 
the chapter. 
 
All cell line work was performed in level 2 microbiology safety cabinets. On every 
occasion the cabinets were sterilised using 70% alcohol to prevent contamination of 
cell culture. Protective face masks and sterile gloves were used for protection. 
Prepared media was pre-warmed in the water bath prior to every cell line procedure 
for 30 minutes. On receipt of the cell line ampoule, it is then transferred immediately 
and slowly swirled a water bath but not immersed at 37°C.  
 
Once thawed, the ampoule was cleaned using 70% alcohol. The ampoule was then 
centrifuged and the cryoprotectant was removed by pipette. 1 ml of freshly prepared 
warm media was introduced and mixed well with the collected cells. The contents of 
the ampoule are then transferred to fresh media in a 25cm2 Greiner® culture flask 
containing 8mls of media. The cells were incubated in an environment of 5% CO2 at 
37°C. Once cell proliferation is established, the cells are then sub-cultured in larger 
50cm2 Greiner® culture flasks maintaining cell culture density of 3 X 106.  
Penicillin/streptomycin was added to all cell culture medium for antimicrobial 
protection. 
 
2.2.2.2 Assessment of cell viability 
Cell viability was assessed using tryphan blue by dye exclusion. A 0.5mls of 
homogenised sample of cells is then collected and 0.1mls of 0.4% tryphan blue 
(Sigma Aldrich Cat. No.  T8154, Dorset, UK) added. The sample was then vortexed 
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and a small sample transferred to a haemacytometer. Observed under a microscope, 
viable cells do not take up staining, hence excluded from staining whereas non-viable 
cells take up dye and stained blue. 
2.2.2.3 Cell count and quantification 
Cell count is useful to ensure optimum cell density is achieved to keep cells healthy. 
For all cells, cell density was maintained at 3 X 106 in culture. It is also useful in 
assessment of cell viability.  Firstly, cells were collected from the flasks and 
centrifuged in a 50ml falcon flask. 10mls of fresh media was then added and cells 
were mixed well using a pipette. A small aliquot of the homogenised sample was 
taken and used for cell counting. A 10µl sample was extracted and used to fill a 
chamber in the bright line haemocytometer (Sigma-Aldrich, cat, no. Z359629, Dorset, 
UK) with cover slips.  
 
The haemocytometer was viewed under a light microscope and the number of cells in 
four of the 1mm X 1mm squares were counted. The following formula was then used 
to estimate cell concentration: [Total number of cells(y) X dilution (10mls)]÷ 4 = y 
X104, hence concentration would be 0.0yX106. The amount of media that needs to be 
added to the original 10ml cell suspension to obtain optimum cell density can be 
estimated.  
Similarly, for estimating percentage of viable cells using tryphan blue, percentage 
viable cells are calculated using the following formula: 
 (Total no. of viable cells ÷ Total no. of cells) X 100. 
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2.2.2.4 Cell subculture 
Initially cells were extracted, counted and resuspended in appropriate media volume 
to a cell density of 1X106 (as described in 2.7). The cell suspension was then 
transferred to a 50cm2 Greiner® culture flasks and incubated in an environment of 5% 
CO2 at 37°C with the flask lying flat. A small sample from each flask is usually 
inspected under a microscope every 1-2 days to ensure the morphology appearances 
of cells are healthy. Every third day, the cells were again collected, counted, and 
resuspended in a calculated volume of media to cell density of 1 X106 and allowed to 
proliferate.  Cells were inspected regularly using light microscopy to ensure intact 
morphology and healthy proliferation. On rare occasions, bacterial contamination can 
be seen as well. If detected the flask of cells were discarded. 
 
2.2.2.5 Cell cryopreservation 
Cryopreservation of cells was required to maintain a supply of cells in event of culture 
failure that are unforeseen. This is achieved using a freeze medium which contains 
70% cell medium, 20% foetal bovine serum and 10% DMSO (dimethyl sulfoxide, 
Sigma-Aldrich, cat. No. C6164, Dorset, UK). Following successful cell proliferation 
and subcultures, cells were collected by centrifuge (150g for 5 minutes) and 
resuspended in pre-prepared freeze medium with cell density of 3 X 106. 1ml aliquots 
of cells were transferred to ampoules transferred to a -20°C freezer for 4 hours then 
transferred to a -80°C freezer overnight. On the following day, the ampoules were 
then transferred to liquid nitrogen for storage. Approximately 3-5days later, an 
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ampoule of cells were retrieved, resuscitated and resuspended in media to assess 
viability. 
 
 
2.2.3 Compounds used in cell culture treatment  
2.2.3.1 Ghrelin and Analogues 
3 different compounds were tested on the cell lines : Octanoyl ghrelin (Phoenix, CA, 
USA; Cat. 031-39), des-octanoyl Ghrelin (Phoenix, CA,USA; Cat. 031-32) and a non-
peptide ghrelin agonist (Pfizer CP-464709). The ghrelin agonist was provided by our 
collaborators at GlaxoSmithKline as part of our shared experimental interest in 
motility work. The compound CP-464709 has previously been studied in animals and 
demonstrated to have prokinetic properties in fed animals with moderate enhanced 
motility stimulation in the gastric antrum  (Komada T et al. 2008). This compound 
has also been shown to induce colonic propulsion and defecation in intact rats when 
administered centrally into the spinal cord (Shimizu et al. 2006). In contrast, previous 
animal studies have shown that ghrelin administered peripherally did not produce 
significant colonic peristalsis  (Ohno et al. 2010). This suggests that ghrelin may not 
cross the blood brain barrier significantly to induce such an effect.  
2.2.3.2 Phytohemagluttinin (PHA) 
Phytohemagluttinin (Cat. No. L1668, Sigma, UK) is a lectin derived from mainly 
from plants. It is found in high concentrations in red kidney beans, which are toxic to 
humans in its raw form if ingested. It is potent mitogen in lymphocytes, inducing cell 
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division and proliferation. In this study, it is used as a lymphocyte activator, in 
particular to artificially induce the NFκB machinery. This allows the study of the 
effects of NFκB activation by different compounds on activated and non-activated 
cells. In powder form, it is diluted in 5 mls of PBS for cell treatment use. Pokeweed 
(phytolacca americana, another source of lectin) was used in isolation as control for 
NFκB activation did not show significant difference in NFκB activation compared to 
PHA in these cell lines. 
 
2.2.4 Cell treatment methods 
Cells cultured in flasks were centrifuged (150g for 10 minutes) and resuspended in 
fresh media. Following this, cells were resuspended in 10mls of fresh media and 
homogenised. Cell count was performed and a calculated amount of fresh media was 
added to dilute to the required cell density of 1 x 106/ml. Subsequently, 1ml 
containing 1 X 106 cells was added to each well of a 6-well culture plate.  Initial 
experiments were conducted to determine the optimal concentration of PHA for these 
cells. Cell viability was determined at 6 and 24 hour following dosing with PHA at 
5µg/ml, 0.5µg/ml and 0.05µg/ml concentrations and compared to controls. 0.5 µg/ml 
appears optimal without excessive toxicity. 
 
The cells were then re-cultured, collected, diluted and added to the 6-well culture 
plates as described above. 0.5 µg/ml of PHA was added to half the wells as ‘activated’ 
cells. Phytohemagluttinin (PHA) was used for lymphocyte activation. The optimal 
concentration of PHA was estimated using tryphan blue staining for cell viability. 
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PHA concentration of 0.5µg/ml was optimal for WILCL cell activation. We assessed 
the effect of the compounds on activated and resting cells. 
 
To assess the effect of ghrelin isoforms and a non-peptide ghrelin agonist on the cell 
line, each treated well was compared to control wells with no additions. A screening 
experiment (n=3) using time points of 6, 24 and 48 hours were performed using 
octanoyl ghrelin on resting and activated cells. A response was detected at 6 hours to 
PHA activation and octanoyl ghrelin. In all subsequent experiments 6 hours 
incubation duration was applied.  
 
 Octanoyl-ghrelin, des-octanoyl ghrelin and the ghrelin agonist was added to the wells 
to make up concentrations of 1nM, 10nM and 100nM. . These compounds were added 
to the wells with resting and PHA activated cells to make up concentrations of control 
cells (no addition), 1nM, 10nM and 100nM. For the ghrelin receptor agonist and 
desoctanoyl ghrelin that are not natural ligands of the ghrelin receptor, we widened 
the concentration range to include 0.1nM and 1000nM. The culture plates were then 
incubated in an environment of 5% CO2 at temperatures of 37oC. The cells were then 
washed, collected and frozen to -80oC. The cell pellets were later lysed and protein 
content were extracted and quantified. 
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2.2.5 Cell preparation and protein extraction 
2.2.5.1 Cell lysis and protein extraction 
Cell lysis and protein solubilisation was achieved with RIPA (Radio-Immuno 
precipitation Assay) buffer (Cat. No. R0278, Sigma-Aldrich, UK) containing 50 mM 
Tris-HCl, pH 8.0, with 150 mM sodium chloride,1.0% Igepal CA-630 (NP-40), 0.5% 
sodium deoxycholate, and 0.1% sodium dodecyl sulphate. Cells were collected from 
each well, centrifuged, washed 3 times with PBS and collected. Subsequently 200µL 
of RIPA buffer was added to the cell pellet. With gentle pipetting, the cells were 
mixed well with the RIPA buffer which promoted mechanical and chemical lysis. The 
mixture is then left to incubate on ice for 5 minutes. Finally, the mixture is centrifuged 
and the supernatant RIPA buffer containing the solubilised cellular protein is 
extracted and frozen to -80oC for later analysis. Remaining cell debris is discarded. 
 
2.2.5.2 Protein quantification 
To determine the protein quantification extracted from cells the Bio Rad DC protein 
assay kit (Bio Rad Laboratories, Ca, USA) was used.  This kit comprises of 3 
reagents: REAGENT A, an alkaline copper tartrate solution; REAGENT B, a dilute 
Folin Reagent 5 and REAGENT S, a surfactant containing solution. Initially, 20µL of 
Reagent S was mixed well with 980µL of Reagent in a curvette, a glass test tube 
(Startstedt, Numbrecht, Germany). 5µL of protein containing RIPA buffer was added 
to this mixture. In addition, 1ml of Reagent B was added to each curvette gently 
swirled to mix well. The mixture is then incubated at room temperature for 15 
minutes.  
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Bovine serum albumin (First Link LTD, UK) was used to make up known 
concentrations of protein which is then used create a standard curve in which 
concentrations of protein in unknown can be determined.  0.01g of BSA was 
dissolved in 1ml of PBS and serial dilutions were then performed and the same 
protein quantification kit described above is used.  
 
Using a spectrophotometer (6505 UV, Jenway, UK), the absorbance of the BSA 
samples were determined and a standard curve was generated. Following this, 
absorbance of each sample was measured, plotted on the standard curve and the 
protein quantity determined. 
  
2.2.6 Detection of cellular ghrelin receptors  
2.2.6.1 General principles of western blot 
Western blot is an immunoassay-based technique that allows identification and 
quantification of specific proteins. In this thsis, it is used to detect the presence of both 
ghrelin receptors, GHSR-1A and 1B in all four cell lines. Proteins contained in 
cellular extracts undergo electrophoresis through a gel under electrical stimulation. 
Proteins was separated according to the molecular weight in this manner. The product 
of the electrophoresis was then transferred to a nitrocellulose membrane. Specific 
antibodies were used to bind to the protein of interest and visualised using an 
chemiluminescent system. Detailed methodology are described below 
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2.2.6.2 Preparation of samples. 
Cell line protein extracts were thawed and vortexed. Volume of samples containing 
20µg of protein was calculated. These samples were then transferred to appendorfs 
and 10 µL loading buffer was added. Finally, dH2O was added up to standardised 
volume for all the samples. To identify the protein of interest, a rainbow molecular 
weight marker (Amersham Cat: RPN800 (10,000-250,000 kDa), Amersham 
Biosciences, UK), was used. Following electrophoresis, the rainbow marker will 
allow identification of a range of proteins with different molecular weights using a 
colour coded molecular weight spectrum following electrophoresis. The sample 
mixture was heated at 95oC to denaturise the protein. 
 
 
2.2.6.3 Western blot set up and electrophoresis 
Gels were prepared using an apparatus according to manufacturers’ instructions. This 
consists of 2 sheets of glass, a glass holder with clamp and a comb which created the 
wells for sample introduction.  The two glass plates were slotted in to the apparatus on 
to a foam bed and clamped. Water tightness is tested using dH2O. Resolving gel (see 
table 2.2.6.3) was the added between the glass plates until it is ¾ height of the smaller 
plate. dH2O was added on top to prevent formation of bubbles within the gel. This 
was then left to set for 30 minutes at room temperature.  
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Following this, the dH2O on the top layer was expelled leaving the set resolving gel. 
Stacking gel (see table 2.2.6.3) is then added above the resolving gel. Wells were 
formed by inserting a 1.5mm thickness comb with 10 teeth. Air bubble formation was 
prevented by inserting the comb at an angle. During the time taken to set, any 
shrinkage of gel leaving air spaces was replaced by added gel using a hypodermic 
needle and syringe. Once set, the comb was removed vertically with care.  
 
The gel formed between the glass sheets are immersed in a tank containing electrode 
buffer. In the tank, it was separated into 2 different compartments, a central 
compartment containing the gel and a peripheral compartment containing electrode 
buffer, which was added. Compartmenting in this manner will then allow completion 
of an electrical circuit through the buffer for electrophoresis. Samples were then 
added to the wells carefully and all air bubbles expelled. Electrophoresis was 
performed at 150v until the blue protein front has run of the bottom of the gel. 
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10%Resolving Gel 
(Reagents) 
Quantity added  
Protogel 6.6mls 
Protogel resolving buffer 5.2mls 
dH2O 7.8mls 
Ammonium persulphate 200μL 
TEMED 20μL 
  
Stacking Gel 
(Reagents) 
 
Protogel 1.3mls 
Protogel stacking buffer 2.5mls 
dH2O 6.1mls 
Ammonium persulphate 50μL 
TEMED 10μL 
 
Table 2.2.6.3 Composition of 10% resolving and stacking gel used for Western 
Blot experiments 
 2.2.6.4 Eletrophoretic Transfer to Membrane (Blotting) 
For electrophoretic transfer, Immobilon-P PVDF membranes (Millipore, Bedford, 
USA) was transiently immersed in 100% methanol. The membranes were then briefly 
washed with distilled H2O and soaked in transfer buffer for 5 minutes. The gel 
containing resolved proteins were carefully separated from the glass sheets and the 
stacking gel was discarded. Gels were then immersed in transfer buffer for 10 minutes 
at room temperature. 2 sets of fibre and filter papers were immersed in transfer buffer 
in preparation for use.  
 
Following this, a fibre pad was layered with filter paper and doused with transfer 
buffer on a transfer casing. The gel was then placed with the protein side facing up. 
The Immobilon-P membrane was then layered over the gel. Any bubbles formed 
between the membrane and gel was removed by adding transfer buffer. A further 
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layer of filter and fibre pad was added. The sandwich is the doused with further 
transfer buffer. The casing was then sealed and transferred to a tank, filled to the top 
with transfer buffer. An ice pack was added to keep the tank cool and a magnetic flea 
placed at the bottom of the tank to circulate the transfer buffer. The apparatus was 
connected to an electrical circuit at 100v and placed on top of a magnetic stirrer in a 
cold room for 1 hour. 
 
Upon completion of transfer, the casing and the layers of filter and fibre pads were 
removed, carefully extracting the membrane from the gel. The membrane was then 
washed in a solution of 10% milk solution (10g milk powder, 50mls PBS and 50mls 
PBS-Tween) on an orbital shaker for 1 hour to minimise non-specific background 
protein binding. Following this, the membranes were washed 3 times with PBS and 
once with PBS-tween. This wash process was repeated twice. 
 
2.2.6.4 Primary Antibody Application 
Primary antibody was added to a solution of 50% PBS and 50% PBS-tween in a 
50mls centrifuge tube, ensuring sufficient volume to cover the membrane. The 
membrane is then carefully rolled-up and inserted into the centrifuge tube. This was 
then placed in an orbital shaker overnight at 4oC. The next day, the membrane was 
removed and washed 3 times with PBS and once in PBS-tween. The membranes were 
then washed 3 times with PBS-tween on an orbital shaker for 10 minutes. 
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2.2.6.5 Secondary Antibody Application 
Secondary antibody was added to a solution of 50% PBS and 50% PBS-tween. 
Similar to the preparation of the primary antibody application, the membranes were 
incubated at room temperature with the secondary antibody on an orbital shaker for 1 
hour. Again, the membrane was washed 3 times with PBS and once in PBS-tween. 
The membranes were then washed 3 times with PBS-tween on an orbital shaker for 10 
minutes. 
2.2.6.6 Detection of Antibody Labelled Proteins 
Detection of specific protein with bound primary and secondary antibody was 
detected using the ECL plus western blotting detection system (Amersham Pharmacia 
Biotech, Buckinghamshire, UK). In this method, the secondary antibody conjugated 
with horseradish-peroxidase (HRP) was bound to the primary antibody attached to the 
protein of interest. Using this detection agent, the combined HRP and peroxidase 
elicits a peroxidase catalysed oxidation of luminol and subsequently enhanced 
chemiluminescence. The resulting light emitted was captured in a photographic X-ray 
film (Hyperfilm ECL Western, Amersham, UK) within seconds and minutes. 
 
Following PBS and PBS-tween washes after secondary antibody incubation, ECL 
plus (Cat. No. RPN2132, Amersham, UK) reagent (a mix 2mls reagent A and 50µL 
reagent B) was applied onto the membrane and incubated at room temperature for 5 
minutes. This was then placed in a plastic wallet cleaned thoroughly with 70% ethanol 
and excess ECL+ was removed. The membrane in the cassette was exposed to the X-
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ray hyperfilms in a dark room for various times and processed using a developer until 
visible protein band of interest is clearly visible. 
2.2.7. NFκB Assay 
TransAM NFκB (Cat. No. 40096, Active Motif, Rixensart, Belgium) is a 
commercially available ELISA based kit to detect and quantify NFκB activation. 
This kit utilises a 96 well plate coated with oligonucleotide containing NFκB 
consensus site (5’-GGGACTTTCC-3’). The activated NFκB P65 subunit binds 
specifically to this oligonucleotide.  
 
Using an antibody that binds to this the NFκB-oligonucleotide complex allows 
detection of activated NFκB. The primary antibodies detect NFκB by recognising the 
P65 epitope which is accessible only when NFκB is activated and bound to the target 
DNA. 0.5µg of cellular extract is recommended by manufacturer for optimum results. 
The procedural principles are otherwise similar to ELISA techniques as described in 
2.1.3.This assay provides detection and quantitative measures of activated NFκB 
within 5 hours. This assay kit has a detection limit of <0.5µg nuclear or whole cell 
extract/well. This provides a detection range of 0.2-0.5µg of nuclear or whole cell 
extracts.  
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2.3 Ghrelin receptor and gastric motility study 
2.3.1 Immunohistochemistry of archival samples  
Immunohistochemistry is the localization of antigens or proteins in tissue sections by 
the use of labelled antibodies as specific reagents through antigen-antibody 
interactions that are visualized by a marker such as fluorescent dye, enzyme, or 
colloidal gold. This method was used to detect neuromuscular agents implicated in 
gastric motility. 
2.3.2  Immunohistochemistry methods 
Gastric tissues taken from patients who did not have chemotherapy and in those 
receiving oesophageal-chemotherapy (cisplatin + 5-fluorouracil) or gastric 
chemotherapy (Cisplatin, 5-fluorouracil and capecitabine); n=6 each. Histological 
paraffin embedded tissue blocks were used for IHC. 5μm thick sections were baked 
onto 3-aminopropyltriethoxy-silane coated slides. Specific antibodies were used to 
look for the expression of specific antigens.  
 
After comparison against enzymatic digestion, (Sigma α-chymotrypsin, Cat. C-4129) 
and pH 6 buffer (Vector Antigen Unmasking Solution Cat. H-3300), optimum 
retrieval was performed by pressure cooking. Antigen retrieval was carried out by 
pressure cooking in Tris EDTA buffer pH 7.8 for 80 seconds. A commercially 
available tween-based buffer was used to prepare all solutions used in this technique 
(excepting DAB) for all washes, detection kit solutions and antibody dilutions 
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(Menarini Optimax Wash Buffer Cat. HK 583-5K). Endogenous peroxidase was 
blocked by incubating sections in a 1.5% Hydrogen peroxide solution for 20 minutes. 
 
Vector Universal Elite ABC kit (Cat. No. PK-6200; Burlingame, CA, USA) with a 
diaminobenzidine tetrahydrachloride visualisation agent (Vector ImPACT DAB 
substrate, Cat. No. SK-4105, Burlingame, CA, USA) was used for detection of bound 
antibody. Following a serum block of 20minutes at room temperature, primary 
antibody was applied to the sections for 1 hour, also at room temperature. Optimised 
antibody dilutions were determined for motilin receptor (MBL International Corp, 
Woburn, MA, USA, Cat. No. LS-A134), ghrelin receptor (Chemicon, Billerica, MA, 
USA, Cat. No. AB9543), nNOS (Abcam, Cambridge, UK, Cat. No. ab40662) and 
AChE (Abcam, Cambridge, UK, Cat. No. ab2803) (see Table 2.3.2)  
 
Sections were then washed twice, 5 minutes each time. The avidin-biotin complex 
solution was applied to the sections, and incubated for 30 minutes at room 
temperature (Vector Elite ABC reagent). Sections were then washed for 5 minutes in 
buffer. DAB solution was prepared according to the manufacturer’s instructions using 
de-ionised water, and applied to the sections for 5 minutes (Menarini Concentrated 
Substrate Cat. HK 153-5K.). Sections were rinsed with de-ionised water, and 
counterstained for 1 minute in Mayers Haematoxylin.  Sections were blued in Scott’s 
tap water, dehydrated, cleared and mounted.    
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Antibody Dilution 
5HT4 Receptor(Novus Biologicals Inc, Littleton, 
CO, Cat No: NLS656)   
 
1/300 
Motilin Receptor (MBL International Corp, 
Woburn, MA. Cat no; LS-A134) 
 
1/1500 
Growth Hormone Secretagogue Receptor 
(Chemicon, Billerica, MA. Cat No; AB9543) 
1/1000 
nNos (Abcam, Cambridge, UK. Cat No; ab40662) 
 
1/10,000 
Acetylcholinesterase (Abcam, Cambridge, UK. Cat 
No; ab2803) 
 
1/350 
 
Table 2.3.2 shows optimum dilutions of the commercially available primary 
antibodies against motility agents of interest. All antibodies have been tested 
previously for immunohistochemistry based on product specification by the 
manufacturer. 
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2.4. Gastric Contractility Methods 
Gastric specimens were obtained at the time of surgery from the tumour free margins 
of the stomach. The specimens were washed with saline to remove any debris or 
blood, and 2 sutures were placed to identify the longitudinal orientation. It was then 
immediately immersed in cold carbogenated (bubbled with 95% O2/ 5% CO2 for at 
least 2 hours) Gey’s salt solution overnight at 4oC to preserve tissue viability.  In 
some cases, the following morning the tissues were placed in fresh carbogenated 
Gey’s solution and then transported to the laboratory.  
 
On arrival the specimens were placed in fresh, oxygenated Krebs solution (containing 
in mM NaCl 121.5, CaCl2 2.5, KH2PO4 1.2, KCl 4.7, MgSO4 1.2, NaHCO3 25, 
glucose 5.6) which had been equilibrated with 5% CO2 and 95% O2.  The mucosa was 
removed and strips (2-4 x 10-15 mm) were cut parallel to the longitudinal or the 
circular muscle.  The strips (2-4 from each patient) were mounted in tissue baths (10 
ml) containing Krebs solution at 37°C and gassed with 5% CO2 in O2.  Tension was 
measured using Dynamometer UF1 force-displacement transducers (Pioden Control 
Ltd., UK).  Data acquisition and analysis were performed using MP100 hardware and 
AcqKnowledge software (Biopac Systems Inc., USA).  Tissues were initially 
suspended under 2-3g tension and allowed to equilibrate for at least 45 min during 
which time bath solutions were changed every 15 min.  During this time, muscle 
tension stabilised at ~1 g. 
 
At the end of the equilibration period, longitudinal muscle strips were stimulated via 
two parallel platinum ring electrodes connected to a stimulator (STG2008, Scientifica 
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Ltd, UK). The stimulation parameters were 50 V (~200 mA), 0.5 ms bipolar pulse 
duration, applied for 10 s, every 1 min.  The frequency was changed every 3 min to 
produce a frequency-response curve, using frequencies of 1, 2, 5, 10, 15 and 20 Hz.  
 
After washing, 10µM erythromycin was added for 15 min.   The tissues were washed 
and left for 30 min.  For both longitudinal and circular muscle strips, a carbachol 
concentration-response curve (1nM – 10 µM) was then constructed, with each 
additional concentration being added after a maximum response was observed to the 
previous, usually between 2-8 min).  Changes in muscle tension (g) evoked by each 
carbachol concentration were expressed in grams. 
 
 
 
2.5 Statistical Analysis 
 
All statistical analysis were performed using the GraphPad Prism software version 
4.0. Threshold for significance is p<0.05. 
 
2.5.1 Chapter 3 “Ghrlein in Crohn’s Disease” 
Data was described in non-parametric terms and comparisons were made using 
Wilcoxon’s Matched pair non-parametric tests. Values were expressed in median 
(range). Interquartiles ranges is incorporated in the ghrelin graphs. 
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2.5.2 Chapter 4 “Ghrelin, NFκB and Human Lymphocytes” 
 
Data in this chapter is reported as mean±SEM. Statistical analysis is undertaken using 
the paired student’s t-test to compare mean values.  
2.5.3 Chapter 5 “Cancer Chemotherapy and Gastric Contractility” 
Data in this chapter ins expressed as mean±SEM or mean with ranges. In the gastric 
contractility study, differences in response to carbachol between the chemotherapy 
exposed and non-chemotherapy exposed tissues were analysed using the 2-way 
ANOVA with Bonferroni post-hoc test. Data from immunohistochemistry study was 
expressed in mean±SEM and analysed using the Student’s paired t-test. 
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Chapter 3 
Ghrelin in Crohn’s Disease 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
60 
 
3.1.1 Overview 
 
Crohn’s disease is a form of inflammatory bowel disease characterised by patchy, 
transmural inflammation that can affect any areas of the gastrointestinal tract. The 
aetiology of Crohn’s disease is unknown, it is understood to have several contributing 
factors including genetic, environmental, infective and even psychological. The 
disease pattern varies, although the terminal ileum remains the most commonly 
affected site.  It can also be differentiated into fistulating, inflammatory or structuring 
disease. Mainstay of treatment is immune-suppression for mucosal healing and 
alleviation of symptoms. 
3.1.2 Prevalence and incidence of Crohn’s disease 
Crohn’s disease has an incidence if 5-10 per 100,000 per year with a prevalence of 
50-100 per 100,000 (Loftus, Jr. et al. 2004). There has been high incidence of CD in 
certain ethnic groups eg.Askenazi Jews, suggesting a genetic predisposition in and 
endogamous population. Peak incidence of CD is between ages 10 to 40 years.  
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3.1.3 Pathogenesis of Crohn’s disease 
Crohn’s disease was thought to arise from an environmental precipitant in a 
genetically susceptible individual. Among environmental agents implicated in 
Crohn’s disease are infection, drugs, diet, vaccination, water supply and cigarette 
smoking (Calkins et al. 1989). Smoking is not only implicated as a precipitant but also 
associated with a more phenotypically aggressive course of disease. Women with CD 
who smoke are more likely to have recurrent surgery (Sutherland et al. 1990) and 
likely to require immunosuppressant because of recurrent disease (Cosnes et al. 1999). 
Dietary association of CD is inconsistent although low residue and high refined sugar 
diet were implicated (Riordan et al. 1998). 
 
There has been considerable interest in genetic mutations that are implicated in CD. 
The first Crohn’s susceptibility gene (IBD1) was identified in 2001 on Chromosome 
16 (NOD2/CARD15) (Hugot et al. 2001). The relative risk of developing Crohn’s 
disease following mutation of this gene locus is increased by 2-4 fold if heterozygote 
and 28-40 fold if homozygous. Mutation in this gene locus is associated with a 
decrease in NFκB activity in response to bacterial LPS and peptiglycans. This impairs 
the ability to clear bacterium and fails to offer protection to the intestinal barrier to 
bacterial invasion. This mutation is associated with small bowel CD in Caucasian 
population. Other lesser known genetic associations include OCTN1 and 2 on 
chromosome 5 and DLG5 on Chromosome 10 (Gazouli et al. 2005).  
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3.1.4 Clinical features of Crohn’s disease 
 
The cardinal symptoms of CD include chronic diarrhoea, weight loss and abdominal 
pain. Colonic involvement of disease can also include rectal bleeding and urgency. 
Fever, malaise and anorexia can be manifestations of CD. In more severe phenotypes 
of CD, fistulae (see below) and abscess formation is a common feature. In addition, 
chronic luminal inflammation may lead to structuring disease and can result in bowel 
obstruction, which occurs in 20-30% of patients.  Clinical features of CD can vary 
depending on the site of disease. Small intestinal involvement presents with diarrhoea, 
weight loss, abdominal pain and malabsoprtion. Colonic involvement frequently 
presents with diarrhoea, rectal bleeding and pain. Anorectal disease may involve 
perianal abscess formation, fistulation and fissures. CD is also known to involve the 
stomach and oesophagus and usually presents with odynophagia, abdominal pain, 
dyspepsia, bleeding and dysphagia. 
 
Fistula formation is a frequent complication of luminal enteric CD. Entero-enteric, 
entero-vesical and entero-peritoneal fistulations are typical in CD. Patients can present 
with pyrexia, abdominal pains, pneumaturia, recurrent urinary infections and also 
cutaneous discharge. Initial symptoms of obstruction are typically due to intestinal 
inflammation and oedema. Persistent active disease will lead to progressive fibrosis, 
causing a fixed stenosis of the bowel. Mucosal inflammation in CD is transmural, 
hence it possible that perforation of the bowel can occur. It is a rare complication of 
CD but can be serious and life threatening. Very occasionally, perforation can be the 
initial presentation which leads to the discovery of CD.  
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Other clinical features of CD are apthous ulceration, fatigue, iron deficiency anaemia, 
osteoporosis and bile acid malabsorption. There is an increased incidence of bowel 
malignancy in long-standing CD, particularly in the diseased colon. Surveillance 
colonoscopy is therefore recommended 10 years after disease development. There are 
other systemic complications that are associated with CD (Table 1). These extra-
manifestations of CD occur in about 24% of patients (Rankin et al. 1979). 
 
 
Related to disease activity Erythema nodosum 
Apthous ulceration 
Episcleritis 
Uveitis 
Episcleritis 
Erythema nodosum 
Arthritis 
Oesteroporosis 
Pyoderma gangrenosum 
Not related to disease activity Gallstones 
Sacroileitis 
Ankolysing spondylitis 
Osteomalacia 
Primary sclerosing cholangitis 
 
Table 3.1 Illustrates the extraintestinal manifestations in Crohn’s disease, both 
related and unrelated to disease activity. 
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3.1.5 Diagnosis of Crohn’s Disease 
 
The diagnosis of Crohn’s disease should be sought in patients with history of chronic 
persistent bloody diarrhoea, recurrent perianal fistulation and abscess, abdominal 
pain, fever of unknown origin and intestinal malabsorption. Laboratory tests are 
usually non-specific. If there is small bowel involvement, there may be deficiencies of 
vitamin B12, iron and vitamin D. Significant diarrhoea can cause electrolyte 
disturbances, namely hyponatraemia, hypokalaemia and hypomagnesaemia.  
 
Low albumin can reflect luminal disease with protein losing enteropathy, 
malabsorption or significant inflammatory activity. Anaemia is a common finding, 
which may result from gastrointestinal blood loss or chronic inflammation affecting 
the bone marrow. Finally, abnormalities of the liver function can represent an 
associated liver disease eg. Primary sclerosing cholangitis, which is a condition, 
related to CD. A combination of endoscopic, radiological and pathological 
examination is usually required to establish not only the diagnosis but also the extent 
of the disease.  
 
Endoscopic examinations e.g. Colonoscopy can firstly establish any macroscopic 
inflammation in the colon and terminal ileum, with the benefit of biopsies to confirm. 
Moreover, colonoscopy can also be used to assess disease extent and severity. In 
addition, endoscopic examination of the bowel can be used for cancer surveillance in 
patients with duration of disease exceeding 10 years. Typical endoscopic findings are 
ulceration of apthous and deep fissuring, granular mucosa with friability, 
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‘cobblestone’ appearances reflecting the irregular mucosa due to submucosal 
inflammation, pseudopolyps, patchy inflammation with ‘skip’ lesions and also 
stenosing disease. MRI visualisation of the small bowel has become an important 
modality in assessing the disease in extent, activity and also assessing for 
complications of CD. Static and dynamic images obtained are particularly helpful in 
assessing the disease. More recently, capsule endoscopy is shown to be a useful tool 
in diagnosing more subtle CD particularly in the small bowel, which is currently 
difficult to reach with push endoscopy. Barium studies are helpful in characterising 
and assessing the luminal disease extent. Depending on the expertise of the 
radiologist, small bowel barium enema is an alternative method of examining the 
extent of disease in the small bowel. Typical finding of CD in barium studies are 
ulceration, loss of mucosa detail, mucosal oedema and structuring disease. 
 
Histological diagnosis of CD are made with finding of  cryptitis, crypt abscesses, 
inflammatory cell infiltrate affecting all layers of the bowel wall, ulceration and also 
the presence of non-caseating granulomata, a collection of macrophages with or 
without giant cells,  are more suggestive of CD.  
 
3.1.6 Treatment of CD 
 
The treatment of CD is complex, as it is dependent on the site, severity and type of 
disease. Treatment of CD involves mainly immunomodulation which is why other 
causes of similar symptoms have been considered including infection. Ileocolonic 
disease can be treated initially with mesalazine, a 5-aminosalicylates (5-ASA) in mild 
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disease (Hanauer et al. 2004). Failure to respond to mesalazine warrants steroid 
treatment which is tapered gradually over 2 months. Budesonide is a suitable 
alternative to systemic  corticosteroid compared to placebo which can be used in 
ileocaecal disease (Seow et al. 2008). 
 
In minor distal colonic disease topical treatments with 5-ASA and steroids are 
effective treatments in delivering the drug to diseased areas. In more severe cases, 
intravenous steroids e.g. hydrocortisone 100mg four times daily is suitable for severe 
in-patient management of an acute flare. Concomitant use of metronidazole with 
corticosteroids are recommended especially in cases where septic complication is 
suspected. For maintenance therapy, 6-thiopurines (Azathioprine and 6-
Mercaptopurine) are considered for rapid escalation in mesalazine treatment failure. 
Thiopurines are recognised as effective steroid sparing agents.  
 
In patients who failed thiopurine treatment, anti-TNF therapy has been demonstrated 
to be an effective treatment for CD. Infliximab is a chimeric antibody active against 
TNFα is an effective treatment for moderately severe Crohn’s disease (Hanauer et al. 
2002). It is effective in both induction of remission and maintenance therapy. Further 
discussions regarding the modes of action, side effects and efficacy of these 
treatments are beyond the scope of this thesis. Finally, nutritional support should 
always be integral part of CD treatment in every patient. Consideration of elemental 
or polymeric feeds and total parenteral nutrition can be considered as part of treatment 
of CD. 
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In perianal disease, metronidazole and ciprofloxacin are recommended first line 
treatment. In complex fistulating disease, azathioprine and infliximab are effective 
medical management. Surgery, including seton drainage and fisulectomy are 
appropriate alternative to failed medical therapy. In all complex disease, treatment is 
based on assessment of anatomy using imaging, availability of nutritional support and 
assessment for surgery. Surgery should always be considered particularly when 
medical therapy has failed, or in event of transmural disease complications eg. abcess 
formation, perforation or fistulating disease.  
3.2  Study design : Ghrelin profiling in patients with Crohn’s disease  
As discussed in chapter 1 of this thesis, ghrelin may have immune-modulating 
properties. In general, the evidence from intact animal studies suggests that ghrelin 
may be anti-inflammatory. Currently there are no human studies in support of this 
finding.  The suggested ability of ghrelin to reduce inflammation raises an exciting 
prospect that may prove to be useful in Crohn’s disease where anti-inflammatory 
properties are desirable. The other possible clinical use of ghrelin would be alleviation 
of cachexia which is a common presentation in presence of active inflammation. 
 
The relationship between ghrelin and inflammation is poorly understood. It is quite 
possible that inflammation will reciprocally regulate ghrelin, which could be a 
plausible mechanism of appetite loss and cachexia in patients with active disease.    
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In this study, we hypothesize that circulating ghrelin concentration may change when 
TNFα activity is altered by infliximab in patients with Crohn’s disease. We 
investigated the effect of infliximab infusion on the total, acylated and desacyl 
isoforms of ghrelin in patients with Crohn’s disease and related this to changes in 
biochemical and clinical measures of inflammation in Crohn’s disease. It is quite 
possible that if inflammatory process were altered, this will in turn affect circulating 
ghrelin concentration in a dynamic fashion. 
3.3 Methods 
3.3.1 Patient characteristics 
 
Fifteen patients with Crohn’s disease who qualified for infliximab treatment were 
recruited. These include patients with moderately severe disease with fistulation, who 
are refractory to other immunomodulators or in which surgery in avoided. Exclusion 
criteria include patients with gastrectomy or gastric by-pass surgery as this may affect 
the ghrelin excretion and regulation. Patients with ulcerative colitis and indeterminate 
diagnosis were also excluded. 
 
Mean age for all patients was 31 (range 21-50) and 9 were male.  Mean body mass 
index was 23 (range 21-34). Table 1 shows demographic and clinical characteristics 
of each patient. There was no change in drug treatment during the study.  
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3.3.2 Protocol  
 
Detailed experimental protocols are discussed in Chapter 2.  Briefly, each patient was 
studied on two occasions, immediately before and 1 week after an infusion of 
infliximab (5mg/kg). In 5 patients, the study done “one week after” infliximab was 
performed first followed by the “immediately before” study performed just before the 
next infusion usually 7 weeks later. On each occasion, an 18G cannula was inserted 
into a forearm vein.  
 
An initial fasting blood sample was taken followed by consumption of a 450 Cal meal 
by the patient. Following this, further samples were taken every 20 minutes for 2 
hours. Blood samples were centrifuged immediately, plasma extracted and stored at -
800 Celsius for later analysis. Assays were performed for plasma total ghrelin, 
acylated ghrelin, desacyl ghrelin, C-reactive protein and a panel of cytokines. The 
Harvey Bradshaw Activity Index (HBAI) were calculated for each patient on each 
study occasion. 
 
 
 
 
 
 
70 
 
 
 
 
3.3.3 Assays 
All samples were assayed in duplicate. Only plasma samples were used. Product 
specific protocols for commercially available assays were followed. General 
principals and assay techniques is described in Chapter 2. 
3.3.3.1 Total ghrelin and desacyl ghrelin assays 
Total ghrelin, was measured by ELISA (Diagnostics Systems Laboratory, Texas, 
USA; Catalogue DSL-10-33700). Desacyl ghrelin was assayed using an EIA kit (SPI-
BIO, Montigny le Bretonneux, France; Catalogue A05119). The Tecan GENios plate 
reader with Magellan ver.4 software was used to analyse the results.  
3.3.3.2 Acyl ghrelin 
Acylated  ghrelin was assayed using Linco Gut Panel Multiplex (Linco Research, St. 
Charles, MO, USA; Catalogue HGT-68K). A multiplex analyser, the Bio-Plex system 
(Bio-Rad Laboratories Inc.) were used to analyse the samples. Results were generated 
using Bio-Plex Manager software ver.4. 
 
3.3.3.4 C-Reactive Protein (CRP) 
CRP was measured by ELISA using the High Sensitivity C-Reactive Protein EIA 
(Life diagnostics Inc., West Chester, PA, USA; Catalogue 2210). 
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3.3.3.5 Cytokines 
TNFα, IL-1β, IL-6 and IFN-γ was measured using the High Sensitivity Human 
Cytokine Lincoplex Kit (Linco Research, St. Charles, MO, USA; Catalogue: 
HSCYTO-60SK) with the Bio-Plex system (Bio-Rad Laboratories Inc.). Results were 
generated using Bio-Plex Manager software ver.4. 
3.4 Data processing 
The principles of data processing was initially agreed with Professor Chuka Nwokolo 
and adhered to strictly. Data loss was defined as failure of an assay to record a value 
for a time point. Since assays were done in duplicate when data was unavailable for 
one or both wells this was regarded as data loss for that time point. If a single time 
point is lost a value is calculated which is the average of the values of the 2 adjacent 
time points. If the lost time point is either the first or last time point in the profile then 
the single adjacent value was assigned to that time point. If data is lost for 2 adjacent 
time points in a 2 hour profile such a profile was declared invalid and the patient 
excluded from the final analyses. The reason for data losses is unclear but may be 
related to post venopuncture processing, including acute haemolysis that may interfere 
with the assays, a faulty batch of blood collection tubes or degradation of the protein 
prior to analysis. 
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3.5 Statistics 
 
For each patient, a 2 hour profile of ghrelin concentration before and after infliximab 
is available. From this data a 2 hour integrated ghrelin concentration or area under the 
curve (AUC) for the study period was calculated using the trapezoid rule.  
 
CRP, cytokines, and glucose and insulin were measured in fasting samples taken 
before infliximab in the first study occasion and after infliximab on the second study 
occasion or vice-versa   
 
Data is described in non-parametric terms and since all comparisons were paired the 
Wilcoxon’s matched pair non-parametric test was used throughout. Graphpad Prism 
software was used for the statistical analysis.  
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3.6 Ethical Considerations 
The study was approved by Coventry Research Ethics Committee and the R & D 
Department of the University Hospital of Coventry. Written informed consent was 
obtained for all participating patients. 
 
 
3.7 Results 
Following adjustment for data loss, data was available for 11, 9 and 15 patients in the 
total ghrelin, acylated ghrelin and des-acyl ghrelin groups respectively. Patient 
demographics are illustrated in table 3.2. The assay for acylated ghrelin was subject to 
most data loss partly because acylated ghrelin is a small fraction of all circulating 
ghrelin isoforms. Moreover, this form of ghrelin is very unstable and vulnerable to 
breakdown by protease activity, hence a half-life estimated to be 9-13 minutes 
(Akamizu et al. 2004). 
 
 
 
 
 
 
 
 
Table 3.2. Patient demographics. Total of 15 patients participated in the study. 
10 patients were male. Mean age was 31and average BMI was 23. 13 patients 
were on Azathioprine and 5 patients underwent gastrointestinal surgery for 
Crohn’s disease. 
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3.7.1 Ghrelin 
3.7.1.1 Total ghrelin (n=11) 
Figure 3.2 shows that following infliximab infusion there was a higher median 
concentration of total ghrelin during the 2 hour study period. It also shows a typical 
post-prandial decrease in plasma ghrelin in both profiles. Figure 3.3 shows plasma 
integrated total ghrelin for the 2 hour study period increased in 9 of the 11 patients 
following infliximab. Figure 3.4 and table 3.3 show that median plasma integrated 
total ghrelin for the 11 subjects increased by 25% from 162 (82-738) pg/ml.hr before 
infliximab to 200 (101-792) pg/ml.hr. (p=0.02) one week after infliximab.  
4 patients were excluded from analysis due to data losses as defined in section 3.4. 
Three patients had data losses of more than 2 adjacent time points, in which 2 patients 
were involving the last time point and 1 patient involving the first time point. In one 
other patient, complete data loss was seen in the post-infliximab analysis apart from 
time point 0. All 4 patient samples were repeated with same findings which rendered 
them unsuitable for analysis.  
 
 
 
 
 
  
 
 
Figure 3.2. Median (inter-quartile range) plasma total ghrelin (pg/ml) 
concentration profiles (N=11) pre and post-infliximab infusion with interquartile 
range. A 450 Cal meal was eaten immediately after the fasting blood sampling at 
t=0. Blood was sampled every 20 minutes. Interquartile ranges were calculated 
for each 20 minute time point. Each data point has been separated at every 20 
minute interval to demonstrate the interquartile range. All samples obtained 
from each time-point were assayed in duplicates. Both curves show the typical 
post-prandial decrease in total ghrelin. Median values were compared using the 
non-parametric Wilcoxon’s matched pair test. GraphPad prism softwarewas 
used to analyse results 
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Figure 3.3. Two-hour integrated plasma total ghrelin (pg/ml.hr) (N=11) pre and 
post infliximab infusion for each individual patient. Integrated ghrelin is 
increased in 9 of 11 patients after infliximab (p=0.02). Median values were used 
for comparison using the non-parametric Wilcoxon’s matched pair test 
performed using GraphPad prism software.  
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Figure 3.4. Median integrated plasma total ghrelin AUC (pg/ml.hr) (N=11) pre- 
and post-infliximab infusion. Wilcoxon’s non-parametric matched pair test was 
used to compare pre- and post-infliximab median values. Statistical analysis was 
performed using GraphPad Prism software. Median (inter-quartile range) 
integrated total ghrelin increased by 25% from 162 (141-208) pg/ml.hr before to 
200 (144-292) pg/ml.hr one week after infliximab infusion (p=0.02). 
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3.7.1.2 Acylated ghrelin (n=9) 
Figure 2.5 shows the profiles of median plasma acylated ghrelin concentration before 
and after infliximab. A normal post-prandial decrease in ghrelin is absent in the before 
infliximab profile. However in the after infliximab profile, at 20 min post-meal, 
median acylated ghrelin concentration decreased below the fasting concentration 
(Table 2.2) and was also significantly lower than the same time point in the before 
infliximab profile  (38.6 (21.9-92.0) pg/ml vs 50.3 (20.1-105.6) pg/ml) (p=0.04). Thus 
in the after infliximab profile the traditional meal-related ghrelin curve with its post-
prandial dip is restored. Over the 2 hour study period integrated acylated ghrelin 
increased non-significantly from 91 (39-196) pg/ml.hr before infliximab to 102 (40-
194) pg/ml.hr after infliximab (Table 2.2), a trend similar to that observed for total 
ghrelin. 
Significant data loss was observed in acylated ghrelin analysis despite utilising a high 
sensitivity bioplex assay. Acylated ghrelin has a very short half-life and sensitive to 
protease degradation.  Six patient samples were excluded from analysis due to data 
losses. In 5 patients, acylated ghrelin was undetectable by the bioplex assays in both 
pre- and post-infliximab samples, presumably related to post venopuncture 
processing. With the benefit of hindsight, it is possible that a different protease 
inhibitor may have limited such data losses. In one patient, sampling errors were 
reported by the bioplex analyser and results were unobtainable, possibly due to an 
unknown contaminant or significant haemolysis of the blood sample interfering with 
the assay.   
 
 
  
 
Figure 3.5. Median (interquartile range) plasma acylated ghrelin concentration 
(N=9) pre and post infliximab infusion. Each data point has been separated at 
every 20 minute interval to demonstrate the interquartile range. Unlike the pre-
infliximab profile, the post-infusion shows a typical post-prandial decrease of 
acylated ghrelin with plasma acylated ghrelin concentration at t=20mins being 
significantly lower than the same time point in the pre-inflixmab curve (38.6 
(22.8-59.63) pg/ml vs 50.3(23.3-89.23) pg/ml) (P=0.04). Total AUC pre- and post-
infliximab was not significantly different. Wilcoxon’s matched pair non-
parametric test was used to compare median results using GraphPad prism 
software. 
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3.7.1.3 Des-acylated ghrelin (n=15) 
There was no statistical difference in integrated des-acylated ghrelin which was 397 
(153-1106) pg/ml.hr before inflixmab and 423 (251-888) pg/ml.hr.hr after (Table 
2.2).
 
Table 3.3. Summary of ghrelin results. Median integrated total ghrelin (N=11) 
increased significantly from 162 to 200 following infliximab. Median acylated 
ghrelin (N=9) at t=20minutes decreased significantly from 50.3 to 38.6 following 
infliximab, suggesting restoration of the traditional post-prandial decrease of 
ghrelin following a meal. However, median integrated acylated ghrelin and 
desacyl ghrelin did not change significantly. 
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3.7.2 Cytokines (Table 2.3) 
3.7.2.1 TNFα 
 
Median (range) TNFα concentration decreased significantly from 2.8 (0.4-5.85) pg/ml 
before infliximab to 1.31 (0-2.08) pg/ml (p=0.002) after infliximab.  
3.7.2.2 IL-1β, IL-6, and IFN-γ   
 
Before and after infliximab median (range) IL-1β was 0.7 (0.27-2.82) and 0.89 (0.37-
3.37) respectively, median (range) IL-6 was 20.6 (4.79-52.49) and 20.7 (4.21-48.22) 
respectively and median (range) IFN-γ was 10.8 (1.23-45.84) and 7.3 (0-46.71) 
respectively. There was no significant difference.  
 
 
 
 
 
  
Table 3.3 Summary of  cytokine results (N=15). TNFα was the only cytokine 
which decreased significantly from 2.8 to 1.31 following infliximab. There were 
no significant changes in IL-1β, IL-6 and IFN-γ. Median values are expressed 
and comparisons were made using the non-parametric Wilcoxon’s matched pair 
test performed with GraphPad prsim software.   
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3.7.3 C-Reactive Protein 
 
CRP concentration decreased non-significantly from 2.1 (0-17) mg/ml before 
infliximab to 0.7 (0-7.8) mg/ml after infliximab. 
 
3.7.4 Harvey Bradshaw Activity Index 
 
Median (range) HBAI decreased by from 5 (2-28) before infliximab to 2 (0-22) after 
infliximab, (p=0.001).  
 
3.8 Discussion 
 
This study design extending over a 2 hour period took account of the pulsatile nature 
of ghrelin secretion in humans. The eating of a meal was also included in the study 
period to test ghrelin regulatory mechanisms.  As expected, a post-prandial decrease 
in ghrelin followed by recovery over 2 hour period was observed presumably when 
food leaves the stomach. We were able to report and compare data as “area under the 
curve” and 2 hour concentration profiles immediately before and one week after the 
infusion of infliximab to improve our detection of changes in circulating ghrelin 
concentration.  
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This study provides novel evidence that systemically altering an important 
inflammatory mediator like TNFα can lead to changes in circulating ghrelin. The 
infusion of infliximab led in Crohn’s disease patients to a 25% increase in total 
ghrelin concentration assessed during a 2 hour period after a meal.  As expected there 
was a significant decrease in TNFα and Crohn’s disease activity following infliximab 
treatment. A similar trend was observed for CRP. The relatively low concentrations of 
TNFα and CRP reflect that our study patients, the majority in maintenance infliximab 
programmes were in clinical remission. It would be of interest to study patients that 
start with a higher inflammatory burden who we believe would show an exaggeration 
of the changes in ghrelin observed in our study. It is possible that ghrelin-producing 
cells can sense and respond to changes in circulating TNFα.  
 
This mechanism may operate at the cellular level with circulating TNFα exerting a 
direct effect on gastric ghrelin producing cells. Another hypothesis is that TNFα 
might act centrally and modulate circulating ghrelin through the efferent vagal nerves 
to the stomach. In a recent study, rats that were rendered hypophagic by TNFα 
administration were found to have decreased gastric and circulating ghrelin leading to 
the conclusion that some of the anorexic effects of TNFα are mediated via ghrelin.  In 
that study the effects of hypophagia induced by TNFα could be reversed by 
administration of ghrelin (Endo et al. 2007b).   
 
Circulating acylated ghrelin was often referred to as “active” ghrelin. This isoform 
stimulates hunger and growth hormone release by acting on hypothalamic nuclei. In 
our Crohn’s patients, at a time of maximum inflammatory activity, the acylated 
ghrelin concentration at the 20 min time point is higher than the preceding fasting 
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value. There was no post-prandial decrease in acylated ghrelin concentration which is 
an accepted feature of a normal ghrelin curve.  Similar abnormalities in post prandial 
ghrelin profiles have been reported in obesity and non-alcoholic steato-hepatitis, 2 
diseases that a have a significant inflammatory contribution to their pathophysiology 
(English et al. 2002; Sajjad et al. 2005). Following infliximab infusion in our patients 
the acylated ghrelin curve was normalised and the 20 min ghrelin concentration is 
lower that the preceding fasting value. Inflammation in general and perhaps TNFα 
specifically affects not only total ghrelin production but modifies the mechanisms that 
regulate ghrelin production in the stomach. 
 
The study also showed that des-acyl ghrelin an isoform which still has an uncertain 
physiological role was not affected either in terms of its profile or area under the 
curve by infliximab.  In conclusion, this study provides novel evidence that altering 
TNFα with a biological agent can affect  circulating ghrelin in humans. It adds further 
evidence that ghrelin and inflammatory mediators interact in inflammatory diseases 
like Crohn’s disease pointing to a possible immuno-modulatory role. Our study 
suggests that neither des-acyl nor acylated ghrelin mediate this role raising the 
possibility that a yet unrecognised biological isoform could be involved.  
 
Inter-assay variability between the 3 assays used could explain the difference in 
results seen with the ghrelin isoforms. An infliximab-induced increase in circulating 
plasma ghrelin if accompanied by increased food intake suggests another mechanism 
by which this drug might improve well-being in Crohn’s disease patients. 
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Chapter 4 
Ghrelin, NFκB and Human Lymphocyte 
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4.1. Introduction 
In Chapter 1, ghrelin has many physiological functions, of which hunger and energy 
homeostasis is most established. However, recent studies suggest that it may have an 
immune-modulatory role. In animal studies ghrelin seems to protect against 
inflammatory damage (Dembinski et al. 2003; Chang et al. 2003; Granado et al. 
2005). The presence of ghrelin receptors on human immune cells  (Hattori et al. 2001) 
and the suppression of inflammatory cytokine (IL-1β, IL-6 and  TNFα ) secretion by 
these cells when exposed to ghrelin in-vitro suggests a possible immnuno-modulatory 
role. This effect appears to be opposite to that of leptin (Dixit et al. 2004). Another 
study with similar findings demonstrated that ghrelin not only inhibits the 
proliferation of splenic T-lymphocytes but also decreases  Th1 (IL-2 and IFN-γ) and 
Th2(IL-4 and IL-10) cytokines mRNA expression  (Xia et al. 2004b). In Chapter 3 of 
this thesis, the study has demonstrated that modulation of inflammation can have a 
reciprocal effect on plasma total ghrelin. This chapter investigates the effect of ghrelin 
at the cellular immune level, in particular human B-lymphocyte, on NFκB activation. 
 
A nuclear factor kappa B (NFκB) a nuclear transcriptional factor discovered in 1986 
(Sen et al. 1986), is involved in the cellular responses to an environmental stress, by 
inducing the production of protective signals. NFκB is held inactive in cellular 
cytoplasm by inhibitory kappa B (IκB). NFκB activation involves dephosphorylation 
of IκB and releasing NFκB (Baldwin, Jr. et al. 1996).  
 
The conserved N-terminus of NFκB then binds to the DNA and promotes the 
transcription of a variety of pro-inflammatory signals. In B-lymphocytes, NFκB plays 
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a significant role in immunoglobulin production. The gene enhancer for κ light chain 
is activated by NFκB and in animal studies found to be crucial for B-cell maturation 
and function against pathogens (Sha et al. 1995). It is recently shown that NFκB plays 
an important role in driving and coordinating the innate and adaptive immune 
response to an antigen (Bonizzi et al. 2004). NFκB has various implications on 
inflammatory diseases, particularly in uncontrolled activation, and has been a subject 
of interest as a therapeutic target. 
 
The objective of this study is to investigate the effect of ghrelin on NFκB activation 
and inflammatory cytokine production in human B-lymphocyte cell line. 
Immunoglobulin production is a measure of primary B-lymphocyte cell function but it 
is uncertain if this characteristic has been established in the cell line used. Therefore 
the study focused the enquiry on cell activation and NFκB expression both upstream 
of immunoglobulin production with established characteristics of the cell line studied.  
4.2 Materials and method 
4.2.1 Cell Line Selection And Preliminary Experiments 
Two cell lines, B-lymphocyte (WILCL, ECACC Cat : 89120565; DAUDI, ECACC : 
Cat: 85011437) and 2 T-lymphocyte (JM, ECACC Cat : 86010201; HUT-78, ECACC 
Cat : 88041901) were tested for expression of the ghrelin receptor. Cells were 
cultured in appropriate medium, collected and lysed. Total protein was extracted and 
quantified. Using western blotting techniques, the GHSR-1a (now known as the 
ghrelin receptor) and the dormant GHSR 1b receptor was detected using 
commercially available antibodies from Phoenix Pharmaceuticals Inc, CA, USA 
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(GHSR 1a, Cat G-001-62; GHSR 1b, Cat G-001-61) (Figure 4.2.1).  Detailed 
methodology is discussed in Chapter 2. 
 
The WILCL cell line, a normal Caucasian human B-cell lymphoblast immortalized by 
the Epstein-Barr virus expressed ghrelin receptors and was used for the rest of the 
study (figure 4.2.2). 
 
 
 
 
 
 
 
 
  
Figure 4.2.1. Western blots of the ghrelin receptor protein in WILCIL human B-
lymphocyte cell line (N=1). Human adipose tissue protein extracts which has 
been confirmed to express both ghrelin and GHSR-1b receptors are used for 
positive controls. The ghrelin receptors (42 kDa) and GHSR 1b (32 kDa) are 
demonstrated in both resting and activated lymphocyte cells.  
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Figure 4.2.2 (a) 
 
Figure 4.2.2 (b) 
 
Figure 4.2.2 Light microscopy of the WILCL normal B-lymphocyte cell line at 
high power (a) and low power (b). Cytoplasmic extensions were clearly visible at 
high power which presumably allows the cells to proliferate in large aggregates 
[4.2.2 (b)]. 
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Detailed cell culture and treatment methods are discussed in Chapter 2 (Section 2.2.4) 
Phytohemagluttinin (PHA) was used for lymphocyte activation. PHA concentration of 
0.5mg/ml was optimal for WILCL cell activation. We assessed the effect of the 
compounds on activated and resting cells. A screening experiment (performed in 
triplicate) with octanoyl gherlin treatment using time points of 6, 24 and 48 hours 
indicated a response at 6 hours (Table 4.2.1). As a result 6 hours incubation was used 
in all experiments. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Table 4.2.1 Results of the screening experiments (N=3) in cells dosed with 
octanoyl ghrelin. There was a demonstrable change in NFκB activation in the 
resting group at T=6 hours although this did not reach significance. Values were 
expressed as mean±SEM. Comparisons were made using Student’s t-test 
analysed by GraphPad prism software. 
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4.2.2 Cell Resuscitation And Culture 
The principles and techniques of cell resuscitation and culture are discussed in detail 
in section 2.2.2. Cells were resuscitated from liquid nitrogen storage and cultured in 
RPMI 1640 media (Invitrogen, UK) enriched with L-glutamine (200mM), penicillin 
(100U/ml), streptomycin (100μg/ml) and 10% fetal bovine serum (Invitrogen, UK) in 
an incubator. Cell density was maintained at 3-5 x 106/ml.  Media was changed every 
2-3 days and cell subculture was performed to maintain cell density. 
 
PHA (Sigma, UK) was used to activate lymphocytes as described earlier and exposed 
to 3 compounds which were octanoyl ghrelin (Phoenix, CA, USA; Cat. 031-39), des-
octanoyl Ghrelin (Phoenix, CA,USA; Cat. 031-32) and a non-peptide ghrelin agonist 
(Pfizer CP-464709).  These compounds were added to the wells with resting and PHA 
activated cells to make up concentrations of control cells (no addition), 1nM, 10nM 
and 100nM. For des-octanoyl ghrelin and ghrelin agonist, we increased the range of 
concentrations to include 0.1nM and 1000nM in attempt to detect an effect as these 
compounds are not natural ligands of the ghrelin receptor. 
4.2.3 NFκB Assay 
NFκB expression was analysed using Active Motif TransAM NFκB p65 (Cat: 
31102,Ca, USA) ELISA-based assay. This assay consists of a 96 well plate each 
coated with an oligonucleotide containing the NFκB consensus region (5’-
GGGACTTTCC-3’) which the active form of NFκB from cell lysates bind. The 
primary antibody only binds to the epitope on p65 only when NFκB is activated and 
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bound to its target. A secondary HRP-conjugated antibody binds to the primary 
complex which then produces a signal quantifiable by spectrophotometry (measurable 
by optical density at 450nm wavelength).  
 
The cell culture medium was analysed for IL-6, IL-8, IL-10 and TNFα  using a high 
sensitivity human cytokine Lincoplex assay (Linco Research, Cat. HSCYTO-60SK, 
St. Charles, MO, USA) using the Bio-Plex system (Bio-Rad Laboratory Inc., 
Hercules, CA, USA). The principles of multiplex assay is discussed in further detail in 
section 2.1.4. Inter-assay variability ranged between 2 to 15% for all cytokines 
measured. Cells exposed to ghrelin and its agonists were compared with resting and 
activated controls.  
4.3 Statistical Analysis 
Data is reported as mean±SEM . A student t-test was used to compare data from cell 
groups using GraphPad Prism software. 
4.4 Results 
4.4.1 Octanoyl-Ghrelin (N=6) 
In the resting state, NFκB activity in the control cells was 0.42±0.10 and increased to 
0.61±0.20, 0.54±0.10, 0.52±0.08 when exposed to 1nM, 10nM and 100nM octanoyl 
ghrelin respectively. The increase in NFκB activity in 1nM and 10nM was statistically 
significant (P=0.044 and P=0.043 respectively). NFκB activity increased by 25-50% 
in the octanoyl ghrelin treated cells when compared to control cells. 
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In the activated state, NFκB activity was 0.56±0.10 in control cells and remained 
unchanged at 0.57±0.08, 0.60±0.09, 0.48±0.07 when exposed to 1nM, 10nM and 
100nM octanoyl ghrelin respectively (Figure 4.4.1).  
 
4.4.2 Desoctanoyl Ghrelin (N=6) 
In the resting state, the NFκB activity in the control cells was 0.35±0.03 and remained 
unchanged at 0.36±0.04, 0.39±0.04, 0.36±0.04, 0.36±0.03 when exposed to 0.1nM, 
1nM, 10nM and 100nM des-octanoyl ghrelin respectively.  
In the activated state, NFκB activity in the control cells was 0.38±0.04 and remained 
unchanged at 0.38±0.03, 0.41±0.04, 0.39±0.04, 0.39±0.04 when exposed to 0.1nM, 
1nM, 10nM and 100nM des-octanoyl ghrelin respectively.  
4.4.3 Ghrelin Receptor Agonist (N=6) 
In the resting state, NFκB activity in control cells was 0.30±0.04 and remained 
unchanged at 0.29±0.03, 0.31±0.04, 0.31±0.05, and 0.29±0.04 when exposed to 1nM, 
10nM, 100nM and 1000nM ghrelin receptor agonist respectively.  
In the activated state, the NFκB activity in control cells was 0.31±0.04 and remained 
unchanged at 0.31±0.04, 0.33±0.05, 0.32±0.05 and 0.31±0.04 when exposed to 1nM, 
10nM, 100nM and 1000nM ghrelin receptor agonist respectively.  
 
 
 
 
 
  
Figure 4.4.1. NFκB activation in resting and activated WILCL human B-
lymphocyte cell line with increasing doses of octanoyl ghrelin (N=6). The student 
t-test was used to compare NFκB activation in increasing concentration of 
octanoyl ghrelin and controls. This illustrates the NFκB profile in resting cells 
and demonstrates a 25-50% increase in NFκB activation at 1nM and 10nM 
concentrations of octanoyl ghrelin (P<0.05). The NFκB activation in PHA 
activated cells and showed no significant change with increasing concentrations 
of octanoyl ghrelin. Values are expressed as mean±SEM. Comparisons were 
made using the Student’s t-test analysed by GraphPad prism software. 
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Figure 4.4.2. NFκB activation with increasing concentration of des-octanoyl 
ghrelin. There was no significant change in NFκB activation in both resting and 
PHA activated cells (N=6). . Values are expressed as mean±SEM. Comparisons 
were made using the Student’s t-test analysed by GraphPad prism software. 
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Figure 4.4.3. NFκB activation in WILCL with increasing concentration of GHSR 
agonist (N=6). There was no significant change in NFκB in both resting and PHA 
activated cells, suggesting a possible mechanism which may circumvent the 
ghrelin receptor.  Values are expressed as mean±SEM. Comparisons were made 
using the Student’s t-test analysed by GraphPad prism software. 
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4.4.4 Cytokines (N=6) 
In resting and activated cells exposed to all concentrations of octanoyl ghrelin, no 
significant change in TNFα IL-6, IL-8, IL-10 concentration in the media was 
demonstrated Table 4.4.4.(a). Table 4.4.4(b) shows that the non-peptide ghrelin 
agonist significantly suppressed lymphocyte IL-13 production in a dose dependent 
manner particularly in resting lymphocytes. This effect was not associated with any 
changes in NFκB. IL-13 is an anti-inflammatory cytokine and its suppression suggests 
that the non-peptide ghrelin agonist could be pro-inflammatory acting via a pathway 
independent of NFκB. This effect was not seen with the biological ligand octanoyl 
ghrelin suggesting that it may be a non-specific effect of the synthetic agonist. 
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 Figure 4.4.4 (a,b,c,d,e) Cytokine expression by WILCL with increasing 
concentration of octanoyl-ghrelin (N=6 each). Although there is significant 
decrease in TNFα at 1nM octanoyl-ghrelin concentration (P=0.03), this did not 
show a convincing trend [Figure 4.4.4 (a)]. Other cytokines measured did not 
show any significant change [figure 4.4.4 (b,c,d,e).  Values are expressed as 
mean±SEM. Comparisons were made using the Student’s t-test analysed by 
GraphPad prism software. 
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Table 4.4.4(a) Results of the cytokine analysis of the media in the octanoyl 
ghrelin dosed cells (N=6). Values are expressed as mean±SEM. Comparisons 
were made using the Student’s t-test analysed by GraphPad prism software. 
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 Table 4.4.4(b) Results of the cytokine analysis of the media in the ghrelin agonist 
dosed cells (N=6). Values are expressed as mean±SEM. Comparisons were made 
using the Student’s t-test analysed by GraphPad prism software. 
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4.5. Discussion 
After a series of screening experiments, an immortalized B lymphocyte cell line 
expressing ghrelin receptors was selected as the target of investigation. Previous 
studies had investigated the role of ghrelin in activated T lymphocytes and monocytes 
but not B-lymphocytes. The physiological role of the ghrelin receptors on B-
lymphocytes are currently not known. The effect of ghrelin and its agonists on NFκB 
has not been investigated on B-lymphocytes. This is a novel study to investigate if 
NFκB may be regulated in this particular B lymphocyte cell line by ghrelin and 
ghrelin receptor agonist treatment. The study shows that physiological concentrations 
of octanoyl ghrelin increased NFκB activation by up to 50% when applied to this 
particular cell line. This effect was not dose dependent but peaked at 1 and 10nM and 
seemed to decline at 100nM concentration. This can be explained by the possible 
toxicity of ghrelin on these cell line at supra physiological levels. Cellular apoptosis is 
a plausible result at high concentrations of ghrelin. 
 
As expected this increase in NFκB activation by octanoyl ghrelin was not seen with 
the ghrelin receptor agonist and des octanoyl ghrelin; neither are the natural ligands 
for the ghrelin receptor. Another possible explanation is that octanoyl ghrelin may act 
on these lymphocytes via another mechanism rather than the ghrelin receptor, which 
may explain lack of effect seen in the ghrelin receptor agonist. The effect of octanoyl 
ghrelin was detected only when the cells were in a resting state. This effect was not 
seen when these cells were activated with PHA.  It is likely that in the active state 
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lymphocytes are probably at a state of maximal NFκB activation and additional 
stimulation via the ghrelin receptor is unable to increase this measurably.   
Previous studies have demonstrated ghrelin receptors on human immune cells and 
also a decrease in cytokine production in T-lymphocytes and monocytes treated with 
ghrelin but not in B-lymphocytes. This in vitro model did not detect any consistent 
change in the panel of cytokines occurring in parallel with the changes in NFκB.  This 
however may be characteristic of this cell line. In this study, we recognize that 
cytokine production is not a primary function of B lymphocyte.  Our experiment 
explored the interaction between B-lymphocyte cell activation and NFκB expression 
both known characteristics of this cell line.   
 
If this was a primary B lymphocyte cell line function would have been best assessed 
by immunoglobulin production but this was not a demonstrated characteristic of this 
particular cell line. In this research laboratory, there is more extensive experience with 
PHA. Although pokeweed was also tested on this cell line, it did not demonstrate 
greater potency in NFκB activation in comparison to PHA. 
 
NFκB is known to regulate the development and maturation of lymphocytes 
(Siebenlist et al. 2005). The uncontrolled activation of NFκB has been implicated in 
many inflammatory diseases and cancer. This has driven much interest in NFκB as a 
therapeutic target in many diseases. There are studies that suggest an  anti-
inflammatory effect of ghrelin on human and animal lymphocytes  (Dixit et al. 2004b; 
Xia et al. 2004a) and although our data points to a contrary conclusion it provides 
further evidence that ghrelin may be part of a complex human immune regulatory 
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repertoire and raises the possibility that ghrelin could be a target for immune-
modulatory therapy.  
 
Indeed there has been contrary evidence that ghrelin increases NFκB activation and 
promote inflammation in the human colon  (Zhao et al. 2006) which suggest that 
ghrelin may also have pro-inflammatory properties.  This is the first study to 
demonstrate the effects of ghrelin on a human B-lymphocytes in vitro model.  Further 
studies are warranted to explore how NFκB regulates the immune system and this will 
be important in understanding a possible role of ghrelin. In addition, further studies of 
ghrelin dosing on other cellular types e.g. T-lymphocytes would be desirable in 
establishing the relationship between NFκB and ghrelin. 
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Chapter 5 
 
Cancer Chemotherapy and Gastric Contractility 
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5.1 Introduction 
Neoadjuvant chemotherapy for oesophageo-gastric cancers prior to surgery are now 
common practice following clinical trials that showed survival improvement  (MRC 
oesophageal cancer working group. 2002; Cunningham et al. 2006). However 
following completion of chemotherapy, many  patients frequently continue to 
experience distressing symptoms resembling dyspepsia and attributed to a disorder in 
gastric emptying  (Nelson et al. 2002).  In a study by Riezzo et al  (Riezzo et al. 
2005), for example, gastric dysmotility-like symptoms (susceptibility to nausea, early 
satiety, post-prandial fullness) and tachygastria were common in patients seven days 
after completion of chemotherapy, during which emesis was well controlled.  
 
 
Such studies raise the possibility that the anti-cancer chemotherapy may somehow 
induce a gastric dysmotility which outlasts the treatment and which may lead to 
prolonged symptoms of dyspepsia.  For this to occur, it is possible that chemotherapy 
may directly affect the integrity of the neuromuscular functions of the stomach.  In rat 
gastro-duodenal muscle, for example, a reduction in the presence of the Ca2+-
calmodulin complex has been observed three days after a single treatment with 
cisplatin  (Jarve et al. 1997). This thesis chapter investigates the hypothesis that 
cancer chemotherapy may cause long term damage to gastric motility. 
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5.2 Study Aims 
To study the possibility that certain anti-cancer chemotherapy treatments may cause 
long-term damage to gastric function, we have looked at the effects of cisplatin-based 
treatments on the function and integrity of human stomach.  For this purpose we 
examined the ability of human isolated stomach to contract in response to carbachol 
and other stimuli, following removal at surgery from patients who had undergone 
chemotherapy up to six weeks previously, compared to patients who had not 
undergone chemotherapy.   
 
The integrity of the motor nerve system was also examined by immunohistochemical 
staining for acetylcholinesterase (AChE) and for the neuronal isoform of nitric oxide 
synthase (nNOS).  In addition, we looked for changes in expression of the gastric 
motility stimulant motilin  (Sanger et al. 2008) and the receptors for ghrelin.  The 
latter was included partly because of an association between ghrelin and changes in 
appetite and gastric motility  (Inui et al. 2004) and partly because of a previous study 
in rats, which showed that the ghrelin receptor may be up-regulated following 
administration of cisplatin  (Malik et al. 2008c).  The results indicate, for the first 
time, that marked changes in the contractility and integrity of the human stomach are 
caused by cisplatin-based chemotherapy.  This may have impact on the clinical 
aspects of cisplatin-based chemotherapy which warrants further investigation. 
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5.3 Materials and Methods 
5.3.1 Ethics 
All patients enrolled were diagnosed with resectable oesophageo-gastric cancers.  The 
patients were staged by computed tomography (CT) scan, endoscopy including 
endoscopic ultrasound and laparoscopy. All patients were staged as TxN0(or x)M0 by 
the TMN staging system and were assessed to be suitable for surgery. The study was 
approved by the local Coventry Research Ethics Committee and written informed 
consent was obtained from all patients. Particular care was taken so deceased patients 
were not contacted cross-referencing patient computer data and also bereavement 
records. 
5.3.2 Patient Selection 
Patients with gastric adenocarcinoma received 3 courses of epirubucin (50mgm-2), 
cisplatin (60mgm-2) and capecitabine (625mgm-2).  For patients with oesophageal 
cancers they received 2 courses of cisplatin (80mgm-2) and 5-fluorouracil (1Gm-2).  
Patients who did not undertake chemotherapy were physically frail, considered at risk 
of severe side effects of chemotherapy or undergoing Whipple’s procedure for 
pancreato-biliary tumours.  All patients underwent surgical resection within a 2 week 
window of 4 to 6 weeks following completion of chemotherapy regime, based on 
local cancer pathway.   
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Immunohistochemistry study 
 
 Non-
chemotherapy
Oesophageal- 
chemotherapy 
Gastric- 
chemotherapy 
 
Female: Male ratio 
 
 
1:5 
 
1:5 
 
2:4 
 
Mean age 
 
 
76 
 
71 
 
63 
Contractility study 
 
 Non Chemotherapy Chemotherapy 
 
Mean Age 
 
74 63 
Female: Male ratio 
 
2:1 0:4 
 
Table 5.4.1.Patient demographics in the immunohistochemistry and the 
contractility study.  
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5.3.3 Histological study (Immunohistochemistry) 
Detailed immunohistochemistry methods are described in section 2.3.2. Histological 
paraffin embedded tissue blocks showing normal which were distant from the tumour 
site were selected. Specific antibodies were used to look for the expression of motilin, 
the ghrelin receptor, AChE and nNOS, in sections of gastric tissues taken from 
patients who did not have chemotherapy and in those receiving oesophageal-
chemotherapy (cisplatin + 5-fluorouracil) or gastric chemotherapy (capecitabine); n=6 
each. Following antigen retrieval by pressure cooking, optimised antibody dilutions 
were determined for motilin receptor (MBL International Corp, Woburn, MA, USA, 
Cat. No. LS-A134), ghrelin receptor (Chemicon, Billerica, MA, USA, Cat. No. 
AB9543), nNOS (Abcam, Cambridge, UK, Cat. No. ab40662) and AChE (Abcam, 
Cambridge, UK, Cat. No. ab2803).  
 
The intensity and distribution of peroxidase staining was examined and scored by a 
histopathologist who was blinded to the group the patients were assigned to.  For all 
procedures, a semi-quantitative scoring system for staining intensity was used (0=no 
staining, 1=weak, 2=moderate, 3=strong expression).  
 
 
 
116 
 
 
 
 
 
 
 
5.3.4 Gastric Contractility Study 
Detailed description on gastric contractility experimental methods are described in 
section 2.4. In the gastric tissue contractility experiments, fresh gastric tissue was 
obtained from tumour free margins during surgery.  The gastric tissue is then 
transported to GSK laboratories and processed within 24 hours of collection. The 
tissues were mounted and tissue baths and tension measured.  
 
Following this, longitudinal muscle strips were stimulated via two parallel platinum 
ring electrodes connected to a stimulator (STG2008, Scientifica Ltd, UK. After washing 
and in tissues not subjected to EFS, 10µM erythromycin was added for 15 min.  As not 
all tissues responded to EFS or erythromycin, the data are expressed simply as the 
number of tissues which responded by contraction, or not.   
 
 For both longitudinal and circular muscle strips, a carbachol concentration-response 
curve (1nM – 10 µM) was then generated, with each additional concentration being 
added a cumulative maximum maximum response was observed , usually between 2-8 
min).   
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5.3.5 Data analysis 
All data are expressed as Means ± the Standard Error of the Mean (SEM), or as Mean 
values with ranges; n values are numbers of patient donors.  In the contractility studies, 
any differences in responses to carbachol between the two treatment groups were 
analysed using a two-way ANOVA with Bonferroni post-hoc test. Data from the 
immunohistochemistry study was analysed using the Student’s paired t test. 
 
5.3.6 Compounds 
All drugs were freshly prepared before use.  Erythromycin (Sigma, Gillingham, Dorset, 
UK) was dissolved in 100% ethanol, with subsequent dilution in distilled water. 
Carbachol (Sigma, UK) was dissolved in distilled water. 
 
5.4 Results 
5.4.1 Immunohistochemistry 
There were no clear differences in age for each of the patient groups.  More males 
than females were recruited although the numbers are too small to observe meaningful 
differences (Table 5.4.1). All patients in the immunohistochemistry study had gastric 
or oesophageal adenocarcinoma 
 
There was a marked decrease in expression of AChE (the scores were, respectively, 
2.3 ± 0.7, 0.5 ± 0.2 and 0 ± 0 in non-chemotherapy, oesophageal- and gastric-
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chemotherapy groups (P<0.03 each) compared with the non-chemotherapy tissues; 
Figures 5.4.1(a,b) and 5.4.2(a,b). By contrast, there was a tendency for ghrelin 
receptors and for motilin to increase (figure 5.4.2(c)), although this did not achieve 
statistical significance (ghrelin receptor: 0.7±0.4 in non-chemotherapy vs 2.0 ± 0.4 
and 1.2 ± 0.2 in oesopheal- and gastric-chemotherapy groups respectively, P=0.04 and 
0.2; motilin: 0.7 ± 0.5 vs 2.2 ± 0.5 and 2.0 ± 0.7, P=0.06 and 0.16, respectively). 
There were no consistent changes in nNOS (1.2±0.6 in non-chemotherapy vs 1.2±0.6 
and 0.5±0.34 in oesophageal and gastric-chemotherapy respectively. P>0.3 each). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.4.1 (a) 
       
Figure 5.4.1 (b)  
        
Fig 5.4.1(a) Gastric section from a non-chemotherapy patient. 
Acetylcholinesterase staining showing positive (brown) cytoplasmic staining 
within ganglion cells (arrows). Fig 5.4.1(b) Gastric section from a chemotherapy 
exposed patient. Despite an intensive search definite ganglion cells were not 
identified in this case, possibly because of degeneration from chemotherapy. The 
image shows a representative field illustrating negative staining in a 
neurovascular bundle. Original magnification x400. 
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 Figure 5.4.2 Immunohistochemistry (IHC) scores for AChE comparing non-
chemotherapy and oesophageal-chemotherapy 5.4.2(a) and gastric-
chemotherapy 5.4.2(b) exposed tissues (P<0.03 using paired student’s t-test). 
Figure 5.4.2(c) demonstrates the IHC scores for ghrelin receptor expression in 
oesophageal-chemotherapy group (P<0.04).  
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5.4.2 Gastric contractility 
Table 5.4.1 illustrates patient demographics. Again, there were more males than 
females recruited. Of the four patients receiving chemotherapy, three had gastric-
chemotherapy and one had oesophageal-chemotherapy. The patient numbers were too 
small for subgroup analysis and hence, were analysed together as a single 
chemotherapy group. Longitudinal muscle preparations from either group did not 
consistently contract in response to EFS or erythromycin.  
 
Contraction could be evoked by EFS in 2 of the 3 non-chemotherapy tissues 
(threshold 2-5 Hz) and in 1 of 4 chemotherapy tissues.  Similarly, erythromycin 10 
µM increased basal tone or contractility in some tissues, but with no obvious 
difference between chemotherapy and non-chemotherapy tissues (4 of 8 non-
chemotherapy tissues responded, compared to 2 of 4 tissues from patients receiving 
chemotherapy).  
 
Application of carbachol 1 nM – 10 µM caused a concentration-dependent contraction 
of both longitudinal and circular muscle tissues from both patient groups (Figure 
5.4.3).  However, there were clear differences between the groups of patients in terms 
of the force of contraction evoked by carbachol.  The maximal contraction produced 
by 10 µM carbachol in longitudinal muscle, for example, was 1.9 ± 0.8 g and 3.7 ± 
0.7 g in chemotherapy and non-chemotherapy tissues respectively (n = 4 and 3, 
respectively, P < 0.05) and in circular muscle, these values were 1.6 ± 0.6 and 3.4 ± 
0.4 g in chemotherapy and non-chemotherapy tissues respectively (n = 4 and 3 
respectively, P < 0.05). 
  
Figure 5.4.3 Concentration-response curves for carbachol-induced contraction of 
human isolated stomach.  The contractions were compared using preparations 
obtained from patients treated with chemotherapy and from those who were not.  
* P < 0.05 (two way ANOVA with bonferroni post-hoc test) when the 
concentration-response curves were compared (chemo longitudinal muscle vs 
non-chemo longitudinal and chemo circular muscle vs non-chemo circular); n = 
4 and 3, respectively, for both longitudinal and circular muscle. 
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5.5 Discussion 
This study is the first to show that cisplatin-based chemotherapy causes marked 
changes in human gastric function that are sustained after chemotherapy has finished.  
In particular, the absence of staining for AChE and the significant reduction in 
contractility to carbachol suggests that cisplatin profoundly influences gastric 
cholinergic function.  Such findings find consistency with the reported ability of 
cisplatin to affect cholinergic function in conscious rats (causing an increase in [3H]-
choline uptake into the cardiac region of the stomach), although not with the lack of 
change in gastric AChE staining, measured three days after treatment in the same 
study  (Aggarwal et al. 1994).  Differences in species, duration of chemotherapy 
and/or length of time after chemotherapy are likely to contribute to the differences 
observed. 
 
The reduction in cholinergic function was not clearly accompanied by a change in 
nNOS expression, suggesting that any sustained influence of cisplatin on enteric nerve 
function is not uniform throughout this nervous system.  The effects of chemotherapy 
on the nNOS isoform has not previously been studied, although in rats receiving 
cisplatin or taxol, reductions in expression of the inducible form of NOS expression 
are reported  (Wang et al. 1997), along with increases in plasma nitric oxide  
(Nagahama et al. 2002).  However, in another study there were no changes in NOS 
localisation or intensity of staining five days after dosing with cisplatin in rats  (Jarve 
et al. 1997).  Together these studies suggest the possibility that NOS expression may 
be affected by cisplatin treatment but that in our study, the changes are either too 
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subtle to be detected using the present methods and/or any changes occur immediately 
on treatment and recover thereafter.  Further studies are required to clarify this. 
 
The tendency for the expression of both ghrelin receptors and of motilin to increase 
up to six weeks after cisplatin treatment does not, by itself, indicate that the function 
of ghrelin and motilin are changed by chemotherapy.  However, the observed trend 
does find at least some consistency with studies in rats.  In another study, ghrelin 
receptor mRNA expression demonstrated in rat stomach was increased two days after 
treatment with cisplatin, at a time when the cisplatin-induced gastric stasis was at its 
greatest (Malik et al. 2008).  
 
The observed up-regulation of ghrelin receptor expression suggested that ghrelin 
might be operating as part of a defence mechanism against the damage caused by 
cisplatin; the hypothesis was suggested because of the known ability of ghrelin to 
inhibit cisplatin-induced emesis, promote appetite and increase gastric emptying  
(Malik et al. 2008; Liu et al. 2006).  However, the present findings, measured up to 
six weeks after discontinuation of treatment with cisplatin, suggest that if ghrelin were 
to play a similar defensive role in humans, any effects of ghrelin are likely to be 
overwhelmed by the more severe reduction in cholinergic function.   
 
A similar defensive role for motilin has not previously been proposed and although 
tempting to speculate that the gastric prokinetic activity of motilin would serve this 
purpose, it would be inappropriate to place too much emphasis on the present data, 
which were not statistically significant.  Interestingly, there is evidence that plasma 
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levels of motilin were transiently decreased during the day after a cisplatin-based 
treatment (Hursti et al. 2005). 
 
In summary, this study suggests that neo-adjuvant chemotherapy can cause marked 
and enduring damage to gastric function.  Most notable was the loss of AChE and 
reduction in contractility evoked by carbachol, providing a plausible explanation for 
some of the symptoms of gastric stasis reported by these patients long after 
completion of chemotherapy.   In addition, the tendency for ghrelin receptors to 
increase may be consistent with studies in animals exposed to cisplatin and suggests 
an attempt to up-regulate compensating systems.   
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6.1 Discovery of Ghrelin 
The discovery of ghrelin was an interesting journey. Although the mechanism of 
ghrelin has been studied for over 2 decades, it was only formally identified in 1999. In 
the beginning, the receptor for ghrelin was discovered prior to the actual ligand. It 
began in 1970 when an endocrine study group led by Cyril Bowers in New Orleans 
made a discovery of opioid based synthetic compounds which provoked the release of 
growth hormones. The receptor for this compound was later discovered to be distinct 
from Growth Hormone Releasing Hormone (GHRH) binding sites.  
 
Further development of similar non-opioid compounds e.g. Growth Hormone 
Releasing Peptide-6 (GHRP-6) were collectively known as Growth Hormone 
Secretagogues (GHS). Consequently, the GHS receptor, a G protein coupled receptor  
was first identified in 1996 (Pong et al. 1996). However, the natural ligand for this 
receptor remained elusive.  
 
To identify the ligand, a Japanese group produced a cell line expressing the GHS-R 
receptor and examined the intracellular calcium activity when exposed to various 
tissue extracts including the stomach  (Kojima et al. 1999a). It was then evident that 
the highest activity seemed to be produced from the stomach extracts, from which a 
28 amino acid peptide was purified. This was later named Ghrelin. The term arose 
from the Indo-European origins of which ‘Ghre’ means ‘to grow’ because of ghrelin’s 
potent ability to stimulate the release of GH. Another possible origin for its name is 
the ability to secrete.  
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Although ghrelin is a potent GH stimulator, it was soon discovered that ghrelin also 
has orexigenic properties, modulating appetite and adiposity. This sparked interest in 
the scientific community as the developed world is now struggling with rising obesity. 
It would also be fitting for the stomach to be the major ghrelin secreting organ, 
functioning as the ‘gatekeeper’ for food intake. 
 
There has been considerable interest in ghrelin since its discovery, with 4,888 
publications to date (July 2011). In many research, it has raised more questions than 
answers about the physiological role of ghrelin. Since the discovery of ghrelin and its 
receptor, it has been established that many organs, tissues and cells express the 
receptor and secrete ghrelin, albeit in much smaller quantities in comparison to the 
stomach. This has left many questions about the role of ghrelin in non-GI tissue types. 
It is most likely that ghrelin is a part of a very complex signalling repertoire that 
maintains physiological function of a particular organ, tissue or cells. However, in 
diseased states, many studies have demonstrated dysregulation of ghrelin.  
  
Ghrelin however, has an established central role in maintaining energy homeostasis, 
in balance with other energy signalling peptides. The balance of ghrelin and leptin is 
probably crucial in maintaining normal physiological balance (discussed in 1.2.1.1). It 
is generally accepted that target tissue resistance to leptin is a plausible cause for 
obesity. This however does not explain why in obesity ghrelin concentrations are 
decreased as well as increased concentrations of leptin. There are other hormonal 
influences that are involved in the regulation of not just energy intake but also energy 
expenditure which contributes to obesity.  
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The association of ghrelin and inflammation is still unclear. There are conflicting 
findings in the interplay of ghrelin and inflammation. Some studies have observed 
elevated ghrelin in some inflammatory diseases  (Mafra et al. 2011; Koch et al. 2010; 
Daniel et al. 2010). There are many possibilities to this. Elevated ghrelin may be a 
defensive response to an inflammatory stimulus in attempt to dampen the 
inflammatory response. Another possibility may be dysregulation of ghrelin by other 
unidentified factors. Conversely, other studies have observed decreased ghrelin in 
diseased state  (Carrero et al. 2010; Kim et al. 2010; Suzuki et al. 2004) . This has 
demonstrated that ghrelin dysregulation may be disease specific and interplay of other 
factors in certain diseases may affect ghrelin secretion. 
 
Such conflicting data has made interpretation of the literature difficult. However, it is 
clear that inflammation alone is unlikely to be the only factor in regulating ghrelin 
secretion. Ghrelin therapy has been has been used by some investigators to address 
the relationship between ghrelin and inflammation. Current animal studies suggests 
that that ghrelin may have anti-inflammatory properties. Majority of the evidence are 
limited to animal studies as discussed in Chapter 1. However, there are also human 
studies which demonstrate the beneficial effect of ghrelin administration in 
inflammatory conditions (Moreno et al. 2010; Kodama et al. 2008; Li et al. 2004).  
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This suggests that ghrelin is likely to be a beneficial therapeutic agent, particularly in 
chronic inflammatory conditions which characteristically have lower ghrelin 
concentration when compared with healthy controls  (Koca et al. 2008; Ukkola et al. 
2006). Further studies involving human trials are warranted to investigate this. 
Understandably, there are some concerns regarding the use of ghrelin as a drug. 
Ghrelin itself has many physiological effects, which involve endocrine, 
cardiovascular, gastrointestinal and central nervous system. Administration of ghrelin 
at supra-physiological concentrations may profoundly affect these systems and 
manifest as side effects. There will be a need for further human studies to probe the 
anti-inflammatory effects and safety of ghrelin further before human trials of ghrelin 
as a drug can materialise.  
 
In many therapeutic ghrelin studies described in Chapter 1, ghrelin was administered 
intravenously or subcutaneously. Development of an oral form ghrelin would be 
difficult due to poor bioavailability and short half-life. However, an oral form of 
ghrelin receptor agonist has been studied on healthy human subjects. EPO-1572 GHS 
receptor agonist has similar characteristics to ghrelin in inducing release of GH in 
healthy subjects  (Broglio et al. 2002; Piccoli et al. 2007). The pharmacokinetics of 
this agonist has also been studied. Intra-duodenal administration of this compound 
appears to have higher bioavailability compared to identical oral dosing. In addition, it 
has been demonstrated that the half-life of the agonist ranged from 73 to 114 minutes. 
In addition, if this agonist is taken with a meal the bioavailability of this drug is 
reduced significantly  (MacLean et al. 2009).  
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6.2 The Role of Ghrelin in Crohn’s Disease 
Crohn’s disease can be a severe debilitation inflammatory condition affecting the 
whole luminal gastrointestinal tract. Crohn’s disease consequently causes cachexia by 
reducing the physiological function of the gut to absorb nutrients, increase in 
inflammatory load, appetite suppression, and an increase in energy expenditure in a 
high catabolic state. With increase in inflammatory load and associated insulin 
resistance is likely to decrease ghrelin availability, hence the lack of desire to eat. 
Treatment of Crohn’s disease involves the modulation of inflammation by 
immunosuppressive drugs, which in turn improves the patients’ nutritional status. The 
accountable mechanism is likely to be the release of ghrelin suppression as 
demonstrated in chapter 2.   
 
The central role of ghrelin in patients with Crohn’s disease is unclear. Previous 
studies had compared fasting spot ghrelin measurements in patients with Crohn’s 
disease with controls but did not find any significant difference  (Nishi et al. 2005). In 
another study, ghrelin levels appear to be higher in patients with active IBD than 
patients in remission. Moreover, the author suggested that measuring ghrelin in these 
patients may be useful in determining disease activity  (Ates et al. 2008). This study 
also suggested the dysregulation of adipocytokines (produced by adipose tissue) in 
inflammatory pathogenesis alongside ghrelin. However, adipokines e.g. .leptin tend to 
be long term signals with little fluctuation over time in contrast to ghrelin. The 
findings in these studies should be treated with caution.  
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Ghrelin was also implicated in the pathogenesis of Crohn’s disease. As study has 
demonstrated a significant increase in ghrelin mRNA expression on colonic tissue 
with Crohn’s disease compared with controls  (Hosomi et al. 2008). The investigators 
have also demonstrated increase in activated T-cells expressing GHSR-1a receptors 
but also an increase reactivity to ghrelin in secreting IL-4 and IL-13 when  compared 
with controls    
 
Ghrelin is a dynamic hormone which has a very short half life and serum plasma 
levels tend to fluctuate significantly hour by hour. A fasting spot sample may not be 
sufficient to justify their findings depending on whether the measurement is at the 
peak or trough level. To avoid this uncertainty, measurement of ghrelin performed as 
a profile over 2 hours, with introduction of the meal to ensure validity (by revealing a 
post-prandial decrease). The calculated AUC would be a more accurate reflection of 
ghrelin status and allow sensitive detection of change. 
 
In Chapter 2 of this thesis investigates the relationship between inflammation in 
Crohn’s disease and ghrelin. It became quite clear that modulating inflammation in 
Crohn’s disease releases the inhibition of ghrelin production and produces plausible 
evidence that ghrelin in involved in the ‘hunger balance’ with TNFα (previously 
known as ‘cachexin’  (Beutler et al. 1985) because of its ability to suppress hunger 
and promote satiety). The decrease in circulating TNFα, following infliximab infusion 
improves the patients nutritional status (Wiese et al. 2008). We demonstrated a 25% 
increase in circulating ghrelin levels as a plausible mechanism for the improvement of 
nutritional status in these patients by modulating TNFα.  
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In this study, the patient results were compared before and after infliximab treatment 
hence they became their own controls, avoiding potential bias.  Although majority of 
these patients have stable disease, evidenced by their low inflammatory markers, there 
was significant change in plasma ghrelin level. It would be expected that patients with 
higher initial inflammatory load would have a more profound effect.  
 
The reciprocal relationship between TNFα and ghrelin is an interesting one and our 
findings are consistent with other studies (Jang et al. 2008; Endo et al. 2007; Birkas et 
al. 2005). This may represent a delicate balance of disease-inducing cachexia, 
regulation of inflammation or even combination of both. Ghrelin has been shown to 
be capable to reversing the effects of cachexia in animals  (Wang et al. 2006; Garcia 
et al. 2008; DeBoer et al. 2007). Ghrelin has been used successfully in cancer patients  
(Neary et al. 2004) and also patients with chronic renal failure on peritoneal dialysis  
(Wynne et al. 2005) to treat disease-induced cachexia. This had led to much interest 
to many clinicians as disease induced weight loss and anorexia has been a significant 
challenge.  
 
As for the modulation of inflammation, current evidence is largely based on animal 
and in-vitro studies. Indeed there are animal studies that showed efficacy of ghrelin as 
a therapeutic agent in inflammatory bowel disease (Gonzalez-Rey et al. 2006). In 
current human studies involving ghrelin administration, inflammatory parameters 
have not been studied. In our Crohn’s disease cohort, the effects of ghrelin on 
cachexia and immune-modulation would be highly desirable, since weight loss and 
anorexia, induced by high inflammatory load, has posed a significant challenge to all 
gastroenterologists. Hence, future clinical trials of ghrelin on patients with 
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inflammatory conditions are warranted and will provide further insight into the 
benefits of its use.  
6.3 Role of Ghrelin on Human Lymphocytes 
The thymus is a critical gland for T-cell development and maturation. There is 
evidence that ghrelin may have protective effects on age–related thymic involution. A 
study on older mice showed that synthetic GHSR-1a agonist administration increases 
the cellularity of the thymic tissues  (Koo et al. 2001; Dixit et al. 2007). This suggests 
that ghrelin may protect against age related degeneration of the immune system and 
promote lymphocyte development with a detectable increase in thymic progenitor 
cells and matured T-lymphocytes in the periphery.  
 
If ghrelin has anti-inflammatory properties, it is not inconceivable that it would have a 
profound inhibition of immune cell activation which directly contributes to 
inflammation. There is currently one in-vitro study on human lymphocytes 
demonstrating apparent attenuation of cytokine production in activated lymphocytes. 
This has so far not been reproduced. The author has taken this further by speculating 
that the action of ghrelin may be mediated by the inhibiting NFκB mediated 
inflammatory pathway. 
 
The study in Chapter 4 showed quite the contrary. NFκB is actually is upregulated 
with octanoyl-ghrelin at concentrations of 1nM and 10nM but decreases with 
increasing concentration. The rise in NFκB did not translate to an increase in cytokine 
production. The reason for this is unclear. Firstly, although the primary function of B-
lymphocyte is not the production of cytokines, our initial experiments suggest the 
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WILCL produces significant cytokines. Secondly, the characteristic of this cell line 
may have influenced the cytokine profile. Further studies involving the production of 
light chain immunoglobulins are warranted.  Thirdly, another possible mechanism 
which drives the anti-inflammatory effects of ghrelin may be NFκB mediated cellular 
apoptosis. NFκB is indeed pivotal in cellular response to environmental stress, 
including cell death. It has been shown that viral induced apoptosis is mediated by 
NFκB  (Kuhnel et al. 2000). Therefore, it possible that NFκB may be responsible for 
immune cell death resulting in overall immune-suppression. We concede that further 
studies are needed to investigate cellular apoptosis in response to ghrelin and NFκB, 
which unfortunately beyond the scope of this thesis. 
 
The study in chapter 4 also demonstrated that lymphocytes in their activated state are 
minimally influenced by exposure to ghrelin. Certainly supra-physiological 
concentration of ghrelin has failed to alter NFκB activation in activated cells. This 
crucial finding suggest that ghrelin may prime the lymphocytes for apoptosis prior to 
activation or that the effects of ghrelin on the immune system is probably weak.   
 
This study raises many important issues about the involvement of ghrelin in NFκB 
activation and lymphocyte response. Future studies are needed to investigate the 
effects of ghrelin on primary lymphocytes, cell apoptosis and also cytokine profile. 
This will provide further insight into the function of ghrelin in the immune process. 
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6.4 Role of Ghrelin in Gastric Motility 
Ghrelin has a similar homology to motilin, a natural hormone which promotes 
gastrointestinal motility. It is then not conceivable that ghrelin may have effect on 
gastric motility and emptying. Previous animal studies supports have been reported to 
induce gastric emptying  (Dornonville de la et al. 2004; Qiu et al. 2008). There are 
human studies demonstrating the increased rate of gastric emptying in healthy 
individuals when infused with ghrelin (Levin et al. 2006). Moreover, ghrelin has also 
been used successfully in diabetic patients with gastroparesis  (Murray et al. 2005).  
 
This effect is  probably physiologically mediated by efferent vagal stimulation 
although another small study suggested that the motility action of ghrelin can be 
independent of vagus innervation  (Binn et al. 2006). In addition, another animal 
study suggests that ghrelin may improve endotoxaemia induced motility disturbances 
(Chen et al. 2010). In addition to initiating peristalsis, ghrelin also has a role in 
regulating GI motility. 
  
In Chapter 5 of this thesis, the study examines the effect of oesophageo-gastric cancer 
chemotherapy on the gastric pro-motility signals by immunohistochemistry and 
gastric contractility. The destruction of the acetylcholinesterase activity in the 
chemotherapy group is apparent. The study also revealed a compensatory 
upregulation of ghrelin receptor, presumably in response to cholinergic pathway 
damage.   
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The destruction of the cholinergic activity may also contribute to the acute and 
chronic emesis following chemotherapy administration, as part of the cancer-
dyspepsia syndrome.  It is widely accepted that cancer chemotherapy induces acute 
vomiting by acting on vagal afferents via 5-HT mechanisms and also by a direct effect 
on area postremia  (Hesketh et al. 2008). There are 2 recognised vomiting syndromes 
following chemotherapy administration, acute (within 24 hours) and delayed emesis 
(occurring after 24 hours). Following this period, chemotherapy induced vomiting 
tends to subside.  
 
It is possible that the destruction of cholinergic pathways may contribute to this initial 
acute vomiting and persists after chemotherapy treatment as destruction of cholinergic 
system is observed two weeks after completion of surgery. The upregulation of 
ghrelin may be compensatory as a result of cholinergic inactivity and help mask 
further symptoms. 
 
This would have significant implications on future chemotherapy design and also 
ghrelin as a potential protector against chemotherapy-induced emesis. In addition, 
further studies involving ghrelin administration following chemotherapy will help 
further elucidate its effectiveness in prevention of vomiting. There may also be a role 
for ghrelin or its agonist in patients who have persistent ‘cancer-associated dyspepsia’ 
following treatment.  
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In summary, this thesis revealed that modulating TNFα in Crohn’s disease can 
increase circulating ghrelin concentration, and suggests an immune-modulating role. 
In addition, ghrelin may also have a crucial role in managing disease induced 
cachexia by not just by reversing the cachectic effects of TNFα but also 
therapeutically inducing appetite and stimulate food intake. Ghrelin is also shown to 
upregulate NFκB in human B-lymphocytes but did not translate to any meaningful 
cytokine production. This raises the possibility that NFκB may have a different role 
e.g. Regulation of apoptosis in human lymphocytes. Thus, ghrelin has a complex 
immune-modulatory role which is still yet to be elucidated.  
 
This thesis has also shown that ghrelin mechanisms are upregulated in response 
cancer chemotherapy induced damage to cholinergic activity, suggesting a protective 
role of ghrelin to regulate gastric motility. The findings also improves our 
understanding of the mechanisms that underpin post chemotherapy dyspepsia, and 
help designing new therapies to relieve the debilitating symptoms, that in the future 
we may be capable of improving the quality of life for these cancer patients. 
 
6.5 Strengths and weaknesses of this thesis 
This thesis is the result of 2 year research work undertaken at the Clinical Sciences 
Research institute at the University Hospital Coventry site without prior laboratory 
experience. All laboratory skills were acquired during time in laboratory. 
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6.5.1 Ghrelin in Crohn’s disease  
 This is a novel study investigating the consequence of anti TNFα therapy on the 
ghrelin profile in patients with Crohn’s disease. No similar studies have been 
published previously. This unique study demonstrates how modulating inflammation 
in Crohn’s disease can alter a hunger mechanism. Previous studies measured spot 
ghrelin concentrations in this patients. In this study, ghrelin when measured as a 
profile over 2 hours provides a more accurate method of analyzing this very dynamic 
hormone with a short half life. The number of patients recruited were small due to 
time constraints as each patient was recruited over a 2 month period, in between anti-
TNFα infusions. New commercially developed ELISAs and Bioplex assays were 
made available upon completion of patient recruitment. Significant data losses were 
observed in quantifying acylated and total ghrelin due to susceptibility of ghrelin to 
degradation. Based on previous experience of this research unit, aprotinin (Triasylol) 
was added to plasma samples on collection to reduce the degradation of ghrelin. It is 
possible that using a different protease inhibitor eg .Pefabloc (Roche) and 
acidification of the samples, as recommended by new ELISA assays, may have 
reduced data losses. Repeating the sample collection from all patients to assess the 
efficacy of the new protease inhibitors was not possible. It would be desirable to 
obtain data on calorie intake in these patients to demonstrate the effects of increased 
ghrelin concentrations after anti-TNFα treatment. Although food diaries have been 
sent to all participants, only one patient diary was retuned partially completed which 
did not allow analysis. 
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6.5.2 Ghrelin, NFκB and Human lymphocytes 
A published study suggest that ghrelin may attenuate pro-inflammatory cytokine 
production in human T-lymphocytes, and these findings were not substantiated by 
other studies. This is the first published experiment investigating the effects of ghrelin 
on NFκB upstream of cytokine production. Although this study established the 
characteristics of the B-lymphocyte cells in producing cytokines, it is not a primary 
function of B-lymphocytes. Analysis of κ-light chain production in the culture 
medium is also a possible endpoint although this was not an established characteristic 
of the cell line and not analyzed due to time constraints. It would be desirable to have 
replicated the experiments with the T-lymphocyte cell lines but this was not possible 
due to time constraints. A positive control would have been useful in validating the 
results of the NFκB activation. It is also accepted that the experiments should have 
been repeated more than 6 occasions and also assayed in triplicates. 
 
6.5.3 Cancer chemotherapy and gastric motility 
This study demonstrates the effect of cancer chemotherapy on gastric neurotransmitter 
expression and contractility. This unique study combines both immunohistochemistry 
work and also contractility experiments to explain the decreased gastric contractility. 
This highlights the toxicity of cancer chemotherapy to gastric function and may be 
important in future cancer chemotherapy design. The study numbers are unfortunately 
small, particularly in the gastric contractility study. There were far fewer patients 
undertaking surgery without chemotherapy which resulted in small patient numbers in 
this group. Participation in this study was frequently declined as these patients were 
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experiencing anxious and worrying times in the face of major, potentially complicated 
surgery. Unfortunately this study is not sufficiently powered to differentiate the 2 
different cancer chemotherapy used (oesophageal and gastric chemotherapy) due to 
small numbers. These patients were grouped collectively as cisplatin-based 
chemotherapy as many animal studies have demonstrated cisplatin has potent 
influences on gastric dysmotility. 
 
The three experiments described in this thesis are novel studies not previously 
reported and it provides an insight into the undiscovered characteristics of ghrelin 
function. Many limitations of this thesis work is attributable to time and cost 
constraints.  
 
 
 
 
 
 
 
 
 
 
 
 
142 
 
Appendix 
 
All experiments described in this thesis were undertaken between May 2006 to May 
2008, during my tenure as clinical research fellow at Warwick University and the 
University Hospital Coventry. This work was supervised by Professor Chuka 
Nwokolo and Dr. Paul O’Hare. Most laboratory work was based at the Clinical 
Sciences Research Institute based at the university hospital, in collaboration with the 
Diabetes and Metabolism group led by Dr. Philip McTernan. The research was funded 
by Professor Nwokolo’s research funds and a research grant from GlaxoSmithKline. 
As part of my collaborative work with GSK, fresh stomach and colonic tissues 
extracted from patients undergoing cancer surgery were couriered to GSK laboratory 
for motility studies. During our collaborative work, it seemed that tissues that have 
been exposed to cancer chemotherapy had poor motility response to stimulation. The 
collaborative work with GSK neurogastroenterology unit fascilitated the completion 
gastric contractility experiment in chapter 5. 
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Publications 
 
There are 2 papers published from the work of this thesis: 
1. Increased plasma ghrelin following infliximab in Crohn’s disease  
Sung E, DA Silva NF, Goodyear S, McTernan PG, Sanger GJ, Nwokolo CU. 
Aliment Pharmacol Ther; Volume 29, Issue 1, January 2009, 83–89 
 
2. Ghrelin Promotes Nuclear Factor Kappa-B in Human B-Lymphocyte Cell 
Line  
Sung EZH, Da Silva NF, Goodyear SJ, McTernan PG, Nwokolo CU 
Mol Bio Rep 2010 Dec 5 (Epub ahead of print) 
 
3. Long- term consequences of neo-adjuvant chemotherapy for oesophago-
gastric cancer on gastric contractility and innervations       
Sung EZH, Jarvie EM, James S, Goodyear SJ, Borman RA, Snead D, Sanger 
GJ, Nwokolo CU (In press, accepted for publication in Molecular Biology  
Reports) 
 
During my time in research, I also co-authored the following in collaborative work: 
1. Dysregulation of plasma ghrelin in alcoholic cirrhosis 
Stephen J Goodyear, Marcus Mottershead, Edmond ZH Sung, Ling S 
Wong, Philip G McTernan, Sudhesh Kumar, Chuka U Nwokolo 
Clin Endocrinol (Oxf) 2010 Sep; 73(3):323-9 Epub 2010 Feb 23 
 
2. Activation of prostaglandin EP receptors by lubiprostone in rat and 
human stomach and colon 
Bassil AK, Borman RA, Jarvie EM, McArthur-Wilson RJ, Thangiah R, Sung 
EZ, Lee K, Sanger GJ. 
Br J Pharmacol. 2008 May;154(1):126-35.  
 
3. Altered mRNA expression of telomere binding proteins (TPP1, POT1, 
RAP1, TRF1 and TRF2) in ulcerative colitis and Crohn’s disease 
 Da Silva N, Arasaradnam R, Getcliffe K, Sung E, Oo Y, Nwokolo C 
 Dig Liver Dis 2010 Aug;42(8):544-8. Epub 2010 Jan 12 
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Presentations at meetings 
 
The work from this thesis has been presented in the following meetings : 
 
1. Midlands Gastroenterological Society (June 2007) 
 Increased plasma ghrelin following infliximab in Crohn’s disease (Oral 
 presentation) 
 
2. British Society of Gastroenterology (March 2008) 
 Ghrelin increases nuclear factor kappa-B expression and activity in 
 human lymphocyte cell line (Oral presentation, Gut 2008; 57:A1-
 A172) 
 
3. Digestive Disease Week (May 2008) 
 Increased plasma ghrelin following infliximab infusion in Crohn’s 
 disease (Gastroenterology 2008; Vol 134, Issue 4, Supplement 1, Page  
 A-667) 
 
4. Digestive Disease Week (June 2009) 
 Long term consequences of neo-adjuvant chemotherapy for 
 oesophago-gastric cancer on gastric contractility and innervation 
 (Gastroenterology 2009l Vol. 136, Issue 5, Supplement 1, Page A-420) 
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SUMMARY
Background
Ghrelin, a potent orexigenic peptide produced by the stomach, may be
affected by circulating inflammatory mediators.
Aim
To assess the effect of an anti-TNFa antibody on ghrelin in patients
with Crohn’s disease (CD).
Methods
Fifteen patients with Crohn’s receiving infliximab were studied before
and 1 week after infusion. Following an overnight fast, blood was sam-
pled before a meal and then every 20 min for 2 h. Total ghrelin and
CRP were measured using ELISA. Acylated ghrelin and TNFa, IFNc, IL-1b
and IL-6 were measured with bioplex. Harvey Bradshaw Activity Index
was assessed.
Results
Median (95% CI) 2-h integrated plasma total ghrelin increased from 162
(99–311) before infliximab to 200 (128–387) pg ⁄mL h, (P = 0.02) after.
Following infliximab, 20 min postmeal, median acylated ghrelin
decreased from 50.3 (24–64) to 38.6 (26–82) pg ⁄mL, (P = 0.04) thus
reverting to a traditional meal related ghrelin curve. Median (range) dis-
ease activity decreased from 5 (2–28) before to 3 (0–22), (P = 0.0001)
and Median (95% CI) TNFa decreased from 2.8 (1.89–4.48) to 1.31
(0.73–2.06) pg ⁄mL (P = 0.002).
Conclusions
Infliximab increases circulating total ghrelin by 25% in CD and restores
the postprandial response of acylated ghrelin to food intake. Acylated
and de-sacyl ghrelin remain unchanged, suggesting that an alternate
isoform could be affected by infliximab.
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INTRODUCTION
Ghrelin is a novel 28 amino acid peptide first discov-
ered in 19991 and is the natural ligand for the growth
hormone secretagogue receptor (GHS-R).2 The stomach
produces two-thirds of circulating ghrelin, demon-
strated by the decrease in plasma ghrelin concentration
following gastrectomy.3 In humans, ghrelin is encoded
in chromosome 3.4 It is initially translated into a pre-
cursor, preproghrelin and subsequent cleavage pro-
duces two main forms. The first is acylated ghrelin, a
28-amino acid peptide with post-translational n-octa-
noylation of its serine at position 3, which is regarded
as the ‘active’ isoform. The octanoylation process is
essential for its biological activity. The second form of
ghrelin is the des-[Gln14] formed from alternate splic-
ing of the ghrelin gene,5 known as des-acyl ghrelin.
The biological role of des-acyl ghrelin remains
unknown with conflicting reports regarding its func-
tion.6, 7 However, this form of ghrelin can also undergo
octanoylation and become biologically active.
The GHS-R receptor for ghrelin is found in abun-
dance in the arcuate nucleus of the hypothalamus.8
Ghrelin is the most potent stimulator of growth hor-
mone release in humans.9 Ghrelin also stimulates hun-
ger, initiates feeding10 and increases food intake in
animals11 and humans.12 It is regarded as the only
known circulating ‘hunger hormone’ in intact mam-
mals and is thought to play an important role in
energy balance. In humans of normal or low body mass
index (BMI), ghrelin concentrations are high during
fasting and decrease immediately after a meal is eaten.
This effect is blunted in obese individuals, suggesting a
dysregulation of ghrelin in these individuals.13
There is emerging evidence that ghrelin may have
immune-modulatory effects. In rats with pancreatitis,
it attenuates pancreatic damage by decreasing the
release of pro-inflammatory IL-1b cytokine.14 Ghrelin,
when infused into rats, protects against ethanol
induced gastric ulcers.15–17 A ghrelin agonist amelio-
rates experimentally induced inflammatory arthritis by
decreasing the production of IL-6.18
Growth hormone secretagogue receptors are
expressed in human immune cells suggesting that
ghrelin may play a role in the function of the lympho-
cytes.19 Studies have shown that ghrelin decreases the
release of proinflammatory cytokines (TNFa, IL-1b and
IL-6) by activated human monocytes and lymphocytes.
This anti-inflammatory action is opposite to that
reported for leptin.20 Further studies on human
endothelial cells suggest that ghrelin may inhibit
nuclear factor kappa-B activation, decrease TNFa-
induced proinflammatory cytokine production and
thus protect against the development of atherosclerotic
disease. On this basis, it has been suggested that the
accelerated atherosclerosis in obesity may be in part
because of low levels of circulating ghrelin observed
in these individuals.21 There are no studies on humans
investigating the link between ghrelin and the immune
system.
Crohn’s disease (CD) is characterized by chronic
inflammation involving the gastrointestinal tract.
While the cause remains unknown, there are several
contributing factors, including genetic, immunological,
infective and environmental factors. It commonly
affects the small intestines, but can affect any part of
the gastrointestinal tract from the mouth to anus, with
transmural inflammation and fistula formation being
its important hallmarks. Weight loss and malnutrition
are commonly reported as resulting from multiple fac-
tors including poor appetite. Infliximab, a chimeric
antibody active against TNFa, is an effective treatment
for moderately severe CD.22
We hypothesized that circulating ghrelin concentra-
tion may change when TNFa activity is altered by
infliximab in patients with CD. In this study, we
assessed the effect of infliximab infusion on the total,
acylated and desacyl isoforms of ghrelin in patients
with CD and related this to changes in biochemical
and clinical measures of inflammation in CD.
METHODS
Patient characteristics
Fifteen patients with CD receiving infliximab were
recruited. Patients with gastrectomy or gastric by-pass
surgery were excluded. Mean age for all patients was
31 (range 21–50) and 10 were male. Mean BMI was 23
(range 19–34). Table 1 shows demographic and clinical
characteristics of each patient. There was no change in
drug treatment during the study.
Protocol
Each patient was studied on two occasions, immedi-
ately before and 1 week after an infusion of infliximab
(5 mg ⁄kg). All studies were started between 08:00 and
10:00 h. In five patients, the study conducted ‘1 week
after’ infliximab was performed first followed by the
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‘immediately before’ study performed just before the
next infusion, usually 7 weeks later. This allowed us
to exclude any effect that could be attributed to the
order in which the studies were conducted. Following
an overnight fast, an 18 G cannula was inserted into a
forearm vein. A 20 mL sample of blood was collected
in a lithium heparin tube containing 20 U ⁄mL of apro-
tonin. A 450 cal meal consisting of a cereal bar, a
slice of buttered toast, a glass of orange juice (250 mL)
and a cup of tea with milk (180 mL) was eaten. Fol-
lowing this, further samples were taken every 20 min
for 2 h. Blood samples were centrifuged immediately,
plasma extracted and stored at )80 C for later analy-
sis. Assays were performed for plasma total ghrelin,
acylated ghrelin, desacyl ghrelin, C-reactive protein
and a panel of cytokines. The Harvey Bradshaw Activ-
ity Index (HBAI) was calculated for each patient on
each study occasion.
Assays
Ghrelin. All samples were assayed in duplicate. Total
ghrelin, was measured by ELISA (Catalogue DSL-10-
33700; Diagnostics Systems Laboratory, Webster, TX,
USA). Inter-assay variation was 7%. Acylated ghrelin
was assayed using Linco Gut Panel Multiplex (Cata-
logue HGT-68K; Linco Research, St. Charles, MO,
USA). Inter-assay variation was 2.06%. Desacyl ghrelin
was assayed using an EIA kit (Catalogue A05119; SPI-
BIO, Montigny le Bretonneux, France). Inter-assay var-
iation was 6.6%. The Tecan GENios plate reader with
Magellan ver.4 software (Tecan Group Ltd., Mannedorf,
Switzerland) was used to analyse the results.
C-reactive protein (CRP). C-reactive protein was
measured by ELISA using the High Sensitivity C-Reac-
tive Protein EIA (Catalogue 2210; Life diagnostics Inc.,
West Chester, PA, USA).
Cytokines. TNFa, IL-1b, IL-6 and IFN-c were mea-
sured using the High Sensitivity Human Cytokine
Lincoplex Kit (Catalogue: HSCYTO-60SK; Linco
Research) with the Bio-Plex system (Bio-Rad Labora-
tories Inc., Hercules, CA, USA). Results were generated
using Bio-Plex Manager software ver.4 (Bio-Rad
Laboratories Inc., Hercules, CA, USA).
Data processing
The principles of data processing were agreed by
investigators before the study and adhered to strictly
during data analysis. Data loss was defined as failure
of an assay to record a value for a time point. As
assays were performed in duplicate when data were
unavailable for one or both wells, this was regarded as
data loss for that time point. If a single time point is
lost, a value is calculated which is the average of the
Table 1. Demographic and clinical data for 15 patients with Crohn’s disease
Patient Age Gender BMI Disease site Immunomodulation Previous surgery
1 27 F 22 Perianal, colonic Azathioprine No surgery
2 22 M 34 Ileal Azathioprine No surgery
3 21 M 21 Ileal, colonic Azathioprine No surgery
4 50 M 24 Perianal Azathioprine No surgery
5 27 M 22 Colonic Azathioprine No surgery
6 23 M 23 Ileal, colonic Azathioprine No surgery
7 30 M 22 Ileal, colonic Azathioprine Panproctocolectomy
8 39 F 21 Ileal, colonic, perianal None Panproctocolectomy
9 29 F 24 Ileal, perianal None Right hemicolectomy
10 45 M 21 Colonic, perianal Azathioprine No surgery
11 30 M 21 Colonic, perianal Azathioprine No surgery
12 23 M 19 Ileal, colonic Azathioprine Right hemicolectomy
13 49 F 25 Ileal, colonic Azathioprine No surgery
14 34 F 24 Ileal Azathioprine Right hemicolectomy
15 24 M 21 Colonic Azathioprine No surgery
BMI, body mass index.
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values of the two adjacent time points. If the lost time
point is either the first or last time point in the profile,
then the single adjacent value was assigned to that
time point. If data are lost for two adjacent time points
in a 2-h profile, such a profile was declared invalid
and the patient was excluded from the final analyses.
Statistics
For each patient, a 2-h profile of ghrelin concentration
before and after infliximab was available. From these
data, a 2-h integrated ghrelin concentration or area
under the curve (AUC) for the study period was calcu-
lated using the trapezoid rule.
C-reactive protein, cytokines and glucose and insu-
lin were measured in fasting samples taken before and
after infliximab.
Data are described in nonparametric terms and as
all comparisons were paired, the Wilcoxon’s matched
pair nonparametric test was used throughout. Graph-
pad Prism software was used for the analysis.
Ethical considerations
The study was approved by Coventry Research Ethics
Committee and the R & D Department of the Univer-
sity Hospital of Coventry. The patients gave written
informed consent.
RESULTS
Following adjustment for data loss, data were avail-
able for 11, 9 and 15 patients in the total ghrelin,
acylated ghrelin and des-acyl ghrelin groups respec-
tively. The assay for acylated ghrelin was subject to
most data loss partly because acylated ghrelin is a
small fraction of all circulating ghrelin isoforms.
Ghrelin
Total ghrelin (n = 11). Figure 1 shows that following
infliximab infusion, there was a higher median con-
centration of total ghrelin during the 2-h study period.
It also shows a typical postprandial decrease in plasma
ghrelin in both profiles.
Figure 2 shows that plasma integrated total ghrelin
for the 2-h study period increased in nine of the 11
patients following infliximab. Figure 3 and Table 2
show that median (95% CI) plasma integrated total
ghrelin for the 11 subjects increased by 25% from 162
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Figure 1. Median plasma total ghrelin (pg ⁄mL) concen-
tration profiles for 11 patients pre- and postinfliximab
infusion. A 450 cal meal was eaten immediately after the
fasting blood sampling at t = 0. Both curves show the
typical postprandial decrease in total ghrelin.
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Figure 2. Two-hour integrated plasma total ghrelin
(pg ⁄mL h) for 11 patients pre- and postinfliximab
infusion. Integrated ghrelin is increased in nine of 11
patients after infliximab.
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Figure 3. Median 2-h integrated plasma total ghrelin area
under the curve (pg ⁄mL h) for 11 patients pre- and
postinfliximab infusion. Median (95% CI) 2-h
integrated total ghrelin increased by 25% from 162 (99–
311) pg ⁄mL h before to 200 (128–387) pg ⁄mL h
1 week after infliximab infusion (P = 0.02).
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(99–341) pg ⁄mL h before infliximab to 200 (128–
387) pg ⁄mL h (P = 0.02) 1 week after infliximab.
Acylated ghrelin (n = 9). Figure 4 shows the profiles
of median plasma acylated ghrelin concentration
before and after infliximab. A normal postprandial
decrease in ghrelin is absent in the before infliximab
profile. However, in the after infliximab profile, at
20 min postmeal, median (95% CI) acylated ghrelin
concentration decreased below fasting concentration
(Table2) and was also significantly lower than the
same time point in the before infliximab profile [38.6
(26–82) pg ⁄mL vs. 50.3 (27–64) pg ⁄mL; P = 0.04].
Thus, in the after infliximab profile, the traditional
meal-related ghrelin curve with its postprandial dip is
restored. Over the 2-h study period, integrated
acylated ghrelin increased nonsignificantly from 91
(49–142) pg ⁄mL h before infliximab to 102
(47–139) pg ⁄mL h after infliximab (Table 2), a trend
similar to that observed for total ghrelin.
Des-acylated ghrelin (n = 15). There was no statisti-
cal difference in median (95% CI) integrated des-acyl-
ated ghrelin, which was 397 (356–648) pg ⁄mL h
before infliximab and 423 (331–651) pg ⁄mL h after
(Table 2).
Cytokines (Table 3)
TNFa. Median (95% CI) TNFa concentration decreased
significantly from 2.8 (1.89–4.48) pg ⁄mL before inflix-
imab to 1.31 (0.73–2.06) pg ⁄mL (P = 0.002) after inf-
liximab.
IL-1b, IL-6, and IFN-c. Before and after infliximab
median (range) IL-1b values were 0.7 (0.55–1.76) and
0.89 (0.69–1.96) respectively, median (95% CI) IL-6
Table 2. Summary of ghrelin
data
Pre-infliximab
(95% CI)
Post-infliximab
(95% CI) P-value
Total ghrelin AUC (pg ⁄mL h) 162 (99–341) 200 (128–387) 0.02
Acylated ghrelin (pg ⁄mL) at t = 20 min 50.3 (24–64) 38.6 (26–82) 0.04
Acylated ghrelin AUC (pg ⁄mL h) 91 (49–142) 102 (47–139) 0.38
Des-acylated ghrelin AUC (pg ⁄mL h) 397 (356–648) 423 (331–651) 0.63
AUC, area under the curve.
P-value is derived from comparison between paired pre- and postinfliximab studies
using the Wilcoxon Rank Sum Test.
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Figure 4. Median plasma acylated ghrelin concentration
profiles for nine patients pre- and postinfliximab
infusion. Unlike the pre-infliximab profile, the post-
infusion shows a typical postprandial decrease in acylated
ghrelin with median (95% CI) plasma acylated ghrelin
concentration at t = 20 min being significantly lower
than the same time point in the pre-inflixmab curve [38.6
(26–82) pg ⁄mL vs. 50.3 (24–64) pg ⁄mL; P = 0.04].
Table 3. Summary of cytokine data
Pre-infliximab
(95% CI)
Postinfliximab
(95% CI) P-value
TNFa (pg ⁄mL) 2.8 (1.89–48) 1.31 (0.73–2.06) 0.002
IL-1b (pg ⁄mL) 0.7 (0.55–1.76) 0.89 (0.69–1.96) 0.16
IL-6 (pg ⁄mL) 20.6 (13.0–29.9) 20.7 (12.5–27.9) 0.10
IFNc (pg ⁄mL) 10.8 (4.7–22.3) 7.3 (4.6–23.9) 0.70
P-value is derived from comparison between paired pre- and
postinfliximab studies using the Wilcoxon Rank Sum Test.
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values were 20.6 (13.0–29.9) and 20.7 (12.5–27.9)
respectively and median (95% CI) IFN-c values were
10.8 (4.7–22.3) and 7.3 (4.6–23.9) respectively. There
was no significant difference.
C-reactive protein
C-reactive protein concentration decreased nonsignifi-
cantly from 2.1 (0.57–7.44) mg ⁄mL before infliximab
to 0.7 (0.11–3.28) mg ⁄mL after infliximab.
Harvey Bradshaw Activity Index
Median (range) HBAI decreased from 5 (2–28) before
infliximab to 3 (0–22) after infliximab, (P = 0.0001).
DISCUSSION
Our study design extending over a 2-h period took
account of the pulsatile nature of ghrelin secretion in
humans. The eating of a meal was also included in the
study period to test ghrelin regulatory mechanisms.
We were able to report and compare data as ‘area
under the curve’ and 2-h concentration profiles imme-
diately before and 1 week after the infusion of inflix-
imab. Our study provides novel evidence that
systemically altering an important inflammatory medi-
ator like TNFa can lead to changes in circulating ghre-
lin. The infusion of infliximab led in CD patients to a
25% decrease in total ghrelin concentration assessed
during a 2-h period after a meal. As expected, there
was a significant decrease in TNFa and CD activity. A
similar trend was observed for CRP. The relatively low
concentrations of TNFa and CRP reflect that our study
patients, the majority in maintenance infliximab pro-
grammes, were in clinical remission. It would be of
interest to study patients who start with a higher
inflammatory burden who, we believe, would show an
exaggeration of the changes in ghrelin observed in
our study. It is possible that ghrelin producing cells
can sense and respond to changes in circulating TNFa.
This mechanism may operate at the cellular level with
circulating TNFa exerting a direct effect on gastric
ghrelin producing cells. Another hypothesis is that
TNFa might act centrally and modulate circulating
ghrelin through the efferent vagal nerves to the stom-
ach. In a recent study, rats that were rendered hypo-
phagic by TNFa administration were found to have
decreased gastric and circulating ghrelin leading to the
conclusion that some of the anorexic effects of TNFa
are mediated via ghrelin. In that study, the effects of
hypophagia induced by TNFa could be reversed by
administration of ghrelin.23
Circulating acylated ghrelin is often referred to as
‘active’ ghrelin. This isoform stimulates hunger and
growth hormone release by acting on hypothalamic
nuclei. In our Crohn’s patients, at the time of maxi-
mum inflammatory activity, the acylated ghrelin con-
centration at the 20-min time point is higher than the
preceding fasting value. There was no postprandial
decrease in acylated ghrelin concentration, which is an
accepted feature of a normal ghrelin curve. Similar
abnormalities in postprandial ghrelin profiles have
been reported in obesity and non-alcoholic steato-
hepatitis, two diseases that a have a significant inflam-
matory contribution to their pathophysiology.13, 24
Following infliximab infusion in our patients, the
acylated ghrelin curve was normalized and the 20-min
ghrelin concentration is lower than the preceding fast-
ing value. Thus, inflammation in general and perhaps
TNFa specifically affect not only total ghrelin produc-
tion but may also modify the mechanisms that regu-
late ghrelin production in the stomach.
Our study also showed that des-acyl ghrelin, an iso-
form that still has an uncertain physiological role, was
not affected either in terms of its profile or AUC by
infliximab.
In conclusion, this study provides novel evidence
that altering TNFa with a biological agent can affect
circulating ghrelin in humans. It adds further evidence
that ghrelin and inflammatory mediators interact in
inflammatory diseases like CD pointing to a possible
immuno-modulatory role. Our study suggests that nei-
ther des-acyl nor acylated ghrelin mediates this role
raising the possibility that a yet unrecognized biologi-
cal isoform could be involved. We acknowledge that
inter-assay variability could explain the difference in
results seen with the ghrelin isoforms. An infliximab-
induced increase in circulating plasma ghrelin, if
accompanied by increased food intake, suggests
another mechanism by which this drug might improve
well-being in CD patients.
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Abstract Ghrelin, an orexigenic hormone of gastric ori-
gin that stimulates growth hormone secretion, may modu-
late inflammation. This experimental study examines the
effect of ghrelin on NFjB (p65 subunit), a transcriptional
factor involved in inflammation on a human B-lymphocyte
cell (WILCL). After confirming the expression of ghrelin
receptor protein using western blotting the cells were
transferred to wells maintaining a density of 1 9 106 cells
per ml and a proportion activated with phytohaemaglutti-
nin. Activated and resting cells were exposed to octanoyl-,
desoctanoyl ghrelin and a non-peptide ghrelin agonist
(Pfizer CP-464709) in increasing concentrations for 6 h.
Cell protein extracts were analyzed for NFjB activation
using Trans AM NFjB p65 assay. IL-6, IL-8, IL-10,
IL-13 and TNFa were measured in the media using
Lincoplex human cytokine assay. In octanoyl ghrelin
treated resting cells, NFjB activity (Optical Density
OD450nm) (mean ± SEM) in control cells was 0.42 ± 0.10
and increased to 0.61 ± 0.20 (P = 0.044), 0.54 ± 0.10
(P = 0.043), 0.52 ± 0.08 at 1, 10 and 100 nM concen-
trations respectively. No effect was detected with desoc-
tanoyl ghrelin or ghrelin agonist and no specific change in
cytokine production. In conclusion, Octanoyl ghrelin
increased NFjB activation by up to 50% in a B-lympho-
cyte cell line suggesting an effect on the inflammatory
process.
Keywords Nuclear factor kappa-B  Lymphocyte 
Ghrelin  Ghrelin receptor  Human
Abbreviations
NFjB Nuclear factor kappa-B
IjB Inhibitory kappa-B
IL Interleukin
TNF Tunour necrosis factor
GHSR Growth hormone secretagogue receptor
PHA Phytohaemagglutinin
Introduction
Ghrelin is a 28 amino acid signaling peptide produced
mainly by the stomach [1] but also in smaller quantities by
other organs. It is the natural ligand for the growth hor-
mone secretagogue receptor, GHSR-1a [2], now recog-
nized widely as the ghrelin receptor. There are two main
isoforms of ghrelin, octanoyl ghrelin which is thought to be
the biologically active and desoctanoyl ghrelin, an isoform
of which the primary function is still undetermined.
Ghrelin is a potent stimulant of growth hormone release
and also has an established role in the control of hunger and
energy hemostasis [3]. Recent studies suggest that it may
have an immunomodulatory role. In animal studies ghrelin
seems to protect against inflammatory damage [4–6]. The
presence of ghrelin receptors on human immune cells [7]
and the suppression of inflammatory cytokine (IL-1b, IL-6
and TNFa) secretion by these cells when exposed to
ghrelin in vitro suggests a possible immnuno-modulatory
role. This effect appears to be opposite to that of leptin [8].
A nuclear factor kappa B (NFjB) a nuclear transcrip-
tional factor discovered in 1986 [9], is involved in the
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cellular responses to an environmental stress, by inducing
the production of protective signals. NFjB is held inactive in
cellular cytoplasm by inhibitory kappa B (IjB). NFjB
activation involves dephosphorylation of IjB and releasing
NFjB [10]. The conserved N-terminus of NFjB then binds
to the DNA and promotes the transcription of a variety of
pro-inflammatory signals. In B-lymphocytes, NFjB plays a
significant role in immunoglobulin production. The gene
enhancer for j light chain is activated by NFjB and found to
be crucial for B-cell maturation and function against
pathogens [11]. More recently, NFjB is demonstrated to
play an important role in driving and coordinating the innate
and adaptive immune response to an antigen [12]. NFjB has
various roles in the inflammatory process, particularly in
uncontrolled lymphocyte activation, and has been a subject
of interest as a therapeutic target [13]. In addition, NFjB
activation is also thought to be involved in cellular apoptosis
[14] and also implicated in tumour invasion [15].
The objective of this study is to investigate the effect of
ghrelin on NFjB activation and inflammatory cytokine
production in human B-lymphocyte cell line. If ghrelin has
immunomodulatory properties, we hypothesize that ghrelin
may decrease NFjB activation in a B-lymphocyte cell line.
Although immunoglobulin production is a measure of
primary B-lymphocyte cell function, it is uncertain if this
characteristic is replicated in the cell line we used. We
therefore focused our enquiry on cell activation and NFjB
expression both upstream of immunoglobulin production
but established characteristics of the cell line we studied.
Materials and methods
Cell line selection and screening experiments
Four cell lines, 2 B-lymphocyte (WILCL, ECACC Cat:
89120565; DAUDI, ECACC Cat: 85011437) and 2 T-lym-
phocyte (JM, ECACC Cat: 86010201; HUT-78, ECACC
Cat: 88041901) were tested for expression of the ghrelin
receptor. Briefly cells were cultured in appropriate medium,
collected and lysed. Total protein was extracted and quan-
tified. Using western blotting techniques, the GHSR 1a (now
known as the ghrelin receptor) and the dormant GHSR 1b
receptor was detected using commercially available anti-
bodies from Phoenix Pharmaceuticals Inc, CA, USA (GHSR
1a, Cat G-001-62; GHSR 1b, Cat G-001-61) (Fig. 1). The
WILCL cell line, a normal Caucasian human B-cell lym-
phoblast immortalized by the Epstein-Barr virus expressed
ghrelin receptors and was used for the rest of the study.
Phyothaemagglutinin (PHA) was used for lymphocyte
activation. The optimal concentration of PHA was esti-
mated using tryphan blue staining for cell viability. PHA
concentration of 0.5 mg/ml was optimal for WILCL cell
activation. We assessed the effect of the compounds on
activated and resting cells.
To assess the effect of ghrelin isoforms and a non-
peptide ghrelin agonist on the cell line, each treated well
was compared to control wells with no additions.
A screening experiment (performed in triplicate) using
time points of 6, 24 and 48 h were performed using octa-
noyl ghrelin on resting and activated cells (Table 1). A
response was detected at 6 h to PHA activation and octa-
noyl ghrelin. In all subsequent experiments 6 h incubation
duration was applied.
Cell resuscitation and culture
Cells were resuscitated from liquid nitrogen storage in a
warm water bath (37C), added to a flask containing 5 ml
of pre-prepared media and were grown in RPMI 1640
media (Invitrogen, UK) enriched with L-glutamine
(200 mM), penicillin (100 U/ml), streptomycin (100 lg/
ml) and 10% fetal bovine serum (Invitrogen, UK). Cell
density was maintained at 3–5 9 106/ml using a haema-
cytometer. They were cultured in an incubator maintaining
an environment of 5% CO2 and 95% air. Media was
changed every 2–3 days and cell subculture was performed
to maintain cell density.
Cells cultured in flasks were centrifuged (150 g for
10 min) and resuspended in fresh media. 1 9 106/cells
were added to each well of a 6-well culture plate.
The lymphocytes were activated by PHA (Sigma, UK) as
described earlier and exposed to 3 different compounds
namely; octanoyl ghrelin (Phoenix, CA, USA; Cat. 031-39),
des-octanoyl Ghrelin (Phoenix, CA, USA; Cat. 031-32) and
Fig. 1 Western blots of the ghrelin receptor protein in WILCIL
human B-lymphocyte cell line. Human adipose tissue protein extracts
which has been confirmed to express both ghrelin and GHSR-1b
receptors are used for positive controls. The ghrelin receptors
(42 kDa) and GHSR 1b (32 kDa) are demonstrated in both resting
and activated lymphocyte cells
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a non-peptide ghrelin agonist (Pfizer CP-464709) [16, 17]
which has been used in motility studies. These compounds
were added to the wells with resting and PHA activated cells
to make up concentrations of control cells (no addition), 1,
10 and 100 nM. For the ghrelin receptor agonist and des-
octanoyl ghrelin that are not natural ligands of the ghrelin
receptor, we widened the concentration range to include 0.1
and 1000 nM. The cells were then washed, collected and
frozen to -80C. The cell pellets were later lysed and pro-
tein content were extracted and quantified.
NFjB assay
NFjB expression was analysed using Active Motif Tran-
sAM NFjB p65 (Cat: 31102, CA, USA) ELISA-based
assay. In brief, this assay consists of a 96 well plate each
coated with an oligonucleotide containing the NFjB con-
sensus region (50-GGGACTTTCC-30) which the active
form of NFjB from cell lysates bind. The primary antibody
only binds to the epitope on p65 only when NFjB is
activated and bound to its target. A secondary HRP-con-
jugated antibody binds to the primary complex which then
produces a signal quantifiable by spectrophotometery
(measurable by optical density at 450 nm wavelength). The
cell culture medium was analysed for IL-6, IL-8, IL-10 and
TNFa using a high sensitivity human cytokine Lincoplex
assay (Linco Research, Cat. HSCYTO-60SK, St. Charles,
MO, USA) using the Bio-Plex system (Bio-Rad Laboratory
Inc., Hercules, CA, USA). Inter-assay variability ranged
between 2 and 15% for all cytokines measured. Cells
exposed to ghrelin and its agonists were compared with
resting and activated controls.
Statistical analysis
Data is reported as mean ± SEM. A Student’s t-test was
used to compare data from cell groups using GraphPad
Prism software.
Results
Octanoyl-ghrelin (N = 6)
In the resting state, NFjB activity in the control cells was
0.42 ± 0.10 and increased to 0.61 ± 0.20, 0.54 ± 0.10,
0.52 ± 0.08 when exposed to 1, 10 and 100 nM octanoyl
ghrelin respectively (Fig. 2a). The increase in NFjB
activity in 1 and 10 nM was statistically significant
(P = 0.044 and P = 0.043 respectively). NFjB activity
increased by 25–50% in the octanoyl ghrelin treated cells
when compared to control cells.
In the activated state, NFjB activity was 0.56 ± 0.10 in
control cells and remained unchanged at 0.57 ± 0.08,
0.60 ± 0.09, 0.48 ± 0.07 when exposed to 1, 10 and
100 nM octanoyl ghrelin respectively (Fig. 2b).
Desoctanoyl ghrelin (N = 6)
In the resting state, the NFjB activity in the control cells
was 0.35 ± 0.03 and remained unchanged at 0.36 ± 0.04,
0.39 ± 0.04, 0.36 ± 0.04, 0.36 ± 0.03 when exposed to
0.1, 1, 10 and 100 nM des-octanoyl ghrelin respectively.
In the activated state, NFjB activity in the control cells
was 0.38 ± 0.04 and remained unchanged at 0.38 ± 0.03,
Table 1 Results of the screening experiments (N = 3) in cells dosed with octanoyl ghrelin. There was a trend towards increased NFjB
activation in the resting group at T = 6 h
Mean and SEM P value Mean and SEM P value
NFkB activation in WILCL at 6 h
Control 0.301 ± 0.044 Control and PHA activation 0.311 ± 0.083
1 nM 0.29 ± 0.05 0.42 1 nM and PHA activation 0.351 ± 0.10 0.1
10 nM 0.371 ± 0.12 0.26 10 nM and PHA activation 0.341 ± 0.13 0.09
100 nM 0.321 ± 0.063 0.34 100 nM and PHA activation 0.321 ± 0.062 0.39
NFkB activation in WILCL at 24 h
Control 0.311 ± 0.04 Control and PHA activation 0.291 ± 0.05
1 nM 0.301 ± 0.04 0.28 1 nM and PHA activation 0.291 ± 0.05 0.15
10 nM 0.311 ± 0.04 0.32 10 nM and PHA activation 0.311 ± 0.04 0.18
100 nM 0.281 ± 0.04 0.03 100 nM and PHA activation 0.321 ± 0.04 0.1
NFkB activation in WILCL at 48 h
Control 0.431 ± 0.10 Control and PHA activation 0.411 ± 0.06
1 nM 0.371 ± 0.05 0.17 1 nM and PHA activation 0.371 ± 0.04 0.26
10 nM 0.421 ± 0.11 0.43 10 nM and PHA activation 0.431 ± 0.09 0.3
100 nM 0.381 ± 0.065 0.17 100 nM and PHA activation 0.451 ± 0.08 0.14
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0.41 ± 0.04, 0.39 ± 0.04, 0.39 ± 0.04 when exposed to
0.1, 1, 10 and 100 nM des-octanoyl ghrelin respectively.
Ghrelin receptor agonist (N = 6)
In the resting state, NFjB activity in control cells was
0.30 ± 0.04 and remained unchanged at 0.29 ± 0.03,
0.31 ± 0.04, 0.31 ± 0.05, and 0.29 ± 0.04 when exposed
to 1, 10, 100 and 1000 nM ghrelin receptor agonist
respectively.
In the activated state, the NFjB activity in control cells
was 0.31 ± 0.04 and remained unchanged at 0.31 ± 0.04,
0.33 ± 0.05, 0.32 ± 0.05 and 0.31 ± 0.04 when exposed
to 1, 10, 100 and 1000 nM ghrelin receptor agonist
respectively.
Cytokines (N = 6)
In resting and activated cells exposed to all concentrations
of octanoyl ghrelin, no significant change in TNFa IL-6,
IL-8, IL-10 concentration in the media was demonstrated
(Table 2). Table 3 showed that the non-peptide ghrelin
agonist significantly suppressed lymphocyte IL-13 pro-
duction in a dose dependent manner particularly in resting
lymphocytes. This effect was not associated with any
changes in NFjB. IL-13 is an anti-inflammatory cytokine
and its suppression suggests that the non-peptide ghrelin
agonist could be pro-inflammatory acting via a pathway
independent of NFjB. This effect is not seen with the
biological ligand octanoyl ghrelin suggesting that it may be
a non-specific effect of the synthetic agonist.
Discussion
After a series of screening experiments we selected an
immortalized B-lymphocyte cell line expressing ghrelin
receptors as the target of investigation. Contrary to our
initial hypothesis, this study shows that physiological
concentrations of octanoyl ghrelin increased NFjB
Fig. 2 a, b NFjB activation in
resting and activated WILCL
human B-lymphocyte cell line
with increasing doses of
octanoyl ghrelin. Data is the
average of six experiments. The
Student’s t-test was used to
compare NFjB activation in
increasing concentration of
octanoyl ghrelin and controls.
a The NFjB profile in resting
cells and demonstrates a
25–50% increase in NFjB
activation at 1 and 10 nM
concentrations of octanoyl
ghrelin. b The NFjB activation
in activated cells and showed no
significant change with
increasing concentrations of
octanoyl ghrelin
4836 Mol Biol Rep (2011) 38:4833–4838
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activation by up to 50% when applied to this cell line. This
effect was not dose dependent but peaked at 1 and 10 nM
and seemed to decline at 100 nM concentration. As
expected this effect was not seen with the non-peptide
ghrelin receptor agonist and des octanoyl ghrelin; neither
are the natural ligands for the ghrelin receptor. The effect
of octanoyl ghrelin was detected only when the cells were
in a resting state and absent when activated with PHA. In
the active state lymphocytes are probably at a state of
maximal NFjB activation and additional stimulation via
the ghrelin receptor is unable to increase this measurably.
Previous studies have demonstrated ghrelin receptors on
human immune cells and also a decrease in cytokine pro-
duction in T-lymphocytes and monocytes treated with
ghrelin but not in B-lymphocytes. As expected, our in vitro
model detected no consistent change in the panel of cyto-
kines occurring in parallel with the changes in NFjB. We
also detected an NFjB-independent non-specific effect of
the non-peptide ghrelin agonist which suppressed IL-13
production in both resting and activated lymphocytes.
However we believe the effect of octanoyl ghrelin on
NFjB detected only in resting lymphocytes is more bio-
logically plausible.
We recognize that cytokine production is not a primary
function of B-lymphocyte. Our experiment explored the
interaction between B-lymphocyte cell activation and
NFjB expression both known characteristics of this cell
line. If this was a primary B lymphocyte cell line function
would have been best assessed by immunoglobulin pro-
duction but we were unable to confirm that this cell line
had this characteristic. We also had more experience with
PHA in our laboratory.
NFjB is known to regulate the development and mat-
uration of lymphocytes [18]. The uncontrolled activation of
NFjB has been implicated in many inflammatory diseases
and cancer. This has driven much interest in NFjB as a
therapeutic target in many diseases. There are studies that
suggest an anti-inflammatory effect of ghrelin on human
Table 2 Cytokine concentration in culture media of lymphocytes
dosed with octanoyl ghrelin (N = 6)
Non-PHA P value PHA P value
IL-6
Control 0.23 ± 0.03 0.31 ± 0.10
1 nM 0.24 ± 0.04 0.729 0.21 ± 0.03 0.2673
10 nM 0.22 ± 0.03 0.252 0.27 ± 0.07 0.190
100 nM 0.19 ± 0.04 0.101 0.23 ± 0.05 0.188
IL-8
Control 1.12 ± 0.93 1.40 ± 1.17
1 nM 1.97 ± 1.54 0.33 1.36 ± 1.12 0.68
10 nM 1.47 ± 1.12 0.16 1.28 ± 1.09 0.11
100 nM 1.58 ± 1.22 0.16 1.28 ± 1.08 0.15
IL-10
Control 1033.15 ± 270.57 1095.37 ± 246.01
1 nM 1018.35 ± 232.24 0.88 1056.51 ± 249.85 0.58
10 nM 1031.57 ± 251.83 0.48 1130.65 ± 283.10 0.36
100 nM 966.62 ± 232.18 0.17 1067.75 ± 241.99 0.31
IL-13
Control 3.83 ± 0.68 4.10 ± 0.50
1 nM 3.91 ± 0.65 0.80 4.06 ± 0.64 0.86
10 nM 3.48 ± 0.60 0.13 4.07 ± 0.73 0.47
100 nM 3.55 ± 0.52 0.22 3.72 ± 0.54 0.06
TNFa
Control 27.93 ± 678 35.54 ± 9.63
1 nM 33.58 ± 12.31 0.44 31.37 ± 8.63 0.03
10 nM 30.40 ± 9.13 0.24 32.46 ± 7.98 0.12
100 nM 30.25 ± 9.22 0.27 30.19 ± 7.24 0.10
Table 3 Cytokine concentration in culture media of lymphocytes
dosed with the non-peptide ghrelin agonist (N = 6)
Non-PHA P value PHA P value
IL-6
Control 0.25 ± 0.06 0.26 ± 0.05
1 nM 0.24 ± 0.05 0.04 0.25 ± 0.04 0.30
10 nM 0.27 ± 0.03 0.16 0.27 ± 0.05 0.45
100 nM 0.25 ± 0.04 0.11 0.25 ± 0.06 0.05
1000 nM 0.28 ± 0.06 0.36 0.26 ± 0.06 0.47
IL-8
Control 12.18 ± 3.86 11.86 ± 3.71
1 nM 12.45 ± 4.19 0.34 11.85 ± 3.77 0.49
10 nM 11.81 ± 3.38 0.28 11.84 ± 3.14 0.49
100 nM 11.03 ± 3.35 0.05 13.35 ± 5.07 0.17
1000 nM 12.40 ± 14.46 0.38 11.74 ± 3.93 0.38
IL-10
Control 790.84 ± 126.17 835.59 ± 134.23
1 nM 764.81 ± 122.30 0.26 775.24 ± 138.14 0.04
10 nM 844.94 ± 195.24 0.27 770.74 ± 134.49 0.06
100 nM 723.14 ± 121.23 0.10 812.52 ± 131.26 0.20
1000 nM 759.59 ± 127.19 0.21 753.79 ± 127.14 0.05
IL-13
Control 5.88 ± 0.67 5.96 ± 0.68
1 nM 5.29 ± 0.65 0.01 5.60 ± 0.73 0.14
10 nM 5.08 ± 0.82 0.00 5.40 ± 0.70 0.06
100 nM 4.88 ± 0.56 0.01 5.35 ± 0.55 0.05
1000 nM 4.97 ± 0.63 0.00 4.55 ± 0.42 0.00
TNFa
Control 99.68 ± 5.29 113.49 ± 7.43
1 nM 95.33 ± 7.33 0.24 116.70 ± 7.31 0.25
10 nM 99.24 ± 8.86 0.46 108.70 ± 7.21 0.18
100 nM 88.17 ± 5.19 0.02 110.74 ± 8.15 0.30
1000 nM 92.64 ± 8.18 0.13 107.25 ± 8.36 0.15
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and animal lymphocytes (8, 19) and although our data
points to a contrary conclusion it provides further evidence
that ghrelin may be part of a complex human immune
regulatory repertoire and raises the possibility that its
receptor could be a target for immune-modulatory therapy.
Indeed there has been contrary evidence that ghrelin
increases NFjB activation and promote inflammation in
the human colon [20] This is the first study to demonstrate
the effects of ghrelin on a human B-lymphocytes in vitro
model. Further evaluation and understanding on how
NFjB regulates the immune system will be important in
understanding a possible role of ghrelin.
Conflict of interest None.
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Abstract Delayed gastric emptying symptoms are often
reported after chemotherapy. This study aims to charac-
terise the effects of chemotherapy on gastric neuro-
muscular function. Patients undergoing elective surgery for
oesophago-gastric cancer were recruited. Acetylcholines-
terase, nNOS, ghrelin receptor and motilin expressions
were studied in gastric sections from patients receiving no
chemotherapy (n = 3) or oesophageal (n = 2) or gastric
(n = 2) chemotherapy. A scoring system quantified stain-
ing intensity (0–3; no staining to strong). Stomach sections
were separately suspended in tissue baths for electrical
field stimulation (EFS) and exposure to erythromycin or
carbachol; three patients had no chemotherapy; four com-
pleted cisplatin-based chemotherapy within 6 weeks prior
to surgery. AChE expression was markedly decreased after
chemotherapy (scores 2.3 ± 0.7, 0.5 ± 0.2 and 0 ± 0 in
non-chemotherapy, oesophageal- and gastric-chemother-
apy groups (p \ 0.03 each) respectively. Ghrelin receptor
and motilin expression tended to increase (ghrelin:
0.7 ± 0.4 vs 2.0 ± 0.4 and 1.2 ± 0.2 respectively;
p = 0.04 and p = 0.2; motilin: 0.7 ± 0.5 vs 2.2 ± 0.5 and
2.0 ± 0.7; p = 0.06 and p = 0.16). Maximal contraction
to carbachol was 3.7 ± 0.7 g and 1.9 ± 0.8 g (longitudi-
nal muscle) and 3.4 ± 0.4 g and 1.6 ± 0.6 (circular) in
non-chemotherapy and chemotherapy tissues respectively
(p \ 0.05 each). There were loss of AChE and reduction in
contractility to carbachol. The tendency for ghrelin recep-
tors to increase suggests an attempt to upregulate com-
pensating systems. Our study offers a mechanism by which
chemotherapy markedly alters neuro-muscular gastric
function.
Keywords Acetylcholinesterase  Ghrelin  Motility 
Stomach  Chemotherapy  Cisplatin
Abbreviations
EFS Electrical field stimulation
AChE Acetylcholinesterase
nNOS Neuronal nitric oxide synthase
Introduction
Neoadjuvant chemotherapy for oesophageo-gastric cancers
prior to surgery is now common practice following clinical
trials that showed survival improvement [1, 2]. However,
following completion of chemotherapy, these patients fre-
quently continue to experience distressing symptoms
resembling dyspepsia and attributed to a disorder in gastric
emptying [3]. Riezzo et al. [4] suggested that gastric
dysmotility-like symptoms (susceptibility to nausea, early
satiety, post-prandial fullness) and tachygastria were
common in patients seven days after completion of che-
motherapy, during which emesis was well controlled. Such
studies raise the possibility that the anti-cancer chemo-
therapy may somehow induce a gastric dysmotility which
outlasts the treatment and which may lead to prolonged
symptoms of dyspepsia. For this to occur, it is certainly not
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inconceivable that chemotherapy directly affects the
integrity of the neuromuscular functions of the stomach. In
rat gastro-duodenal muscle, for example, a reduction in the
presence of the Ca2?-calmodulin complex has been
observed three days after a single treatment with cisplatin
[5].
To test the possibility that certain anti-cancer chemo-
therapy treatments may cause long-term damage to gastric
function, we have looked at the effects of cisplatin-based
treatments on the function and integrity of human stomach.
For this purpose we examined the ability of human isolated
stomach to contract in response to carbachol and other
stimuli, following removal at surgery from patients who
had undergone chemotherapy up to six weeks previously,
compared to patients who had not undergone chemother-
apy. The integrity of the motor nerve system was also
examined by immunohistochemical staining for acetyl-
cholinesterase (AChE) and for the neuronal isoform of
nitric oxide synthase (nNOS). In addition, we looked for
changes in expression of the gastric motility stimulant
motilin [6] and the receptors for ghrelin. The latter was
included because of an association between ghrelin and
changes in appetite and gastric motility [7] and also
because of a previous study in rats, which showed that the
ghrelin receptor may be up-regulated following adminis-
tration of cisplatin [8].
Methods
All patients enrolled were diagnosed with resectable
oesophageo-gastric cancers. The patients were staged by
computed tomography (CT) scan, endoscopy including
endoscopic ultrasound and laparoscopy. All patients were
staged as TxN0(or x)M0 by the TMN staging system and
were assessed to be suitable for surgery. The study was
approved by the local Coventry research ethics committee
and written informed consent was obtained from all
patients.
Patients with gastric adenocarcinomas (n = 2) received
three courses of epirubucin (50 mgm-2), cisplatin
(60 mgm-2) and capecitabine (625 mgm-2). Patients with
oesophageal cancers (n = 2) received two courses of cis-
platin (80 mgm-2) and 5-fluorouracil (1 gm-2). Patients
who did not undertake chemotherapy (n = 3) were physi-
cally frail, deemed at risk of severe side effects of che-
motherapy or undergoing Whipple’s procedure for
pancreatobiliary tumours. All patients underwent surgical
resection within a 2 week window of 4–6 weeks following
completion of chemotherapy regime, based on local cancer
pathway.
For the histological studies, paraffin-embedded samples
were used for staining and immunohistochemistry. In the
gastric tissue contractility experiments, gastric tissue
was obtained from tumour free margins during surgery.
Samples were then stored at 4 C in Gey’s balanced salt
solution (Sigma, Gillingham, Dorset, UK) which was
pre-bubbled with 95 % O2/5 % CO2. These tissues were
processed within 24 h of collection (see below).
Immunohistochemistry and histological staining
Histological paraffin embedded tissue blocks showing
normal tissue adjacent and distant from the tumour site
were selected. 5 lm thick sections were baked onto
3-aminopropyltriethoxy-silane coated slides. Specific anti-
bodies were used to look for the expression of motilin, the
ghrelin receptor, AChE and nNOS, in sections of gastric
tissues taken from patients who did not have chemotherapy
and in those receiving oesophageal-chemotherapy (cis-
platin ? 5-fluorouracil) or gastric chemotherapy (epirubu-
cin, cisplatin and capecitabine) (n = 6 each).
Antigen retrieval was carried out by pressure cooking in
Tris EDTA buffer pH 7.8 for 80 s. Vector Universal Elite
ABC kit (Catalogue Number PK-6200; Burlingame, CA,
USA) with a diaminobenzidine tetrahydrachloride visual-
isation agent (Vector ImPACT DAB substrate, Cat. No.
SK-4105, Burlingame, CA, USA) was used for visualization
of bound antibody. Optimised antibody dilutions were
determined for motilin receptor (MBL International Corp,
Woburn, MA, USA, Cat. No. LS-A134), ghrelin receptor
(Chemicon, Billerica, MA, USA, Cat. No. AB9543), nNOS
(Abcam, Cambridge, UK, Cat. No. ab40662) and AChE
(Abcam, Cambridge, UK, Cat. No. ab2803). Haematoxylin
was used as a counter stain, dehydrated, cleared and moun-
ted. The intensity and distribution of peroxidase staining was
examined and scored by a histopathologist who was blinded
to the patient groups. For all procedures, a semi-quantitative
scoring system for staining intensity was used (0 = no
staining, 1 = weak, 2 = moderate, 3 = strong expression).
Gastric contractility
Specimens of stomach were placed in oxygenated (95 %
O2, 5 % CO2) Gey’s salt solution overnight. In some cases,
on the following morning the tissues were placed in fresh
Krebs solution, bubbled and then transported to the labo-
ratory. On arrival the specimens were placed in fresh,
oxygenated Krebs solution (containing in mM NaCl 121.5,
CaCl2 2.5, KH2PO4 1.2, KCl 4.7, MgSO4 1.2, NaHCO3 25,
glucose 5.6) which had been equilibrated with 5 % CO2
and 95 % O2. The mucosa was removed and strips
(2–4 9 10–15 mm) were cut parallel to the longitudinal or
the circular muscle. The strips (2–4 from each patient)
were mounted in tissue baths (10 ml) containing Krebs
solution at 37 C and gassed with 5 % CO2 in O2. Tension
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was measured using Dynamometer UF1 force–displace-
ment transducers (Pioden Control Ltd., UK). Data acqui-
sition and analysis were performed using MP100 hardware
and AcqKnowledge software (Biopac Systems Inc., USA).
Tissues were initially suspended under 2–3 g tension and
allowed to equilibrate for at least 45 min during which time
bath solutions were changed every 15 min. During this
time, muscle tension stabilised at *1 g.
At the end of the equilibration period, some longitudinal
muscle strips were stimulated via two parallel platinum
ring electrodes connected to a stimulator (STG2008, Sci-
entifica Ltd, UK). The stimulation parameters were 50 V
(*200 mA), 0.5 ms bipolar pulse duration, applied for
10 s, every 1 min. The frequency was changed every 3 min
to produce a frequency–response curve, using frequencies
of 1, 2, 5, 10, 15, and 20 Hz. After washing and in tissues
not subjected to EFS, 10 lM erythromycin was added for
15 min. As not all tissues responded to EFS or erythro-
mycin, the data are expressed simply as the number of
tissues which responded by contraction, or not. The tissues
were washed and left for 30 min. For both longitudinal and
circular muscle strips, a carbachol concentration–response
curve (1 nM–10 lM) was then constructed, with each
additional concentration being added after a maximum
response was observed to the previous, usually between 2
and 8 min). Changes in muscle tension (g) evoked by each
carbachol concentration were expressed in grams.
Data analysis
All data are expressed as means ± the standard error of the
mean (SEM.), or as mean values with ranges; n values are
numbers of patient donors. In the contractility studies, any
differences in responses to carbachol between the two
treatment groups were analysed using a two-way ANOVA
with Bonferroni post hoc test. Data from the immunohis-
tochemistry study was analysed using the Student’s paired t
test.
Compounds
All drugs were freshly prepared before use. Erythromycin
(Sigma, Gillingham, Dorset, UK) was dissolved in 100 %
ethanol, with subsequent dilution in distilled water. Car-
bachol (Sigma, UK) was dissolved in distilled water.
Results
Histology and immunohistochemistry
There were no clear differences in age for each of the
patient groups. More males than females were recruited
although the numbers are too small to observe meaningful
differences (Table 1).
All patients in the immunohistochemistry study had
gastric or oesophageal adenocarcinoma. There was a
marked decrease in expression of AChE (the scores were,
respectively, 2.3 ± 0.7, 0.5 ± 0.2 and 0 ± 0 in non-che-
motherapy vs oesophageal- and gastric-chemotherapy
groups (p = 0.03 and p \ 0.001 respectively)—each
compared with the non-chemotherapy tissues; Figs. 1 and
2. By contrast, there was a tendency for ghrelin receptors
and for motilin to increase, although this did not always
achieve statistical significance (ghrelin receptor: 0.7 ± 0.4
in non-chemotherapy vs 2.0 ± 0.4 and 1.2 ± 0.2 in oe-
sopheal- and gastric-chemotherapy groups respectively,
p = 0.04 and p = 0.2; motilin: 0.7 ± 0.5 vs 2.2 ± 0.5 and
2.0 ± 0.7, p = 0.06 and p = 0.16, respectively). There
were no consistent changes in nNOS (1.2 ± 0.6 in non-
chemotherapy vs 1.2 ± 0.6 and 0.5 ± 0.34 in oesophageal
and gastric-chemotherapy p = 0.3 respectively).
Gastric contractility
Table 1 illustrates patient demographics. As before, there
were more males than females. Of the four patients
receiving chemotherapy, three had gastric-chemotherapy
for gastric adenocarcinoma and one had oesophageal-che-
motherapy for squamous cell carcinoma of oesophagus.
The patient numbers were too small for subgroup analysis
and hence, were analysed together as a single chemother-
apy group. Longitudinal muscle preparations from either
group did not consistently contract in response to EFS or
erythromycin. Contraction could be evoked by EFS in two
of the three non-chemotherapy tissues (threshold 2–5 Hz)
and in one of four chemotherapy tissues. Similarly, eryth-
romycin 10 lM increased basal tone or contractility in
some tissues, but with no obvious difference between
chemotherapy and non-chemotherapy tissues (four of eight
Table 1 Patient demographics in the immunohistochemistry and the
contractility study
Immunohistochemistry study
Non-
chemotherapy
Oesophageal-
chemotherapy
Gastric-
chemotherapy
Female:male
ratio
1:5 1:5 2:4
Mean age 76 71 63
Contractility study
Non chemotherapy Chemotherapy
Mean age 74 63
Female:male ratio 2:1 0:4
Mol Biol Rep
123
non-chemotherapy tissues responded, compared to two of
four tissues from patients receiving chemotherapy).
Application of carbachol 1 nM–10 lM caused a con-
centration-dependent contraction of both longitudinal and
circular muscle tissues from both patient groups (Fig. 3).
However, there were clear differences between the groups
of patients in terms of the force of contraction evoked by
carbachol. The maximal contraction produced by 10 lM
carbachol in longitudinal muscle, for example, was
1.9 ± 0.8 g and 3.7 ± 0.7 g in chemotherapy and non-
chemotherapy tissues respectively (p \ 0.05) and in cir-
cular muscle, these values were 1.6 ± 0.6 and 3.4 ± 0.4 g
in chemotherapy and non-chemotherapy tissues (p \ 0.05).
Discussion
Our preliminary results indicate, for the first time, that
marked changes in the contractility and integrity of
the human stomach are caused by cisplatin-based
chemotherapy.
The absence of staining for AChE and the significant
reduction in contractility to carbachol suggests that cis-
platin profoundly influences gastric cholinergic function.
These findings are consistent with the reported ability of
cisplatin to affect cholinergic function in conscious rats
(causing an increase in [3H]-choline uptake into the cardiac
region of the stomach), although not with accompanying
change in gastric AChE staining, measured three days after
treatment in the same study [9]. Differences in species,
duration of chemotherapy and or length of time after che-
motherapy are likely to contribute to the differences
observed.
The reduction in cholinergic function was not clearly
accompanied by a change in nNOS expression, suggesting
that any sustained influence of cisplatin on enteric nerve
function is not uniform throughout this nervous system.
The effects of chemotherapy on the nNOS isoform has
previously not been studied in humans, although in rats
receiving cisplatin or taxol, reductions in expression of the
inducible form of NOS expression are reported [10], along
with increases in plasma nitric oxide [11]. Conversely
Jarve et al. [5] showed no changes in NOS localisation or
intensity of staining five days after dosing with cisplatin in
Fig. 1 Immunohistochemistry (IHC) scores for AChE comparing
non-chemotherapy and oesophageal-chemotherapy (a) and gastric-
chemotherapy (b) exposed tissues. Mean IHC scores were compared
using the Student’s paired t test. p \ 0.03 when comparing AChE
scores in non-chemotherapy and chemotherapy groups
Fig. 2 a Gastric section from a non-chemotherapy patient. Acetyl-
cholinesterase staining showing positive (brown) cytoplasmic staining
within ganglion cells (arrows). b Gastric section from a chemother-
apy exposed patient. Despite an intensive search definite ganglion
cells were not identified in this case, possibly because of degeneration
from chemotherapy. The image shows a representative field illustrat-
ing negative staining in a neurovascular bundle. Original magnifica-
tion 9400. (Color figure online)
Mol Biol Rep
123
rats. Taken together, these studies suggest the possibility
that NOS expression may be affected by cisplatin treatment
but in our study, the changes are either too subtle to be
detected using the present methods or perhaps changes
occur immediately on treatment and recover thereafter.
The tendency for the expression of both ghrelin recep-
tors and of motilin to be increased up to six weeks after
cisplatin treatment does not, by itself, indicate that the
functions of ghrelin and motilin are changed by chemo-
therapy. However, the observed trend is consistent with
rodent studies. For example, Malik et al. [8] found that
ghrelin receptor mRNA expression in rat stomach was
increased two days after treatment with cisplatin, at a time
when the cisplatin-induced gastric stasis was at its greatest;
there were no changes in ghrelin mRNA expression. This
up-regulation of ghrelin receptor expression suggested that
ghrelin might be operating as part of a defence mechanism
against the damage caused by cisplatin; this hypothesis is
proposed because of the known ability of ghrelin to inhibit
cisplatin-induced emesis, promote appetite and increase
gastric emptying [8, 12]. However, the present findings,
measured up to six weeks after discontinuation of treatment
with cisplatin, suggest that if ghrelin were to play a similar
defensive role in humans, any effects of ghrelin are likely
to be overwhelmed by the more severe reduction in cho-
linergic function. A similar defensive role for motilin has
not previously been proposed and although tempting to
speculate that the gastric prokinetic activity of motilin
would serve this purpose—the small numbers and lack of
statistical significance limits our interpretation. Interest-
ingly, Hursti et al. [13] found that plasma levels of motilin
were transiently decreased 4 days after a cisplatin-based
treatment.
In summary, our study suggests that neo-adjuvant che-
motherapy can cause marked and enduring damage to
neuro-muscular gastric function. Most notable was the loss
of AChE and reduction in contractility evoked by carba-
chol, providing a plausible explanation for some of the
severe symptoms of gastric stasis reported by patients long
after completion of chemotherapy. In addition, the ten-
dency for ghrelin receptors to increase may be consistent
with studies in animals exposed to cisplatin and suggests an
attempt to up-regulate compensating systems. The conse-
quences of these changes merits further assessment in the
clinical setting.
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